

2026 Clinical Diagnostic Laboratory Fee Schedule							
CPT codes, descriptions and other data only are copyright 2026 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.							
YEAR	HCPCS	MOD	EFF_DATE	INDICATOR	RATE	LONGDESC	EXTENDEDLONGDESC
2026	0001U		20260101	N	\$720.00	Red blood cell typing	Red blood cell antigen typing, dna, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common rbc alleles reported

2026	0002M		20260101	N	\$503.40	Molecular pathology test for liver disease, including alcohol liver disease	Liver disease, ten biochemical assays (alt, a2-macroglobulin, apolipoprotein a-1, total bilirubin, ggt, haptoglobin, ast, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic steatohepatitis (ash)
------	-------	--	----------	---	----------	---	---

2026	0002U		20260101	N	\$25.00	Measurement of substances in urine to predict likelihood of polyps in large	Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps
------	-------	--	----------	---	---------	---	---

2026	0003M		20260101	N	\$503.40	Molecular pathology test for liver disease, including non-alcohol liver disease	Liver disease, ten biochemical assays (alt, a2-macroglobulin, apolipoprotein a-1, total bilirubin, ggt, haptoglobin, ast, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (nash)
------	-------	--	----------	---	----------	---	---

2026	0003U		20260101	N	\$950.00	Measurement of proteins associated with ovarian cancer in serum	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein a-1, ca 125 ii, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score
2026	0004M		20260101	N	\$79.00	Molecular pathology test for genetic analysis of curved spine deformity	Scoliosis, dna analysis of 53 single nucleotide polymorphisms (snps), using saliva, prognostic algorithm reported as a risk score

2026	0005U		20260101	N	\$760.00	Test for detecting genes associated with prostate cancer in urine	Oncology (prostate) gene expression profile by real-time rt-pcr of 3 genes (erg, pca3, and spdef), urine, algorithm reported as risk score
2026	0006M		20260101	N	\$150.00	Molecular pathology test for genetic analysis of liver tumor (HeproDX)	Oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier

2026	0007M		20260101	N	\$375.00	Molecular pathology test for genetic analysis of tumors in the digestive system	Oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index
2026	0007U		20260101	N	\$114.43	Testing for presence of drug in urine	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including dna authentication in comparison to buccal dna, per date of service

2026	0008U		20260101	N	\$597.91	Test for detecting Helicobacter pylori genes associated with antibiotic	Helicobacter pylori detection and antibiotic resistance, dna, 16s and 23s rrna, gyra, pbp1, rdx and rpoB, next generation sequencing, formalin-fixed paraffin embedded or fresh tissue or fecal sample, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline and rifabutin
------	-------	--	----------	---	----------	---	---

2026	0009U		20260101	N	\$107.00	Gene analysis of breast tumor tissue	Oncology (breast cancer), erbb2 (her2) copy number by fish, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (dep) sorting, reported as erbb2 gene amplified or non-amplified
2026	0010U		20260101	N	\$427.26	Typing of bacterial strain	Infectious disease (bacterial), strain typing by whole genome sequencing, phylogenetic-based report of strain relatedness, per submitted isolate

2026	0011M		20260101	N	\$760.00	Molecular pathology test for genetic analysis of prostate tumor (NeoLAB	Oncology, prostate cancer, mrna expression assay of 12 genes (10 content and 2 housekeeping), rt-pcr test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk
2026	0011U		20260101	N	\$114.43	Prescription drug monitoring in oral fluid	Prescription drug monitoring, evaluation of drugs present by lc-ms/ms, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites

2026	0012M		20260101	N	\$760.00	Molecular pathology test for genetic analysis of bladder tumor (Cxbladder	Oncology (urothelial), mrna, gene expression profiling by real-time quantitative pcr of five genes (mdk, hoxa13, cdc2 [cdk1], igfbp5, and cxcr2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma
2026	0013M		20260101	N	\$760.00	Molecular pathology test for genetic analysis of recurrent bladder tumor	Oncology (urothelial), mrna, gene expression profiling by real-time quantitative pcr of five genes (mdk, hoxa13, cdc2 [cdk1], igfbp5, and cxcr2), utilizing urine, algorithm reported as a risk score for having recurrent urothelial carcinoma

2026	0015M		20260101	N	\$1,305.37	Molecular pathology test for genetic analysis of kidney gland tumor (Adrenal	Adrenal cortical tumor, biochemical assay of 25 steroid markers, utilizing 24-hour urine specimen and clinical parameters, prognostic algorithm reported as a clinical risk and integrated clinical steroid risk for adrenal cortical carcinoma, adenoma, or other adrenal malignancy
------	-------	--	----------	---	------------	--	---

2026	0016M		20260101	N	\$3,489.63	Molecular pathology test for genetic analysis of bladder tumor (Decipher	Oncology (bladder), mrna, microarray gene expression profiling of 219 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like)
------	-------	--	----------	---	------------	--	---

2026	0016U		20260101	N	\$163.96	RNA test for detecting gene abnormality associated with blood and lymphatic	Oncology (hematolymphoid neoplasia), rna, bcr/abl1 major and minor breakpoint fusion transcripts, quantitative pcr amplification, blood or bone marrow, report of fusion not detected or detected with quantitation
2026	0017M		20260101	N	\$2,510.21	mRNA gene expression profiling by fluorescent probe hybridization of 20 genes	Oncology (diffuse large b-cell lymphoma [dlbcl]), mrna, gene expression profiling by fluorescent probe hybridization of 20 genes, formalin-fixed paraffin-embedded tissue, algorithm reported as cell of origin

2026	0017U		20260101	N	\$91.66	JAK2 mutation test for detecting gene abnormality associated with blood and	Oncology (hematolymphoid neoplasia), jak2 mutation, dna, pcr amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of jak2 mutation not detected or detected
2026	0018M		20260101	N	\$640.73	Measurement of kidney donor and third-party-induced CD154+T-cytotoxic memory	Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced cd154+t-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score

2026	0018U		20260101	N	\$3,002.09	MicroRNA gene analysis of thyroid nodule tissue	Oncology (thyroid), microrna profiling by rt-pcr of 10 microrna sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy
2026	0019M		20260101	N	\$712.40	Analysis of protein biomarkers in plasma with results reported as likelihood	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations

2026	0019U		20260101	N	\$3,675.00	RNA gene analysis of tumor tissue	Oncology, rna, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents
2026	0020M		20260101	N	\$2,500.00	Analysis of DNA from tumor tissue with results reported as probability of	Oncology (central nervous system), analysis of 30000 dna methylation loci by methylation array, utilizing dna extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass

2026	0021U		20260101	N	\$760.00	Detection of 8 autoantibodies in prostate tissue	Oncology (prostate), detection of 8 autoantibodies (arf 6, nkx3-1, 5'-utr-bmi1, cep 164, 3'-utr-ropporin, desmocollin, aurkaip-1, csnk2a2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score
------	-------	--	----------	---	----------	--	--

2026	0022U		20260101	N	\$1,950.00	DNA and RNA targeted sequencing analysis of 1-23 genes associated with	Targeted genomic sequence analysis panel, non-small cell lung neoplasia, dna and rna analysis, 23 genes, interrogation for sequence variants and rearrangements , reported as presence or absence of variants and associated therapy(ies) to consider
------	-------	--	----------	---	------------	--	---

2026	0023U		20260101	N	\$248.51	DNA gene analysis for acute myelogenous leukemia	Oncology (acute myelogenous leukemia), dna, genotyping of internal tandem duplication, p. d835, p.i836, using mononuclear cells, reported as detection or non-detection of flt3 mutation and indication for or against the use of midostaurin
2026	0024U		20260101	N	\$34.19	Measurement of glycosylated acute phase proteins	Glycosylated acute phase proteins (glyca), nuclear magnetic resonance spectroscopy, quantitative
2026	0025U		20260101	N	\$114.43	Measurement of tenovir in urine	Tenofovir, by liquid chromatography with tandem mass spectrometry (lc-ms/ms), urine, quantitative

2026	0026U		20260101	N	\$3,600.00	DNA and microRNA gene analysis of thyroid nodule tissue	Oncology (thyroid), dna and mrna of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("positive, high probability of malignancy" or "negative, low probability of malignancy")
2026	0027U		20260101	N	\$121.91	Gene analysis (Janus kinase 2) of targeted sequence exons 12-15	Jak2 (janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15

2026	0029U		20260101	N	\$742.27	Gene analysis of targeted sequences for adverse drug reactions and drug response	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, cyp1a2, cyp2c19, cyp2c9, cyp2d6, cyp3a4, cyp3a5, cyp4f2, slco1b1, vkorc1 and rs12777823)
2026	0030U		20260101	N	\$134.13	Gene analysis of targeted sequences for warfarin drug response	Drug metabolism (warfarin drug response), targeted sequence analysis (ie, cyp2c9, cyp4f2, vkorc1, rs12777823)
2026	0031U		20260101	N	\$174.81	Gene analysis (cytochrome P450 family 1, subfamily A, member 2) for common	Cyp1a2 (cytochrome p450 family 1, subfamily a, member 2) (eg, drug metabolism) gene analysis, common variants (ie, *1f, *1k, *6, *7)

2026	0032U		20260101	N	\$174.81	Gene analysis (catechol-O-methyltransferase) for c. 472G>A (rs4680) variant	Comt (catechol-o-methyltransferase) (drug metabolism) gene analysis, c. 472g>a (rs4680) variant
2026	0034U		20260101	N	\$466.17	Gene analysis (thiopurine S-methyltransferase) for common variants	Tpmt (thiopurine s-methyltransferase), nudt15 (nudix hydroxylase 15) (eg, thiopurine metabolism), gene analysis, common variants (ie, tpmt *2, *3a, *3b, *3c, *4, *5, *6, *8, *12; nudt15 *3, *4, *5)
2026	0035U		20260101	N	\$540.99	Testing for presence of prion protein in cerebrospinal fluid	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative

2026	0036U		20260101	N	\$4,780.00	Exome gene analysis for somatic mutation in tumor tissue	Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses
2026	0037U		20260101	N	\$3,500.00	DNA gene analysis of 324 genes in solid organ tumor tissue	Targeted genomic sequence analysis, solid organ neoplasm, dna analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements , microsatellite instability and tumor mutational burden

2026	0038U		20260101	N	\$29.60	Measurement of vitamin D in serum	Vitamin d, 25 hydroxy d2 and d3, by lc-ms/ms, serum microsample, quantitative
2026	0039U		20260101	N	\$13.74	Testing for anti-DNA antibody	Deoxyribonucleic acid (dna) antibody, double stranded, high avidity
2026	0040U		20260101	N	\$409.90	Gene analysis (t(9;22)) for translocation analysis	Bcr/abl1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative
2026	0041U		20260101	N	\$17.21	IgM antibody detection test for Borrelia burgdorferi	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, igm

2026	0042U		20260101	N	\$17.21	IgG antibody detection test for Borrelia burgdorferi	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, igg
2026	0043U		20260101	N	\$14.86	IgM antibody detection test for Tick-Borne Relapsing Fever Borrelia group (IgM)	Tick-borne relapsing fever borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, igm
2026	0044U		20260101	N	\$14.86	IgM antibody detection test for Tick-Borne Relapsing Fever Borrelia group (IgG)	Tick-borne relapsing fever borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, igg

2026	0045U		20260101	N	\$3,873.00	mRNA gene analysis of 12 genes in breast ductal carcinoma in situ tumor tissue	Oncology (breast ductal carcinoma in situ), mrna, gene expression profiling by real-time rt-pcr of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score
2026	0046U		20260101	N	\$407.43	Gene analysis (fms-related tyrosine kinase 3) for internal tandem duplication	FIt3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (itd) variants, quantitative

2026	0047U		20260101	N	\$3,873.00	mRNA gene analysis of 17 genes in prostate tumor tissue	Oncology (prostate), mrna, gene expression profiling by real-time rt-pcr of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score
------	-------	--	----------	---	------------	---	---

2026	0048U		20260101	N	\$2,919.60	DNA gene analysis of 468 genes in solid organ tumor tissue	Oncology (solid organ neoplasia), dna, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)
2026	0049U		20260101	N	\$407.43	Gene analysis (nucleophosmin)	Npm1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative

2026	0050U		20260101	N	\$2,916.60	DNA gene analysis of targeted sequences in 194 genes for acute myelogenous	Targeted genomic sequence analysis panel, acute myelogenous leukemia, dna analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements
2026	0051U		20260101	N	\$246.92	Testing for presence of 31 prescription drugs in urine or blood specimen	Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrometry (lc-ms/ms), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service

2026	0052U		20260101	N	\$33.86	Measurement of all five major lipoprotein classes and subclasses in blood	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of hdl, ldl, and vldl by vertical auto profile ultracentrifugation
------	-------	--	----------	---	---------	---	--

2026	0054U		20260101	N	\$198.74	Measurement of 14 or more drug classes in capillary blood	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service
2026	0055U		20260101	N	\$3,240.00	DNA gene analysis of 96 target sequences in plasma for heart transplant	Cardiology (heart transplant), cell-free dna, pcr assay of 96 dna target sequences (94 single nucleotide polymorphism targets and two control targets), plasma

2026	0058U		20260101	N	\$322.96	Measurement of antibodies to Merkel cell polyoma virus oncoprotein in serum	Oncology (merkel cell carcinoma), detection of antibodies to the merkel cell polyoma virus oncoprotein (small t antigen), serum, quantitative
2026	0059U		20260101	N	\$322.96	Test for presence of antibodies to Merkel cell polyoma virus oncoprotein in	Oncology (merkel cell carcinoma), detection of antibodies to the merkel cell polyoma virus capsid protein (vp1), serum, reported as positive or negative
2026	0060U		20260101	N	\$759.05	Gene analysis for identical twins in maternal blood	Twin zygosity, genomic-targeted sequence analysis of chromosome 2, using circulating cell-free fetal dna in maternal blood

2026	0061U		20260101	N	\$25.10	Spatial frequency domain imaging of skin	Transcutaneous measurement of five biomarkers (tissue oxygenation [sto2], oxyhemoglobin [ctho2], deoxyhemoglobin [cthr], papillary and reticular dermal hemoglobin concentrations [cthb1 and cthb2]), using spatial frequency domain imaging (sfdi) and multi-spectral analysis
2026	0062U		20260101	N	\$380.72	IgG and IgM analysis of 80 biomarkers of systemic lupus erythematosus in serum	Autoimmune (systemic lupus erythematosus) , igg and igm analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score

2026	0063U		20260101	N	\$750.00	Testing for amines associated with autism spectrum disorder in plasma	Neurology (autism), 32 amines by lc-ms/ms, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder
2026	0064U		20260101	N	\$31.33	Antibody testing for syphilis	Antibody, treponema pallidum, total and rapid plasma reagin (rpr), immunoassay, qualitative
2026	0065U		20260101	N	\$18.09	Non-antibody testing for syphilis	Syphilis test, non-treponemal antibody, immunoassay, qualitative (rpr)

2026	0067U		20260101	N	\$1,897.00	Protein expression profiling of 4 biomarkers of breast cancer in precancerous	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [mmp-1], carcinoembryonic antigen-related cell adhesion molecule 6 [ceacam6], hyaluronoglucosaminidase [hyal1], highly expressed in cancer protein [hec1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score
------	-------	--	----------	---	------------	---	---

2026	0068U		20260101	N	\$142.63	Detection of Candida species by amplified probe	Candida species panel (c. albicans, c. glabrata, c. parapsilosis, c. kruseii, c. tropicalis, and c. auris), amplified probe technique with qualitative report of the presence or absence of each species
2026	0069U		20260101	N	\$380.00	mRNA expression profiling of miR-31-3 in colon tumor tissue	Oncology (colorectal), microrna, rt-pcr expression profiling of mir-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression sco

2026	0070U		20260101	N	\$676.37	Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) for	Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4n, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14a, *14b, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xn)
2026	0071U		20260101	N	\$600.00	Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) full	Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (list separately in addition to code for primary procedure)

2026	0072U		20260101	N	\$450.91	Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted	Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, cyp2d6-2d7 hybrid gene) (list separately in addition to code for primary procedure)
2026	0073U		20260101	N	\$450.91	Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted	Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, cyp2d7-2d6 hybrid gene) (list separately in addition to code for primary procedure)

2026	0074U		20260101	N	\$450.91	Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted	Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (list separately in addition to code for primary procedure)
------	-------	--	----------	---	----------	--	---

2026	0075U		20260101	N	\$450.91	Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted	Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5' gene duplication/multiplication) (list separately in addition to code for primary procedure)
------	-------	--	----------	---	----------	--	---

2026	0076U		20260101	N	\$450.91	Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) targeted	Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3' gene duplication/ multiplication) (list separately in addition to code for primary procedure)
2026	0077U		20260101	N	\$43.43	Detection of Immunoglobulin paraprotein (M-protein) in blood or urine	Immunoglobulin paraprotein (m-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype

2026	0080U		20260101	N	\$3,520.00	Analysis of galectin-3-binding protein and scavenger receptor cysteine-rich	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein m130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy
------	-------	--	----------	---	------------	---	---

2026	0082U		20260101	N	\$246.92	Definitive drug testing for 90 or more drugs in urine	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service
------	-------	--	----------	---	----------	---	--

2026	0083U		20260101	N	\$167.35	Evaluation of response to chemotherapy drugs using motility contrast tomography	Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations
2026	0084U		20260101	N	\$720.00	DNA red blood cell antigen typing	Red blood cell antigen typing, dna, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens

2026	0086U		20260101	N	\$200.00	FISH identification of organisms in blood culture	Infectious disease (bacterial and fungal), organism identification, blood culture, using rrna fish, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (mic)-based antimicrobial susceptibility
2026	0087U		20260101	N	\$3,159.42	mRNA gene expression profiling of genes in heart transplant biopsy tissue to	Cardiology (heart transplant), mrna gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score

2026	0088U		20260101	N	\$3,159.42	mRNA gene expression profiling of genes in kidney transplant tissue to evaluate	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection
2026	0089U		20260101	N	\$760.00	Gene expression profiling of melanoma in superficial sample collected by	Oncology (melanoma), gene expression profiling by rtqpcr, prame and linc00518, superficial collection using adhesive patch (es)

2026	0090U		20260101	N	\$1,950.00	mRNA gene expression profiling of 23 genes in skin melanoma tissue sample	Oncology (cutaneous melanoma), mrna gene expression profiling by rt-pcr of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)
2026	0092U		20260101	N	\$2,488.00	Measurement of 3 protein biomarkers for lung cancer in plasma	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy

2026	0093U		20260101	N	\$62.14	Prescription drug monitoring for 65 common drugs in urine	Prescription drug monitoring, evaluation of 65 common drugs by lc-ms/ms, urine, each drug reported detected or not detected
2026	0094U		20260101	N	\$7,582.20	Rapid sequence gene testing	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis

2026	0095U		20260101	N	\$771.98	Test for markers of eosinophilic inflammation of esophagus	Eosinophilic esophagitis, 2 protein biomarkers (eotaxin-3 [ccl26 {c-c motif chemokine ligand 26}] and major basic protein [prg2 {proteoglycan 2, pro eosinophil major basic protein}], enzyme-linked immunosorbent assays (elisa), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis
------	-------	--	----------	---	----------	--	---

2026	0096U		20260101	N	\$35.09	Test for detection of high-risk human papillomavirus in male urine	Human papillomavirus (hpv), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine
------	-------	--	----------	---	---------	--	--

2026	0101U		20260101	N	\$1,743.95	Gene sequence analysis panel of 15 genes associated with hereditary colon	Hereditary colon cancer disorders (eg, lynch syndrome, pten hamartoma syndrome, cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of ngs, sanger, mlpa, and array cgh, with mmrna analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], epcam and grem1 [deletion/duplication only])
------	-------	--	----------	---	------------	---	---

2026	0102U		20260101	N	\$1,303.95	Gene sequence analysis panel of 17 genes associated with hereditary breast	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of ngs, sanger, mlpa, and array cgh, with mmrna analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])
------	-------	--	----------	---	------------	--	--

2026	0103U		20260101	N	\$1,743.95	Gene sequence analysis panel of 24 genes associated with hereditary ovarian	Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of ngs, sanger, mlpa, and array cgh, with mmrna analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], epcam [deletion/duplication only])
------	-------	--	----------	---	------------	---	--

2026	0105U		20260101	N	\$950.00	Measurement of tumor necrosis factor receptor 1A, receptor superfamily 2	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (eclia) of tumor necrosis factor receptor 1a, receptor superfamily 2 (tnfr1, tnfr2), and kidney injury molecule-1 (kim-1) combined with longitudinal clinical data, including apol1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (rkfd)
------	-------	--	----------	---	----------	--	---

2026	0106U		20260101	N	\$874.49	Evaluation of gastric emptying by measurement of radiolabeled carbon dioxide in	Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13c) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13co2 excretion
2026	0107U		20260101	N	\$16.00	Antigen test for detection of Clostridium difficile toxin in stool	Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method

2026	0108U		20260101	N	\$4,950.00	Computer-assisted digital imaging of esophagus specimen slides to evaluate risk	Gastroenterology (barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, amacr, p53, cd68, cox-2, cd45ro, hif1a, her-2, k20) and morphology, formalin-fixed paraffinembedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer
------	-------	--	----------	---	------------	---	---

2026	0109U		20260101	N	\$142.63	DNA test for detection of 4 Aspergillus species	Infectious disease (aspergillus species), real-time pcr for detection of dna from 4 species (a. fumigatus, a. terreus, a. niger, and a. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species
------	-------	--	----------	---	----------	---	---

2026	0110U		20260101	N	\$27.11	Monitoring of anti-cancer drugs in patient blood, serum, or plasma	Prescription drug monitoring, one or more oral oncology drug (s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug (s) when detected
2026	0111U		20260101	N	\$682.29	Gene analysis (KRAS and NRAS) in prostate tumor tissue	Oncology (colon cancer), targeted kras (codons 12, 13, and 61) and nras (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue

2026	0112U		20260101	N	\$356.13	Gene analysis for detection of infectious agent and drug resistance gene	Infectious agent detection and identification, targeted sequence analysis (16s and 18s rna genes) with drugresistance gene
2026	0113U		20260101	N	\$760.00	Measurement of PCA3 gene in urine and prostate-specific antigen (PSA) in serum	Oncology (prostate), measurement of pca3 and tmprss2-erg in urine and psa in serum following prostatic massage, by rna amplification and fluorescencebased detection, algorithm reported as risk score

2026	0114U		20260101	N	\$1,938.01	Gene analysis (VIM and CCNA1 methylation) in esophageal cells to evaluate	Gastroenterology (barrett's esophagus), vim and ccna1 methylation analysis, esophageal cells, algorithm reported as likelihood for barrett's esophagus
2026	0115U		20260101	N	\$275.35	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral	Respiratory infectious agent detection by nucleic acid (dna and rna), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for rna targets, each analyte reported as detected or not detected

2026	0116U		20260101	N	\$246.92	Analysis of 35 or more drugs in mouth fluid to evaluate risk of prescription	Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with lc-ms/ms, oral fluid, algorithm results reported as a patient compliance measurement with risk of drug to drug interactions for prescribed medications
------	-------	--	----------	---	----------	--	--

2026	0117U		20260101	N	\$840.65	Analysis of 11 biochemical substances in urine to evaluate likelihood of	Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5hydroxyindole acetic acid, hydroxymethylg lutarate, ethylmalonate, 3hydroxypropyl mercapturic acid (3-hpma), quinolinic acid, kynurenic acid), lcms/ms, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain
------	-------	--	----------	---	----------	--	--

2026	0118U		20260101	N	\$2,753.25	Measurement of transplant donor cell-free DNA in transplant recipient plasma	Transplantation medicine, quantification of donor-derived cell-free dna using whole genome next-generation sequencing, plasma, reported as percentage of donorderived cell-free dna in the total cell-free dna
2026	0119U		20260101	N	\$83.76	Measurement of ceramides for assessment of heart disease risk	Cardiology, ceramides by liquid chromatograph y-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events

2026	0120U		20260101	N	\$2,510.21	mRNA, gene expression profiling of 58 genes in tissue sample for B-cell	Oncology (b-cell lymphoma classification), mrna, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal b-cell lymphoma (pmbcl) and diffuse large b-cell lymphoma (dlbcl) with cell of origin subtyping in the latter
2026	0121U		20260101	N	\$509.20	Blood test for sickle cells using VCAM-1	Sickle cell disease, microfluidic flow adhesion (vcam-1), whole blood

2026	0122U		20260101	N	\$526.23	Blood test for sickle cells using P-Selectin	Sickle cell disease, microfluidic flow adhesion (p-selectin), whole blood
2026	0123U		20260101	N	\$357.63	Test for fragility of red blood cells	Mechanical fragility, rbc, shear stress and spectral analysis profiling
2026	0129U		20260101	N	\$1,303.95	Gene analysis of genes associated with hereditary breast cancer and related	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (atm, brca1, brca2, cdh1, chek2, palb2, pten, and tp53)

2026	0130U		20260101	N	\$584.90	Targeted mRNA sequence analysis of genes associated with hereditary colon	Hereditary colon cancer disorders (eg, lynch syndrome, pten hamartoma syndrome, cowden syndrome, familial adenomatosis polyposis), targeted mrna sequence analysis panel (apc, cdh1, chek2, mlh1, msh2, msh6, mutyh, pms2, pten, and tp53) (list separately in addition to code for primary procedure)
------	-------	--	----------	---	----------	---	--

2026	0133U		20260101	N	\$690.29	Targeted mRNA sequence analysis of 11 genes associated with hereditary prostate	Hereditary prostate cancer-related disorders, targeted mrna sequence analysis panel (11 genes) (list separately in addition to code for primary procedure)
2026	0134U		20260101	N	\$748.39	Targeted mRNA sequence analysis of 18 genes associated with hereditary pan	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mrna sequence analysis panel (18 genes) (list separately in addition to code for primary procedure)

2026	0136U		20260101	N	\$407.43	mRNA gene analysis (ataxia telangiectasia mutated)	Atm (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mrna sequence analysis (list separately in addition to code for primary procedure)
2026	0137U		20260101	N	\$282.88	mRNA gene analysis (partner and localizer of BRCA2)	Palb2 (partner and localizer of brca2) (eg, breast and pancreatic cancer) mrna sequence analysis (list separately in addition to code for primary procedure)

2026	0138U		20260101	N	\$468.33	mRNA gene analysis (BRCA1, DNA repair associated and BRCA2, DNA repair	Brca1 (brca1, dna repair associated), brca2 (brca2, dna repair associated) (eg, hereditary breast and ovarian cancer) mrna sequence analysis (list separately in addition to code for primary procedure)
2026	0140U		20260101	N	\$156.75	Amplified DNA probe detection of fungus in blood culture specimen	Infectious disease (fungi), fungal pathogen identification, dna (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected

2026	0141U		20260101	N	\$156.75	Amplified DNA probe detection of 20 gram-positive bacterial targets, 4	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, dna (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan candida target), blood culture, amplified probe technique, each target reported as detected or not detected
------	-------	--	----------	---	----------	--	--

2026	0142U		20260101	N	\$156.75	Amplified DNA probe detection of 20 gram-positive bacterial targets, 6	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, dna (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan candida target), amplified probe technique, each target reported as detected or not detected
------	-------	--	----------	---	----------	--	--

2026	0152U		20260101	N	\$2,126.20	Cell-free DNA sequencing of disease-causing organisms in plasma specimen, with	Infectious disease (bacteria, fungi, parasites, and dna viruses), microbial cell-free dna, plasma, untargeted next-generation sequencing, report for significant positive pathogens
2026	0153U		20260101	N	\$3,159.42	mRNA gene expression profiling of 101 genes in breast growth tissue specimen	Oncology (breast), mrna, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype (s) with information on immune cell involvement

2026	0154U		20260101	N	\$482.14	RNA gene analysis for detection of fibroblast growth factor receptor 3 gene	Oncology (urothelial cancer), rna, analysis by real-time rt-pcr of the fgfr3 (fibroblast growth factor receptor 3) gene analysis (ie, p.r248c [c.742c>t], p.s249c [c.746c>g], p.g370c [c.1108g>t], p.y373c [c.1118a>g], fgfr3-tacc3v1, and fgfr3-tacc3v3) utilizing formalin-fixed paraffin-embedded urothelial cancer tumor tissue, reported as fgfr gene alteration status
------	-------	--	----------	---	----------	---	--

2026	0155U		20260101	N	\$274.83	DNA analysis for detection of PIK3CA gene mutation in breast growth tissue	Oncology (breast cancer), dna, pik3ca (phosphatidylinositol-4,5 bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.c420r, p.e542k, p.e545a, p.e545d [g.1635g>t only], p.e545g, p.e545k, p.q546e, p.q546r, p.h1047l, p.h1047r, p.h1047y), utilizing formalin-fixed paraffin-embedded breast tumor tissue, reported as pik3ca gene mutation status
2026	0156U		20260101	N	\$1,740.00	Gene analysis copy number sequence analysis	Copy number (eg, intellectual disability, dysmorphology), sequence analysis

2026	0157U		20260101	N	\$282.88	mRNA gene analysis of APC regulator of WNT signaling pathway	Apc (apc regulator of wnt signaling pathway) (eg, familial adenomatosis polyposis [fap]) mrna sequence analysis (list separately in addition to code for primary procedure)
2026	0158U		20260101	N	\$282.88	mRNA gene analysis of mutL homolog 1	Mlh1 (mutl homolog 1) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure)

2026	0159U		20260101	N	\$282.88	mRNA gene analysis of mutS homolog 2	Msh2 (muts homolog 2) (eg, hereditary colon cancer, lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure)
2026	0160U		20260101	N	\$282.88	mRNA gene analysis of mutS homolog 6	Msh6 (muts homolog 6) (eg, hereditary colon cancer, lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure)

2026	0161U		20260101	N	\$282.88	mRNA gene analysis of PMS1 homolog 2, mismatch repair system component	Pms2 (pms1 homolog 2, mismatch repair system component) (eg, hereditary nonpolyposis colorectal cancer, lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure)
2026	0162U		20260101	N	\$486.54	Targeted mRNA sequence analysis for genes associated with hereditary colon	Hereditary colon cancer (lynch syndrome), targeted mrna sequence analysis panel (mlh1, msh2, msh6, pms2) (list separately in addition to code for primary procedure)

2026	0163U		20260101	N	\$390.75	Screening test for 3 protein biomarkers of colorectal cancer in serum or plasma	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (elisa) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [tdgf-1, cripto-1], carcinoembryonic antigen [cea], extracellular matrix protein [ecm]), with demographic data (age, gender, crc-screening compliance) using a proprietary algorithm and reported as likelihood of crc or advanced adenomas
------	-------	--	----------	---	----------	---	---

2026	0164U		20260101	N	\$112.02	Test for detection of antibodies associated with irritable bowel syndrome in	Gastroenterology (irritable bowel syndrome [ibs]), immunoassay for anti-cdtb and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results
2026	0165U		20260101	N	\$463.76	Test for detection of antigens associated with peanut allergy in blood	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (elisa), blood, individual epitope results and probability of peanut allergy

2026	0166U		20260101	N	\$503.40	Liver disease test panel in serum specimen	Liver disease, 10 biochemical assays (a2-macroglobulin, haptoglobin, apolipoprotein a1, bilirubin, ggt, alt, ast, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation
2026	0169U		20260101	N	\$466.17	Gene analysis (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase)	Nudt15 (nudix hydrolase 15) and tpmt (thiopurine s-methyltransferase) (eg, drug metabolism) gene analysis, common variants

2026	0170U		20260101	N	\$1,950.00	RNA gene sequencing for probability of autism spectrum disorder in saliva	Neurology (autism spectrum disorder [asd]), rna, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of asd diagnosis
2026	0171U		20260101	N	\$1,519.06	DNA analysis of targeted sequences in 23 genes for detection of abnormalites	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, dna analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence

2026	0172U		20260101	N	\$3,030.00	DNA gene analysis (BRCA1, DNA repair associated and BRCA2, DNA repair	Oncology (solid tumor as indicated by the label), somatic mutation analysis of brca1 (brca1, dna repair associated), brca2 (brca2, dna repair associated) and analysis of homologous recombination deficiency pathways, dna, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score
2026	0173U		20260101	N	\$466.17	Gene analysis panel for detection of variants in 14 genes associated with	Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes

2026	0174U		20260101	N	\$1,305.37	Mass spectrometry testing for 30 protein targets in tissue specimen to predict	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents
2026	0175U		20260101	N	\$1,336.09	Gene analysis panel for detection of variants in 15 genes associated with	Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes
2026	0176U		20260101	N	\$64.19	Test for detection of IgG antibodies associated with irritable bowel syndrome	Cytotoxic distending toxin b (cdtb) and vinculin igg antibodies by immunoassay (ie, elisa)

2026	0177U		20260101	N	\$274.83	DNA gene analysis (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic	Oncology (breast cancer), dna, pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as pik3ca gene mutation status
2026	0178U		20260101	N	\$459.86	Test for detection of antigens associated with peanut allergy in blood	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (elisa), blood, report of minimum eliciting exposure for a clinical reaction

2026	0179U		20260101	N	\$1,943.21	Cell-free DNA analysis of targeted sequences in 23 genes for detection of	Oncology (non-small cell lung cancer), cell-free dna, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)
------	-------	--	----------	---	------------	---	--

2026	0180U		20260101	N	\$274.83	Red blood cell antigen genotyping, ABO blood group	Red cell antigen (abo blood group) genotyping (abo), gene analysis sanger/chain termination/conventional sequencing, abo (abo, alpha 1-3-n-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons
2026	0181U		20260101	N	\$185.20	Red blood cell antigen genotyping, Colton blood group	Red cell antigen (colton blood group) genotyping (co), gene analysis, aqp1 (aquaporin 1 [colton blood group]) exon 1

2026	0182U		20260101	N	\$301.35	Red blood cell antigen genotyping, CD55 molecule [Cromer blood group] exons 1-10	Red cell antigen (cromer blood group) genotyping (crom), gene analysis, cd55 (cd55 molecule [cromer blood group]) exons 1-10
2026	0183U		20260101	N	\$185.20	Red blood cell antigen genotyping, solute carrier family 4 member 1 [Diego	Red cell antigen (diego blood group) genotyping (di), gene analysis, slc4a1 (solute carrier family 4 member 1 [diego blood group]) exon 19
2026	0184U		20260101	N	\$185.20	Red blood cell antigen genotyping, ADP-ribosyltransferase 4 [Dombrock blood	Red cell antigen (dombrock blood group) genotyping (do), gene analysis, art4 (adp-ribosyltransferase 4 [dombrock blood group]) exon 2

2026	0185U		20260101	N	\$185.20	Red blood cell antigen genotyping, fucosyltransferase 1 [H blood group] exon 4	Red cell antigen (h blood group) genotyping (fut1), gene analysis, fut1 (fucosyltransferase 1 [h blood group]) exon 4
2026	0186U		20260101	N	\$185.20	Red blood cell antigen genotyping, fucosyltransferase 2 [H blood group] exon 2	Red cell antigen (h blood group) genotyping (fut2), gene analysis, fut2 (fucosyltransferase 2) exon 2
2026	0187U		20260101	N	\$274.83	Red blood cell antigen genotyping, atypical chemokine receptor 1 [Duffy blood	Red cell antigen (duffy blood group) genotyping (fy), gene analysis, ackr1 (atypical chemokine receptor 1 [duffy blood group]) exons 1-2
2026	0188U		20260101	N	\$274.83	Red blood cell antigen genotyping, glycoporphin C [Gerbich blood group] exons 1-4	Red cell antigen (gerbich blood group) genotyping (ge), gene analysis, gypc (glycophorin c [gerbich blood group]) exons 1-4

2026	0189U		20260101	N	\$274.83	Red blood cell antigen genotyping, glycophorin A [MNS blood group] introns 1,	Red cell antigen (mns blood group) genotyping (gypa), gene analysis, gypa (glycophorin a [mns blood group]) introns 1, 5, exon 2
2026	0190U		20260101	N	\$274.83	Red blood cell antigen genotyping, glycophorin B [MNS blood group] introns 1,	Red cell antigen (mns blood group) genotyping (gypb), gene analysis, gypb (glycophorin b [mns blood group]) introns 1, 5, pseudoexon 3
2026	0191U		20260101	N	\$274.83	Red blood cell antigen genotyping, CD44 molecule [Indian blood group] exons 2,	Red cell antigen (indian blood group) genotyping (in), gene analysis, cd44 (cd44 molecule [indian blood group]) exons 2, 3, 6

2026	0192U		20260101	N	\$274.83	Red blood cell antigen genotyping, solute carrier family 14 member 1 [Kidd	Red cell antigen (kidd blood group) genotyping (jk), gene analysis, slc14a1 (solute carrier family 14 member 1 [kidd blood group]) gene promoter, exon 9
2026	0193U		20260101	N	\$282.88	Red blood cell antigen genotyping, ATP binding cassette subfamily G member 2	Red cell antigen (jr blood group) genotyping (jr), gene analysis, abcg2 (atp binding cassette subfamily g member 2 [junior blood group]) exons 2-26
2026	0194U		20260101	N	\$185.20	Red blood cell antigen genotyping, Kell metallo-endopeptidase [Kell blood	Red cell antigen (kell blood group) genotyping (kel), gene analysis, kel (kell metallo-endopeptidase [kell blood group]) exon 8

2026	0195U		20260101	N	\$375.25	Gene analysis (Kruppel-like factor 1) targeted sequence analysis	Klf1 (kruppel-like factor 1), targeted sequencing (ie, exon 13)
2026	0196U		20260101	N	\$185.20	Red blood cell antigen genotyping, basal cell adhesion molecule [Lutheran blood	Red cell antigen (lutheran blood group) genotyping (lu), gene analysis, bcam (basal cell adhesion molecule [lutheran blood group]) exon 3
2026	0197U		20260101	N	\$185.20	Red blood cell antigen genotyping, intercellular adhesion molecule 4	Red cell antigen (landsteiner-wiener blood group) genotyping (lw), gene analysis, icam4 (intercellular adhesion molecule 4 [landsteiner-wiener blood group]) exon 1

2026	0198U		20260101	N	\$282.88	Red blood cell antigen genotyping, Rh blood group D antigen exons 1-10 and Rh	Red cell antigen (rh blood group) genotyping (rhd and rhce), gene analysis sanger/chain termination/conventional sequencing, rhd (rh blood group d antigen) exons 1-10 and rhce (rh blood group ccee antigens) exon 5
2026	0199U		20260101	N	\$274.83	Red blood cell antigen genotyping, erythroblast membrane associated protein	Red cell antigen (scianna blood group) genotyping (sc), gene analysis, ermap (erythroblast membrane associated protein [scianna blood group]) exons 4, 12
2026	0200U		20260101	N	\$274.83	Red blood cell antigen genotyping, X-linked Kx blood group exons 1-3	Red cell antigen (kx blood group) genotyping (xk), gene analysis, xk (x-linked kx blood group) exons 1-3

2026	0201U		20260101	N	\$185.20	Red blood cell antigen genotyping, acetylcholinesterase [Cartwright blood	Red cell antigen (yt blood group) genotyping (yt), gene analysis, ache (acetylcholinesterase [cartwright blood group]) exon 2
2026	0202U		20260101	N	\$416.78	Test for detection of respiratory disease-causing organisms from back of nose	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (dna or rna), 22 targets including severe acute respiratory syndrome coronavirus 2 (sars-cov-2), qualitative rt-pcr, nasopharyngeal swab, each pathogen reported as detected or not detected

2026	0203U		20260101	N	\$760.00	mRNA gene expression profiling of 17 genes in whole blood specimen for	Autoimmune (inflammatory bowel disease), mrna, gene expression profiling by quantitative rt-pcr, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness
------	-------	--	----------	---	----------	--	---

2026	0205U		20260101	N	\$47.00	Gene analysis for detection of variants in 3 genes in cheek swab specimen for	Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 cfh gene, 1 arms2 gene), using pcr and maldi-tof, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements
------	-------	--	----------	---	---------	---	---

2026	0206U		20260101	N	\$2,215.40	Cell aggregation testing of cultured skin cells for Alzheimer disease, reported	Neurology (alzheimer disease); cell aggregation using morphometric imaging and protein kinase c-epsilon (pkce) concentration in response to amylospheroid treatment by elisa, cultured skin fibroblasts, each reported as positive or negative for alzheimer disease
------	-------	--	----------	---	------------	---	--

2026	0207U		20260101	N	\$511.20	Immunofluorescence testing of cultured skin cells for Alzheimer disease,	Neurology (alzheimer disease); quantitative imaging of phosphorylated erk1 and erk2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for alzheimer disease (list separately in addition to code for primary procedure)
------	-------	--	----------	---	----------	--	---

2026	0209U		20260101	N	\$787.15	Cytogenomic analysis of whole genome for abnormal chromosomes	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities
2026	0210U		20260101	N	\$18.63	Measurement of nontreponemal antibodies associated with syphilis	Syphilis test, non-treponemal antibody, immunoassay, quantitative (rpr)

2026	0211U		20260101	N	\$8,455.00	Next-generation sequencing of DNA and RNA in tumor tissue specimen with	Oncology (pan-tumor), dna and rna by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association
------	-------	--	----------	---	------------	---	--

2026	0212U		20260101	N	\$5,475.20	Rare diseases genetic testing of complete DNA of first affected person in family	Rare diseases (constitutional/ heritable disorders), whole genome and mitochondrial dna sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband
------	-------	--	----------	---	------------	--	---

2026	0213U		20260101	N	\$2,709.95	Rare diseases genetic testing of complete DNA of relative of affected person in	Rare diseases (constitutional/ heritable disorders), whole genome and mitochondrial dna sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling)
------	-------	--	----------	---	------------	---	--

2026	0214U		20260101	N	\$5,224.60	Rare diseases genetic testing of protein coding genes of first affected person	Rare diseases (constitutional/ heritable disorders), whole exome and mitochondrial dna sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband
------	-------	--	----------	---	------------	--	--

2026	0215U		20260101	N	\$2,574.65	Rare diseases genetic testing of protein coding genes of relative of affected	Rare diseases (constitutional/ heritable disorders), whole exome and mitochondrial dna sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling)
------	-------	--	----------	---	------------	---	--

2026	0216U		20260101	N	\$1,537.02	DNA analysis of gene sequence of 12 genes for identification and	Neurology (inherited ataxias), genomic dna sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants
------	-------	--	----------	---	------------	--	---

2026	0217U		20260101	N	\$2,198.35	DNA analysis of gene sequence of 51 genes for identification and	Neurology (inherited ataxias), genomic dna sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants
------	-------	--	----------	---	------------	--	--

2026	0218U		20260101	N	\$2,279.00	DNA analysis of gene sequence for identification and characterization of	Neurology (muscular dystrophy), dmd gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants
------	-------	--	----------	---	------------	--	--

2026	0219U		20260101	N	\$725.00	Gene analysis of human immunodeficiency virus targeted sequence analysis for	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [pr], reverse transcriptase [rt], integrase [int]), algorithm reported as prediction of antiviral drug susceptibility
2026	0220U		20260101	N	\$706.25	Image analysis of breast cancer cell specimen with artificial intelligence	Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score

2026	0221U		20260101	N	\$274.83	Red blood cell antigen genotyping, ABO, alpha	Red cell antigen (abo blood group) genotyping (abo), gene analysis, next-generation sequencing, abo (abo, alpha 1-3-n-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene
2026	0222U		20260101	N	\$282.88	Red blood cell antigen genotyping, RH proximal promoter, exons 1-10, portions	Red cell antigen (rh blood group) genotyping (rhd and rhce), gene analysis, next-generation sequencing, rh proximal promoter, exons 1-10, portions of introns 2-3

2026	0223U		20260101	N	\$416.78	Test for detection of respiratory disease-causing organisms from back of nose	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (dna or rna), 22 targets including severe acute respiratory syndrome coronavirus 2 (sars-cov-2), qualitative rt-pcr, nasopharyngeal swab, each pathogen reported as detected or not detected
2026	0224U		20260101	N	\$51.43	Measurement of antibody to severe acute respiratory syndrome coronavirus 2	Antibody, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), includes titer(s), when performed

2026	0225U		20260101	N	\$416.78	Test for detection of respiratory disease-causing organisms, 21 target	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific dna and rna, 21 targets, including severe acute respiratory syndrome coronavirus 2 (sars-cov-2), amplified probe technique, including multiplex reverse transcription for rna targets, each analyte reported as detected or not detected
2026	0226U		20260101	N	\$42.28	Surrogate viral neutralization test (sVNT) for detection of antibodies to	Surrogate viral neutralization test (svnt), severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), elisa, plasma, serum

2026	0227U		20260101	N	\$62.14	Presumptive drug testing for 30 or more drugs in urine	Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring (mrm), with drug or metabolite description, includes sample validation
------	-------	--	----------	---	---------	--	---

2026	0228U		20260101	N	\$173.03	Detection test by photometric technique for macromolecules in urine to evaluate	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer
2026	0229U		20260101	N	\$384.00	Gene analysis (branched chain amino acid transaminase 1 and IKAROS family zinc	Bcat1 (branched chain amino acid transaminase 1) and ikzf1 (ikaros family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis

2026	0230U		20260101	N	\$301.35	Gene analysis (androgen receptor), full sequence analysis	Ar (androgen receptor) (eg, spinal and bulbar muscular atrophy, kennedy disease, x chromosome inactivation), full sequence analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (str) expansions, mobile element insertions, and variants in non-uniquely mappable regions
------	-------	--	----------	---	----------	---	---

2026	0231U		20260101	N	\$846.27	Gene analysis (calcium voltage-gated channel subunit alpha 1A), full gene	Cacna1a (calcium voltage-gated channel subunit alpha 1a) (eg, spinocerebellar ataxia), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (str) gene expansions, mobile element insertions, and variants in non-uniquely mappable regions
------	-------	--	----------	---	----------	---	--

2026	0232U		20260101	N	\$274.83	Gene analysis (cystatin B), full gene analysis	Cstb (cystatin b) (eg, progressive myoclonic epilepsy type 1a, unverricht-lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (str) expansions, mobile element insertions, and variants in non-uniquely mappable regions
------	-------	--	----------	---	----------	--	---

2026	0233U		20260101	N	\$274.83	Gene analysis (frataxin)	Fxn (frataxin) (eg, friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (str) expansions, mobile element insertions, and variants in non-uniquely mappable regions
------	-------	--	----------	---	----------	--------------------------	---

2026	0234U		20260101	N	\$527.87	Gene analysis (methyl CpG binding protein 2), full gene analysis	Mecp2 (methyl cpg binding protein 2) (eg, rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
------	-------	--	----------	---	----------	--	--

2026	0235U		20260101	N	\$600.00	Gene analysis (phosphatase and tensin homolog), full gene analysis	Pten (phosphatase and tensin homolog) (eg, cowden syndrome, pten hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
------	-------	--	----------	---	----------	--	--

2026	0236U		20260101	N	\$602.70	Gene analysis (survival of motor neuron 1, telomeric and survival of motor	Smn1 (survival of motor neuron 1, telomeric) and smn2 (survival of motor neuron 2, centromeric) (eg, spinal muscular atrophy) full gene analysis, including small sequence changes in exonic and intronic regions, duplications and deletions, and mobile element insertions
------	-------	--	----------	---	----------	--	--

2026	0237U		20260101	N	\$584.90	Gene analysis for cardiac ion channelopathies, genomic sequence analysis	Cardiac ion channelopathies (eg, brugada syndrome, long qt syndrome, short qt syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including ank2, casq2, cav3, kcne1, kcne2, kcnh2, kcnj2, kcnq1, ryr2, and scn5a, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
------	-------	--	----------	---	----------	--	---

2026	0238U		20260101	N	\$584.90	DNA sequence analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM for Lynch syndrome	Oncology (lynch syndrome), genomic dna sequence analysis of mlh1, msh2, msh6, pms2, and epcam, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
------	-------	--	----------	---	----------	---	---

2026	0239U		20260101	N	\$3,500.00	Gene analysis of 311 or more genes associated with solid organ cancer in	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free dna, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements , and copy number variations
2026	0242U		20260101	N	\$5,000.00	Gene analysis of 55-74 genes associated with solid organ cancer in cell-free	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating dna analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements

2026	0243U		20260101	N	\$64.41	Time-resolved fluorescence immunoassay of placental-growth factor in maternal	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia
------	-------	--	----------	---	---------	---	---

2026	0244U		20260101	N	\$3,500.00	Gene analysis of 257 genes associated with solid organ cancer in tumor tissue	Oncology (solid organ), dna, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements , tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue
------	-------	--	----------	---	------------	---	---

2026	0245U		20260101	N	\$1,266.07	Gene analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers,	Oncology (thyroid), mutation analysis of 10 genes and 37 rna fusions and expression of 4 mrna markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage
2026	0246U		20260101	N	\$720.00	Blood typing for 16 or more blood groups with phenotype prediction of 51 or	Red blood cell antigen typing, dna, genotyping of at least 16 blood groups with phenotype prediction of at least 51 red blood cell antigens

2026	0247U		20260101	N	\$750.00	Quantitative measurement of insulin-like growth factor-binding protein 4 and	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (ibp4), sex hormone-binding globulin (shbg), quantitative measurement by lc-ms/ms, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth
2026	0248U		20260101	N	\$3,033.86	Culture of brain cancer cells to predict tumor response to a 12-drug panel	Oncology, spheroid cell culture in 3d microenvironment, 12-drug panel, brain- or brain metastasis-response prediction for each drug

2026	0249U		20260101	N	\$2,219.13	Analysis of 32 phosphoproteins and protein analytes associated with breast	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection , with algorithmic analysis and interpretative report
------	-------	--	----------	---	------------	--	---

2026	0250U		20260101	N	\$2,919.60	Gene analysis of 505 genes associated with solid organ cancer in tumor tissue	Oncology (solid organ neoplasm), targeted genomic sequence dna analysis of 505 genes, interrogation for somatic alterations (snvs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden
2026	0251U		20260101	N	\$17.27	ELISA assay for hepacidin-25 in serum or plasma	Hepcidin-25, enzyme-linked immunosorbent assay (elisa), serum or plasma

2026	0252U		20260101	N	\$759.05	Analysis of fetal DNA, short tandem-repeat comparative analysis, for abnormal	Fetal aneuploidy short tandem-repeat comparative analysis, fetal dna from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy
------	-------	--	----------	---	----------	---	---

2026	0253U		20260101	N	\$3,159.42	RNA gene expression profiling of 238 genes by next-generation sequencing	Reproductive medicine (endometrial receptivity analysis), rna gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)
------	-------	--	----------	---	------------	--	--

2026	0254U		20260101	N	\$759.05	Preimplantation genetic assessment of embryo by gene sequence analysis of 24	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic dna genomic sequence analysis for aneuploidy, and a mitochondrial dna score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy, per embryo tested
------	-------	--	----------	---	----------	--	---

2026	0255U		20260101	N	\$31.60	Evaluation of sperm using fluorescence microscopic evaluation of ganglioside	Andrology (infertility), sperm-capacitation assessment of ganglioside gm1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score
2026	0256U		20260101	N	\$159.95	Tandem mass spectroscopy (MS/MS) profile of trimethylamine /trimethylamine	Trimethylamine /trimethylamine n-oxide (tma/tmao) profile, liquid chromatography tandem mass spectrometry (lc-ms/ms), urine, with algorithmic analysis and interpretive report

2026	0257U		20260101	N	\$712.47	Evaluation of very long chain acyl-coenzyme A (CoA) dehydrogenase (VLCAD) white	Very long chain acyl-coenzyme a (coa) dehydrogenase (vlcad), leukocyte enzyme activity, whole blood
2026	0258U		20260101	N	\$3,675.00	mRNA gene expression profiling of 50-100 genes in skin surface specimen,	Autoimmune (psoriasis), mrna, nextgeneration sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics

2026	0259U		20260101	N	\$52.71	Nuclear MR spectroscopy measurement of myo-inositol, valine, and creatinine,	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin c (by immunoassay) and demographic data to determine estimated glomerular filtration rate (gfr), serum, quantitative
------	-------	--	----------	---	---------	--	---

2026	0260U		20260101	N	\$1,263.53	Optical genome mapping for detection of abnormalities associated with rare	Rare diseases (constitutional/ heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
2026	0261U		20260101	N	\$2,513.25	Image analysis with artificial intelligence assessment of 4 cellular and immune	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (cd3 and cd8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score

2026	0262U		20260101	N	\$3,200.00	mRNA gene expression profiling of 7 gene pathways in solid organ tumor tissue	Oncology (solid tumor), gene expression profiling by real-time rt-pcr of 7 gene pathways (er, ar, pi3k, mapk, hh, tgfb, notch), formalin-fixed paraffinembedded (ffpe), algorithm reported as gene pathway activity score
------	-------	--	----------	---	------------	---	---

2026	0263U		20260101	N	\$750.00	LC-MS/MS spectroscopy of 16 central carbon metabolites associated with autism	Neurology (autism spectrum disorder [asd]), quantitative measurements of 16 central carbon metabolites (ie, ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, s-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (lc-ms/ms), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of asd)
------	-------	--	----------	---	----------	---	---

2026	0264U		20260101	N	\$1,263.53	Detection of abnormalities associated with rare heritable diseases by optical	Rare diseases (constitutional/ heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
2026	0265U		20260101	N	\$5,475.80	Whole genome and mDNA sequence analysis for detection of abnormalities	Rare constitutional and other heritable disorders, whole genome and mitochondrial dna sequence analysis, blood, frozen and formalin-fixed paraffinembedded (ffpe) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants

2026	0266U		20260101	N	\$3,200.00	Gene expression profiling by whole transcriptome and next-generation sequencing	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (ffpe) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes
------	-------	--	----------	---	------------	---	--

2026	0267U		20260101	N	\$6,739.33	Optical genome mapping and whole genome sequencing for detection of	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing
2026	0268U		20260101	N	\$608.17	Genomic sequence analysis of 15 genes for detection of abnormalities associated	Hematology (atypical hemolytic uremic syndrome [ahus]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid

2026	0269U		20260101	N	\$608.17	Genomic sequence analysis of 22 genes for detection of abnormalities associated	Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 22 genes, blood, buccal swab, or amniotic fluid
2026	0270U		20260101	N	\$608.17	Genomic sequence analysis of 20 genes for detection of abnormalities associated	Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid
2026	0271U		20260101	N	\$608.17	Genomic sequence analysis of 24 genes for detection of abnormalities associated	Hematology (congenital neutropenia), genomic sequence analysis of 24 genes, blood, buccal swab, or amniotic fluid

2026	0272U		20260101	N	\$608.17	Comprehensive genomic sequence analysis of 60 genes for detection of	Hematology (genetic bleeding disorders), genomic sequence analysis of 60 genes and duplication/deletion of plau, blood, buccal swab, or amniotic fluid, comprehensive
2026	0273U		20260101	N	\$608.17	Genomic sequence analysis of 9 genes for detection of abnormalities associated	Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of 8 genes (f13a1, f13b, fga, fgb, fgg, serpina1, serpine1, serpinf2, plau), blood, buccal swab, or amniotic fluid

2026	0274U		20260101	N	\$608.17	Genomic sequence analysis of 62 genes for detection of abnormalities associated	Hematology (genetic platelet disorders), genomic sequence analysis of 62 genes and duplication/deletion of plau, blood, buccal swab, or amniotic fluid
2026	0275U		20260101	N	\$18.37	Flow cytometry detection of platelet antibody reactivity in serum for	Hematology (heparin-induced thrombocytopenia), platelet antibody reactivity by flow cytometry, serum
2026	0276U		20260101	N	\$2,448.56	Genomic sequence analysis of 42 genes for detection of abnormalities associated	Hematology (inherited thrombocytopenia), genomic sequence analysis of 42 genes, blood, buccal swab, or amniotic fluid

2026	0277U		20260101	N	\$608.17	Genomic sequence analysis of 40 genes for detection of abnormalities associated	Hematology (genetic platelet function disorder), genomic sequence analysis of 40 genes and duplication/deletion of plau, blood, buccal swab, or amniotic fluid
2026	0278U		20260101	N	\$608.17	Genomic sequence analysis of 14 genes for detection of abnormalities associated	Hematology (genetic thrombosis), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid
2026	0279U		20260101	N	\$11.53	ELISA detection of von Willebrand factor (VWF) and collagen III binding in	Hematology (von willebrand disease [vwd]), von willebrand factor (vwf) and collagen iii binding by enzyme-linked immunosorbent assays (elisa), plasma, report of collagen iii binding

2026	0280U		20260101	N	\$17.27	ELISA detection of von Willebrand factor (VWF) and collagen IV binding in	Hematology (von willebrand disease [vwd]), von willebrand factor (vwf) and collagen iv binding by enzyme-linked immunosorbent assays (elisa), plasma, report of collagen iv binding
2026	0281U		20260101	N	\$17.27	ELISA measurement of von Willebrand propeptide in plasma specimen, diagnostic	Hematology (von willebrand disease [vwd]), von willebrand propeptide, enzyme-linked immunosorbent assays (elisa), plasma, diagnostic report of von willebrand factor (vwf) propeptide antigen level

2026	0282U		20260101	N	\$720.00	Red blood cell antigen genotyping of 12 blood group system genes to predict 44	Red blood cell antigen typing, dna, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes
2026	0283U		20260101	N	\$18.40	Radioimmunoassay platelet-binding evaluation of von Willebrand factor (VWF),	Von willebrand factor (vwf), type 2b, platelet-binding evaluation, radioimmunoassay, plasma
2026	0284U		20260101	N	\$17.27	ELISA evaluation of von Willebrand factor (VWF), type 2N, factor VIII and VWF	Von willebrand factor (vwf), type 2n, factor viii and vwf binding evaluation, enzyme-linked immunosorbent assays (elisa), plasma

2026	0285U		20260101	N	\$443.31	Evaluation of response to radiation in cell-free DNA by quantitative branched	Oncology, disease progression and response monitoring to radiation, chemotherapy, or other systematic cancer treatments, cell-free dna, quantitative branched chain dna amplification, plasma, reported in ng/ml
2026	0286U		20260101	N	\$134.13	Gene analysis of centrosomal protein, 72-Kda (CEP72), nudix hydrolase 15	Cep72 (centrosomal protein, 72-kda), nudt15 (nudix hydrolase 15) and tpmt (thiopurine s-methyltransferase) (eg, drug metabolism) gene analysis, common variants

2026	0287U		20260101	N	\$3,600.00	Next-generation DNA and RNA sequencing of 112 genes in tumor specimen, with	Oncology (thyroid), dna and mrna, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (ffpe) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)
------	-------	--	----------	---	------------	---	--

2026	0288U		20260101	N	\$3,873.00	PCR measurement of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11,	Oncology (lung), mrna, quantitative pcr analysis of 11 genes (bag1, brca1, cdc6, cdk2ap1, erbb3, fut3, il11, lck, rnd3, sh3bgr, wnt3a) and 3 reference genes (esd, tbp, yap1), formalin-fixed paraffin-embedded (ffpe) tumor tissue, algorithmic interpretation reported as a recurrence risk score
2026	0289U		20260101	N	\$760.00	mRNA gene expression profiling of 24 genes in whole blood for detection of	Neurology (alzheimer disease), mrna, gene expression profiling by rna sequencing of 24 genes, whole blood, algorithm reported as predictive risk score

2026	0290U		20260101	N	\$760.00	mRNA gene expression profiling of 36 genes in whole blood for pain management	Pain management, mrna, gene expression profiling by rna sequencing of 36 genes, whole blood, algorithm reported as predictive risk score
2026	0291U		20260101	N	\$1,755.00	mRNA gene expression profiling of 144 genes in whole blood for detection of	Psychiatry (mood disorders), mrna, gene expression profiling by rna sequencing 144 genes, whole blood, algorithm reported as predictive risk score

2026	0292U		20260101	N	\$1,755.00	mRNA gene expression profiling of 72 genes in whole blood for detection of	Psychiatry (stress disorders), mrna, gene expression profiling by rna sequencing of 72 genes, whole blood, algorithm reported as predictive risk score
2026	0293U		20260101	N	\$760.00	mRNA gene expression profiling of 54 genes in whole blood for detection of	Psychiatry (suicidal ideation), mrna, gene expression profiling by rna sequencing of 54 genes, whole blood, algorithm reported as predictive risk score

2026	0294U		20260101	N	\$760.00	mRNA gene expression profiling of 18 genes in whole blood for detection of	Longevity and mortality risk, mrna, gene expression profiling by rna sequencing of 18 genes, whole blood, algorithm reported as predictive risk score
------	-------	--	----------	---	----------	--	---

2026	0295U		20260101	N	\$5,435.00	Protein expression profiling by immunohistochemistry of 7 proteins (COX2,	Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (cox2, foxa1, her2, ki-67, p16, pr, siah2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reported as a recurrence risk score
------	-------	--	----------	---	------------	---	--

2026	0296U		20260101	N	\$1,950.00	mRNA gene expression profiling of at least 20 molecular features in saliva,	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by rna sequencing of at least 20 molecular features (eg, human and/or microbial mrna), saliva, algorithm reported as positive or negative for signature associated with malignancy
------	-------	--	----------	---	------------	---	---

2026	0297U		20260101	N	\$2,919.60	Whole genome sequencing of paired tumor and normal DNA specimens, in tissue,	Oncology (pan tumor), whole genome sequencing of paired malignant and normal dna specimens, fresh or formalin-fixed paraffin-embedded (ffpe) tissue, blood or bone marrow, comparative sequence analyses and variant identification
------	-------	--	----------	---	------------	--	---

2026	0298U		20260101	N	\$2,919.60	Whole transcriptome sequencing of paired tumor and normal DNA specimens, in	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal rna specimens, fresh or formalin-fixed paraffin-embedded (ffpe) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification
------	-------	--	----------	---	------------	---	---

2026	0299U		20260101	N	\$1,863.22	Whole transcriptome sequencing of paired tumor and normal DNA specimens, in	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal dna specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification
2026	0300U		20260101	N	\$4,183.13	Whole genome sequencing and optical genome mapping of paired tumor and normal	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal dna specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification

2026	0301U		20260101	N	\$262.72	Droplet digital PCR (ddPCR) detection of Bartonella henselae and Bartonella	Infectious agent detection by nucleic acid (dna or rna), bartonella henselae and bartonella quintana, droplet digital pcr (ddpcr)
2026	0302U		20260101	N	\$361.37	Droplet digital PCR (ddPCR) detection of Bartonella henselae and Bartonella	Infectious agent detection by nucleic acid (dna or rna), bartonella henselae and bartonella quintana, droplet digital pcr (ddpcr); following liquid enrichment

2026	0303U		20260101	N	\$2,201.62	Functional assessment of red blood cell adhesion to endothelial/sub endothelial	Hematology, red blood cell (rbc) adhesion to endothelial/sub endothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an rbc adhesion index; hypoxic
2026	0304U		20260101	N	\$2,075.80	Functional assessment of red blood cell adhesion to endothelial/sub endothelial	Hematology, red blood cell (rbc) adhesion to endothelial/sub endothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an rbc adhesion index; normoxic

2026	0305U		20260101	N	\$662.58	Evaluation of red blood cell functionality and deformability under shear stress	Hematology, red blood cell (rbc) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index
2026	0306U		20260101	N	\$3,878.45	Initial baseline gene analysis for minimum residual disease in cancer,	Oncology (minimal residual disease [mrd]), next-generation targeted sequencing analysis, cell-free dna, initial (baseline) assessment to determine a patient-specific panel for future comparisons to evaluate for mrd

2026	0307U		20260101	N	\$794.49	Subsequent gene analysis for minimum residual disease in cancer,	Oncology (minimal residual disease [mrd]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free dna, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for mrd
------	-------	--	----------	---	----------	--	--

2026	0308U		20260101	N	\$390.75	Analysis of 3 proteins in plasma specimen, algorithm reported as risk score for	Cardiology (coronary artery disease [cad]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [kim-1] with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive cad
------	-------	--	----------	---	----------	---	--

2026	0309U		20260101	N	\$390.75	Analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of	Cardiology (cardiovascular disease), analysis of 4 proteins (nt-probnp, osteopontin, tissue inhibitor of metalloproteinase-1 [timp-1], and kidney injury molecule-1 [kim-1]), plasma, algorithm reported as a risk score for major adverse cardiac event
2026	0310U		20260101	N	\$390.75	Analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake) for	Pediatrics (vasculitis, kawasaki disease [kd]), analysis of 3 biomarkers (nt-probnp, c-reactive protein, and t-uptake), plasma, algorithm reported as a risk score for kd

2026	0311U		20260101	N	\$8.08	Measurement of bacterial susceptibility to antibiotics, reported as phenotypic	Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (mic)-based antimicrobial susceptibility for each organism identified
------	-------	--	----------	---	--------	--	---

2026	0312U		20260101	N	\$840.65	Analysis of 8 IgG autoantibodies and 2 cell-bound complement activation	Autoimmune diseases (eg, systemic lupus erythematosus [sle]), analysis of 8 igg autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (elisa), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic sle-likelihood assessment
------	-------	--	----------	---	----------	---	--

2026	0313U		20260101	N	\$3,600.00	DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of	Oncology (pancreas), dna and mrna next-generation sequencing analysis of 74 genes and analysis of cea (ceacam5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)
------	-------	--	----------	---	------------	--	--

2026	0314U		20260101	N	\$1,950.00	mRNA gene expression profiling by real-time polymerase chain reaction (RT-PCR)	Oncology (cutaneous melanoma), mrna gene expression profiling by rt-pcr of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)
------	-------	--	----------	---	------------	--	---

2026	0315U		20260101	N	\$8,500.00	mRNA gene expression profiling by real-time polymerase chain reaction (RT-PCR)	Oncology (cutaneous squamous cell carcinoma), mrna gene expression profiling by rt-pcr of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reported as a categorical risk result (ie, class 1, class 2a, class 2b)
2026	0316U		20260101	N	\$18.66	Evaluation of outer surface protein A (OspA) of Borrelia burgdorferi (Lyme	Borrelia burgdorferi (lyme disease), ospa protein evaluation, urine

2026	0317U		20260101	N	\$2,030.00	Four-probe fluorescence in situ hybridization (FISH) (3q29, 3p22.1, 10q22.3, 3,	Oncology (lung cancer), four-probe fish (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer
2026	0318U		20260101	N	\$1,770.48	Whole genome methylation analysis by microarray for 50 or more genes associated	Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood

2026	0319U		20260101	N	\$2,650.00	RNA gene expression profiling by select transcriptome sequencing in peripheral	Nephrology (renal transplant), rna expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection
2026	0320U		20260101	N	\$2,650.00	RNA gene expression profiling by select transcriptome sequencing in peripheral	Nephrology (renal transplant), rna expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection

2026	0321U		20260101	N	\$634.84	Detection test by nucleic acid (DNA or RNA) multiplex amplified probe technique	Infectious agent detection by nucleic acid (dna or rna), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique
------	-------	--	----------	---	----------	---	--

2026	0322U		20260101	N	\$750.00	Measurement of 14 acyl carnitines and microbiome-derived metabolites associated	Neurology (autism spectrum disorder [asd]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (lc-ms/ms), plasma, results reported as negative or positive for risk of metabolic subtypes associated with asd
------	-------	--	----------	---	----------	---	---

2026	0323U		20260101	N	\$2,126.20	DNA and mRNA next-generation sequencing analysis in cerebrospinal fluid	Infectious agent detection by nucleic acid (dna and rna), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (csf), identification of pathogenic bacteria, viruses, parasites, or fungi
------	-------	--	----------	---	------------	---	---

2026	0326U		20260101	N	\$5,000.00	Targeted genomic sequence analysis of 83 or more genes in cell free circulating	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating dna analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements , microsatellite instability and tumor mutational burden
------	-------	--	----------	---	------------	---	--

2026	0327U		20260101	N	\$795.00	DNA sequence analysis of selected regions for detection of abnormal fetal	Fetal aneuploidy (trisomy 13, 18, and 21), dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed
------	-------	--	----------	---	----------	---	---

2026	0328U		20260101	N	\$114.43	Definitive drug testing for 120 or more drugs and metabolites in urine specimen	Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient-adverse event, per date of service
------	-------	--	----------	---	----------	---	--

2026	0329U		20260101	N	\$3,437.98	Exome and transcriptome sequence analysis of DNA and RNA from tumor with DNA	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements , microsatellite instability and tumor mutational burden utilizing dna and rna from tumor with dna from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations
------	-------	--	----------	---	------------	--	--

2026	0330U		20260101	N	\$416.78	Amplified nucleic acid probe for identification of 27 vaginal disease agents in	Infectious agent detection by nucleic acid (dna or rna), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab
2026	0331U		20260101	N	\$1,863.22	Optical genome mapping of DNA from blood or bone marrow specimen, report of	Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing dna from blood or bone marrow, report of clinically significant alterations

2026	0332U		20260101	N	\$1,142.06	Genetic profiling of 8 epigenetic markers to evaluate probability of responding	Oncology (pan-tumor), genetic profiling of 8 dna-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qpcr), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy
------	-------	--	----------	---	------------	---	--

2026	0333U		20260101	N	\$662.32	Surveillance for liver cancer in high risk patients using algorithm	Oncology (liver), surveillance for hepatocellular carcinoma (hcc) in highrisk patients, analysis of methylation patterns on circulating cell-free dna (cfdna) plus measurement of serum of afp/afp-l3 and oncoprotein des-gammaprothrombin (dcp), algorithm reported as normal or abnormal result
------	-------	--	----------	---	----------	---	---

2026	0334U		20260101	N	\$3,500.00	Targeted genomic sequence analysis of 84 or more genes for detection of	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffinembedded (ffpe) tumor tissue, dna analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements , microsatellite instability and tumor mutational burden
------	-------	--	----------	---	------------	---	---

2026	0335U		20260101	N	\$5,224.60	Whole genome sequence analysis of fetal sample for detection of abnormalities	Rare diseases (constitutional/ heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (upd), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (str) gene expansions, fetal sample, identification and categorization of genetic variants
------	-------	--	----------	---	------------	---	---

2026	0336U		20260101	N	\$2,574.65	Whole genome sequence analysis of comparator genome (parent) for detection of	Rare diseases (constitutional/ heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (upd), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (str) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent)
------	-------	--	----------	---	------------	---	---

2026	0337U		20260101	N	\$2,435.00	Evaluation of plasma cells for detection of abnormalities associated with	Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential cd138, cd38, cd19, and cd45 protein biomarker expression, peripheral blood
------	-------	--	----------	---	------------	---	---

2026	0338U		20260101	N	\$2,435.00	Evaluation of circulating solid tumor cells in peripheral blood	Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential epcam, cytokeratins 8, 18, and 19, and cd45 protein biomarkers, and quantification of her2 protein biomarker-expressing cells, peripheral blood
------	-------	--	----------	---	------------	---	---

2026	0339U		20260101	N	\$760.00	mRNA expression profiling of genes associated with high-grade prostate cancer	Oncology (prostate), mrna expression profiling of hoxc6 and dlx1, reverse transcription polymerase chain reaction (rt-pcr), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer
------	-------	--	----------	---	----------	---	---

2026	0340U		20260101	N	\$3,590.00	DNA assays for detection of minimal residual disease in cancer	Oncology (pan-cancer), analysis of minimal residual disease (mrd) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline dna, reported as absence or presence of mrd, with disease-burden correlation, if appropriate
------	-------	--	----------	---	------------	--	--

2026	0341U		20260101	N	\$1,900.20	Fetal DNA sequencing of products of conception for detection of abnormal	Fetal aneuploidy dna sequencing comparative analysis, fetal dna from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid
------	-------	--	----------	---	------------	--	--

2026	0342U		20260101	N	\$897.00	Multiplex immunoassay for markers of pancreatic cancer in serum	Oncology (pancreatic cancer), multiplex immunoassay of c5, c4, cystatin c, factor b, osteoprotegerin (opg), gelsolin, igfbp3, ca125 and multiplex electrochemiluminescent immunoassay (eclia) for ca19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline
------	-------	--	----------	---	----------	---	---

2026	0343U		20260101	N	\$760.00	Exosome-based analysis of 442 small noncoding RNAs in urine to evaluate risk of	Oncology (prostate), exosome-based analysis of 442 small noncoding rnas (snrnas) by quantitative reverse transcription polymerase chain reaction (rt-qpcr), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer
------	-------	--	----------	---	----------	---	---

2026	0344U		20260101	N	\$792.17	Evaluation of 28 lipid markers for risk of nonalcoholic fatty liver disease	Hepatology (nonalcoholic fatty liver disease [nafld]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (lc-ms/ms), serum, reported as at-risk for nonalcoholic steatohepatitis (nash) or not nash
2026	0345U		20260101	N	\$1,336.09	Genomic analysis panel of 15 genes for detection of abnormalities associated	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [adhd]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of cyp2d6

2026	0347U		20260101	N	\$1,336.09	DNA analysis of 16 genes involved in drug metabolism or processing	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, dna analysis, 16 gene report, with variant analysis and reported phenotypes
2026	0348U		20260101	N	\$742.27	DNA analysis of 25 genes involved in drug metabolism or processing	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, dna analysis, 25 gene report, with variant analysis and reported phenotypes

2026	0349U		20260101	N	\$742.27	DNA analysis of 27 genes involved in drug metabolism or processing, report	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, dna analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions
2026	0350U		20260101	N	\$1,336.09	DNA analysis of 27 genes involved in drug metabolism or processing, analysis	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, dna analysis, 27 gene report, with variant analysis and reported phenotypes

2026	0351U		20260101	N	\$260.50	Biochemical assays for markers of bacterial infection	Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (trail), interferon gamma-induced protein-10 (ip10), and c-reactive protein, serum, or venous whole blood, algorithm reported as likelihood of bacterial infection
2026	0355U		20260101	N	\$137.00	Evaluation of apolipoprotein L1 risk variants	ApoL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (g1, g2)

2026	0356U		20260101	N	\$1,800.00	Evaluation of 17 DNA biomarkers reported as a risk score for tonsil or anal	Oncology (oropharyngeal or anal), evaluation of 17 dna biomarkers using droplet digital pcr (ddpcr), cell-free dna, algorithm reported as a prognostic risk score for cancer recurrence
2026	0358U		20260101	N	\$260.50	Enzyme immunoassay analysis of beta-amyloid fragments in cerebral spinal fluid	Neurology (mild cognitive impairment), analysis of b-amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative

2026	0359U		20260101	N	\$760.00	Phase separation and immunoassay evaluation of prostate-specific antigen (PSA)	Oncology (prostate cancer), analysis of all prostate-specific antigen (psa) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer
2026	0360U		20260101	N	\$840.65	Enzyme-linked immunosorbent assay of autoantibodies in plasma to evaluate risk	Oncology (lung), enzyme-linked immunosorbent assay (elisa) of 7 autoantibodies (p53, ny-eso-1, cage, gbu4-5, sox2, mage a4, and hud), plasma, algorithm reported as a categorical result for risk of malignancy

2026	0362U		20260101	N	\$3,600.00	Gene-expression profiling--enrichment RNA sequencing of 82 content genes and 10	Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment rna sequencing of 82 content genes and 10 housekeeping genes, fine needle aspirate or formalin-fixed paraffin embedded (ffpe) tissue, algorithm reported as one of three molecular subtypes
------	-------	--	----------	---	------------	---	---

2026	0363U		20260101	N	\$760.00	Gene-expression profiling of 5 genes in urine reported as a risk score for	Oncology (urothelial), mrna, geneexpression profiling by real-time quantitative pcr of 5 genes (mdk, hoxa13, cdc2 [cdk1], igfbp5, and cxcr2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma
------	-------	--	----------	---	----------	--	---

2026	0364U		20260101	N	\$2,007.25	Genomic sequence testing for presence or absence of cancer cells after	Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (pcr) and next-generation sequencing with algorithm, quantification of dominant clonal sequence (s), reported as presence or absence of minimal residual disease (mrd) with quantitation of disease burden, when appropriate
------	-------	--	----------	---	------------	--	--

2026	0365U		20260101	N	\$897.00	Test for 10 protein biomarkers for bladder cancer	Oncology (bladder), 10 protein biomarkers (a1at, ang, apoe, ca9, il8, mmp9, mmp10, pai1, sdc1 and vegfa), by immunoassays, urine, diagnostic algorithm, including patient's age, race and gender, reported as a probability of harboring urothelial cancer
------	-------	--	----------	---	----------	---	--

2026	0366U		20260101	N	\$897.00	Test for 10 protein biomarkers for recurrent bladder cancer	Oncology (bladder), analysis of 10 protein biomarkers (a1at, ang, apoe, ca9, il8, mmp9, mmp10, pai1, sdc1 and vegfa) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer
------	-------	--	----------	---	----------	---	--

2026	0367U		20260101	N	\$902.18	Test for 10 protein biomarkers for rapid recurrent, recurrent, or persistent	Oncology (bladder), analysis of 10 protein biomarkers (a1at, ang, apoe, ca9, il8, mmp9, mmp10, pai1, sdc1 and vegfa) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection
------	-------	--	----------	---	----------	--	--

2026	0368U		20260101	N	\$416.78	Test for risk of colorectal cancer	Oncology (colorectal cancer), evaluation for mutations of apc, braf, cttnb1, kras, nras, pik3ca, smad4, and tp53, and methylation markers (myo1g, kcnq5, c9orf50, fli1, clip4, znf132 and twist1), multiplex quantitative polymerase chain reaction (qpcr), circulating cell-free dna (cfdna), plasma, report of risk score for advanced adenoma or colorectal cancer
------	-------	--	----------	---	----------	------------------------------------	---

2026	0371U		20260101	N	\$416.78	Test for 16 genitourinary bacterial organisms and 1 genitourinary fungal	Infectious agent detection by nucleic acid (dna or rna), genitourinary pathogen, semiquantitative identification, dna from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qpcr), urine
2026	0372U		20260101	N	\$416.78	Test for genitourinary pathogen antibiotic-resistance genes	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score

2026	0375U		20260101	N	\$897.00	Test for proteins to determine risk for ovarian cancer	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein a-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score
------	-------	--	----------	---	----------	--	---

2026	0376U		20260101	N	\$706.25	Test to determine potential risk of prostate cancer spread and mortality	Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation-therapy response, if appropriate
------	-------	--	----------	---	----------	--	--

2026	0377U		20260101	N	\$47.58	Test of lipoprotein profile in cardiovascular disease	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (nmr) spectrometry with report of a lipoprotein profile (including 23 variables)
2026	0378U		20260101	N	\$137.00	Test for RFC1 (replication factor C subunit 1) in neurological conditions	Rfc1 (replication factor c subunit 1), repeat expansion variant analysis by traditional and repeat-primed pcr, blood, saliva, or buccal swab

2026	0379U		20260101	N	\$3,288.51	Genomic testing for solid organ cancer	Targeted genomic sequence analysis panel, solid organ neoplasm, dna (523 genes) and rna (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements , microsatellite instability, and tumor mutational burden
------	-------	--	----------	---	------------	--	---

2026	0381U		20260101	N	\$44.12	Test for monitoring maple syrup urine disease	Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of allo-isoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (lc-ms/ms)
2026	0382U		20260101	N	\$51.64	Test for monitoring hyperphenylalaninemia	Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (lc-ms/ms)

2026	0383U		20260101	N	\$52.05	Test for monitoring tyrosinemia type I	Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitrotyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)
------	-------	--	----------	---	---------	--	---

2026	0384U		20260101	N	\$750.00	Test for predictive risk of progression of high-stage kidney disease	Nephrology (chronic kidney disease), carboxymethyl lysine, methylglyoxal hydroimidazole, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (lc-ms/ms) and hba1c and estimated glomerular filtration rate (gfr), with risk score reported for predictive progression to high-stage kidney disease
------	-------	--	----------	---	----------	--	---

2026	0385U		20260101	N	\$390.75	Testing for risk of developing diabetic kidney disease	Nephrology (chronic kidney disease), apolipoprotein a4 (apoa4), cd5 antigen-like (cd5l), and insulin-like growth factor binding protein 3 (igfbp3) by enzyme-linked immunoassay (elisa), plasma, algorithm combining results with hdl, estimated glomerular filtration rate (gfr) and clinical data reported as a risk score for developing diabetic kidney disease
------	-------	--	----------	---	----------	--	---

2026	0387U		20260101	N	\$948.50	Tissue evaluation for proteins to report risk of skin cancer progression	Oncology (melanoma), autophagy and beclin 1 regulator 1 (ambra1) and loricrin (amlo) by immunohistochemistry, formalin-fixed paraffin-embedded (ffpe) tissue, report for risk of progression
2026	0388U		20260101	N	\$3,500.00	Next-generation sequencing in plasma of 37 cancer-related genes, with report	Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection

2026	0389U		20260101	N	\$70.20	Reverse transcription polymerase chain reaction (RT-qPCR) testing of blood for	Pediatric febrile illness (kawasaki disease [kd]), interferon alphas inducible protein 27 (ifi27) and mast cell-expressed membrane protein 1 (mcomp1), rna, using reverse transcription polymerase chain reaction (rt-qpcr), blood, reported as a risk score for kd
2026	0390U		20260101	N	\$64.41	Immunoassay of serum for proteins, reported as a risk score for preeclampsia	Obstetrics (preeclampsia), kinase insert domain receptor (kdr), endoglin (eng), and retinol-binding protein 4 (rbp4), by immunoassay, serum, algorithm reported as a risk score

2026	0391U		20260101	N	\$3,600.00	DNA and RNA next-generation sequencing of tissue for 437 genes with algorithm	Oncology (solid tumor), dna and rna by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (ffpe) tissue, 437 genes, interpretive report for single nucleotide variants, splicesite variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score
------	-------	--	----------	---	------------	---	--

2026	0392U		20260101	N	\$1,336.09	Evaluation of gene-drug interactions for 16 genes reported as impact of	Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [adhd]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of cyp2d6, reported as impact of gene-drug interaction for each drug
2026	0393U		20260101	N	\$540.99	Detection of protein by seed amplification assay for neurological disorders	Neurology (eg, parkinson disease, dementia with lewy bodies), cerebrospinal fluid (csf), detection of misfolded - synuclein protein by seed amplification assay, qualitative

2026	0394U		20260101	N	\$198.74	Testing of plasma or serum for 16 perfluoroalkyl substances (PFAS) compounds	Perfluoroalkyl substances (pfas) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 16 pfas compounds by liquid chromatography with tandem mass spectrometry (lc-ms/ms), plasma or serum, quantitative
2026	0395U		20260101	N	\$797.45	Multi-omics testing of plasma reported as risk of malignancy for lung nodules	Oncology (lung), multi-omics (microbial dna by shotgun nextgeneration sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease

2026	0398U		20260101	N	\$1,755.00	DNA methylation analysis using polymerase chain reaction testing of tissue for	Gastroenterology (barrett esophagus), p16, runx3, hpp1, and fbn1 dna methylation analysis using pcr, formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer
------	-------	--	----------	---	------------	--	---

2026	0399U		20260101	N	\$300.00	Enzyme-linked assay detection in serum of IgG-binding antibody and blocking	Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor iggbinding antibody and blocking autoantibodies by enzyme-linked immunoassay (elisa), qualitative, and blocking autoantibodies, using a functional blocking assay for igg or igm, quantitative, reported as positive or not detected
------	-------	--	----------	---	----------	---	---

2026	0400U		20260101	N	\$1,456.88	Next-generation sequencing of DNA for 145 genes reported as carrier positive or	Obstetrics (expanded carrier screening), 145 genes by nextgeneration sequencing, fragment analysis and multiplex ligationdependent probe amplification, dna, reported as carrier positive or negative
2026	0401U		20260101	N	\$489.68	Targeted variant genotyping using blood, saliva, or buccal swab of 9 genes for	Cardiology (coronary heart disease [cad]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event

2026	0402U		20260101	N	\$142.63	Detection of organisms causing sexually transmitted infection by multiplex	Infectious agent (sexually transmitted infection), chlamydia trachomatis, neisseria gonorrhoeae, trichomonas vaginalis, mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each pathogen reported as detected or not detected
2026	0403U		20260101	N	\$760.00	mRNA expression profiling of 18 genes to detect potential risk of prostate	Oncology (prostate), mrna, gene expression profiling of 18 genes, first-catch urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer

2026	0404U		20260101	N	\$322.96	Analysis of serum using immunoassay technique for thymidine kinase activity in	Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression
2026	0405U		20260101	N	\$1,770.48	Sequencing of methylation haplotype block markers in plasma in pancreatic cancer	Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected

2026	0406U		20260101	N	\$760.00	Flow cytometry detection of 5 markers in sputum to evaluate potential for lung	Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [tcp], cd206, cd66b, cd3, cd19), algorithm reported as likelihood of lung cancer
------	-------	--	----------	---	----------	--	---

2026	0407U		20260101	N	\$950.00	Measurement of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor	Nephrology (diabetic chronic kidney disease [ckd]), multiplex electrochemiluminescent immunoassay (eclia) of soluble tumor necrosis factor receptor 1 (stnfr1), soluble tumor necrosis receptor 2 (stnfr2), and kidney injury molecule 1 (kim-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function
------	-------	--	----------	---	----------	---	---

2026	0408U		20260101	N	\$14.13	Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by	Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])
2026	0409U		20260101	N	\$2,919.60	Next-generation sequencing of DNA (80 genes) and RNA (39 genes) in plasma	Oncology (solid tumor), dna (80 genes) and rna (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability

2026	0410U		20260101	N	\$1,160.00	Whole genome sequencing of DNA in whole blood or plasma to detect pancreatic	Oncology (pancreatic), dna, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected
2026	0411U		20260101	N	\$1,336.09	Genomic analysis of 15 genes to evaluate for psychiatric disorders	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [adhd]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of cyp2d6

2026	0412U		20260101	N	\$750.00	Measurement of AB42/40 ratio in plasma to evaluation for brain amyloid pathology	Beta amyloid, ab42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (lc-ms/ms) and qualitative apoe isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology
------	-------	--	----------	---	----------	--	---

2026	0413U		20260101	N	\$1,263.53	Optical genome mapping of DNA in blood or bone marrow for changes in copy	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, dna from blood or bone marrow, report of clinically significant alterations
------	-------	--	----------	---	------------	---	---

2026	0414U		20260101	N	\$706.25	Whole slide imaging analysis for 8 genes for evaluation of lung cancer	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (alk, braf, egfr, erbb2, met, ntrk1-3, ret, ros1), and kras g12c and pd-1, if performed, formalin-fixed paraffin-embedded (ffpe) tissue, reported as positive or negative for each biomarker
------	-------	--	----------	---	----------	--	--

2026	0415U		20260101	N	\$390.75	Test of biomarkers in blood combined with patient factors to determine a 5-year	Cardiovascular disease (acute coronary syndrome [acs]), il-16, fas, fasligand, hgf, ctack, eotaxin, and mcp-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for acs
------	-------	--	----------	---	----------	---	---

2026	0417U		20260101	N	\$2,842.53	Whole genome sequence analysis of 335 nuclear genes in blood or saliva for	Rare diseases (constitutional/ heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants
------	-------	--	----------	---	------------	--	--

2026	0418U		20260101	N	\$706.25	Image analysis of breast cancer cell specimen with autonomous assessment	Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score
2026	0419U		20260101	N	\$1,336.09	Genomic sequence analysis of 13 genes in saliva for evolution of psychiatric	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype

2026	0420U		20260101	N	\$1,328.32	mRNA expression profiling of 6 single-nucleotide polymorphisms (SNPs) in urine	Oncology (urothelial), mrna expression profiling by real-time quantitative pcr of mdk, hoxa13, cdc2, igfbp5, and cxcr2 in combination with droplet digital pcr (ddpcr) analysis of 6 single-nucleotide polymorphisms (snps) genes tert and fgfr3, urine, algorithm reported as a risk score for urothelial carcinoma
------	-------	--	----------	---	------------	--	--

2026	0421U		20260101	N	\$508.87	Screening test for 8 RNA markers and blood in stool reported as positive or	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 rna markers (gapdh, smad4, acy1, areg, cdh1, kras, tnfrsf10b, egl2) and fecal hemoglobin, algorithm reported as a positive or negative for colorectal cancer risk
------	-------	--	----------	---	----------	---	--

2026	0422U		20260101	N	\$1,943.21	Analysis of DNA biomarker response to anti-cancer therapy reported as a change	Oncology (pan-solid tumor), analysis of dna biomarker response to anti-cancer therapy using cell-free circulating dna, biomarker comparison to a previous baseline pre-treatment cell-free circulating dna analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate
------	-------	--	----------	---	------------	--	---

2026	0423U		20260101	N	\$416.78	Genomic analysis panel of 26 genes from cheek swab, report including	Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition
2026	0424U		20260101	N	\$760.00	Exosome-based analysis of 53 small non coding RNAs (sncRNAs) in urine, reported	Oncology (prostate), exosome-based analysis of 53 small noncoding rnas (sncrnas) by quantitative reverse transcription polymerase chain reaction (rt-qpcr), urine, reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer

2026	0425U		20260101	N	\$4,094.39	Genome rapid sequence analysis, each comparator gene (eg, parents, siblings)	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings)
2026	0426U		20260101	N	\$7,582.20	Genome ultra-rapid sequence analysis for unexplained constitutional or	Genome (eg, unexplained constitutional or heritable disorder or syndrome), ultra-rapid sequence analysis
2026	0427U		20260101	N	\$4.48	Monocyte distribution width in whole blood	Monocyte distribution width, whole blood (list separately in addition to code for primary procedure)

2026	0429U		20260101	N	\$35.09	Testing for Human papillomavirus (HPV) from throat swab	Human papillomavirus (hpv), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
2026	0430U		20260101	N	\$61.54	Malabsorption evaluation in stool	Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative
2026	0431U		20260101	N	\$36.57	Glycine receptor alpha1 IgG live cell-binding assay in serum or cerebral spinal	Glycine receptor alpha1 igg, serum or cerebrospinal fluid (csf), live cell-binding assay (lcba), qualitative

2026	0432U		20260101	N	\$36.57	Kelch-like protein 11 (KLHL11) antibody cell-binding assay in serum or	Kelch-like protein 11 (klhl11) antibody, serum or cerebrospinal fluid (csf), cell-binding assay, qualitative
2026	0433U		20260101	N	\$760.00	Testing for 5 DNA regulatory markers by quantitative PCR in whole blood,	Oncology (prostate), 5 dna regulatory markers by quantitative pcr, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer
2026	0434U		20260101	N	\$416.78	Genomic analysis panel of 25 genes to evaluation drug metabolism	Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes

2026	0435U		20260101	N	\$3,033.86	Chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), reported	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (cscs), from cultured cscs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations
2026	0436U		20260101	N	\$1,504.24	Plasma analysis of 388 proteins reported as clinical benefit from immune	Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy

2026	0437U		20260101	N	\$760.00	mRNA, gene expression profiling by RNA sequencing of 15 biomarkers in whole	Psychiatry (anxiety disorders), mrna, gene expression profiling by rna sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score
2026	0438U		20260101	N	\$416.78	Variant analysis of gene-drug interactions of 33 genes from cheek swab to	Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of cyp2d6, including reported phenotypes and impacted gene-drug interactions

2026	0439U		20260101	N	\$854.00	qPCR and digital PCR DNA analysis of 5 single-nucleotide polymorphisms (SNPs)	Cardiology (coronary heart disease [chd]), dna, analysis of 5 single-nucleotide polymorphisms (snps) (rs11716050 [loc105376934], rs6560711 [wdr37], rs3735222 [scin/loc107986769], rs6820447 [intergenic], and rs9638144 [esyt2]) and 3 dna methylation markers (cg00300879 [transcription start site {tss200} of cnksr1], cg09552548 [intergenic], and cg14789911 [body of spatc1]), qpcr and digital pcr, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic chd
------	-------	--	----------	---	----------	---	---

2026	0440U		20260101	N	\$854.00	qPCR and digital PCR DNA, analysis of 10 single-nucleotide polymorphisms (SNPs)	Cardiology (coronary heart disease [chd]), dna, analysis of 10 single-nucleotide polymorphisms (snps) (rs710987 [linc010019], rs1333048 [cdkn2b-as1], rs12129789 [kcnd3], rs942317 [ktn1-as1], rs1441433 [ppp3ca], rs2869675 [prex1], rs4639796 [zbtb41], rs4376434 [linc00972], rs12714414 [tmem18], and rs7585056 [tmem18]) and 6 dna methylation markers (cg03725309 [sars1], cg12586707 [cxcl1, cg04988978 [mpo], cg17901584 [dhcr24-dt], cg21161138 [ahrr], and cg12655112 [ehd4]), qpcr and digital pcr
------	-------	--	----------	---	----------	---	---

2026	0441U		20260101	N	\$444.08	Semiquantitative biomechanical assessment (via deformability cytometry) in	Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index
2026	0442U		20260101	N	\$41.38	Fingerstick test of whole blood, result reported as present or absent for	Infectious disease (respiratory infection), myxovirus resistance protein a (mxa) and c-reactive protein (crp), fingerstick whole blood specimen, each biomarker reported as present or absent

2026	0443U		20260101	N	\$116.23	Ultra-sensitive immunoassay of serum or cerebrospinal fluid for evaluation of	Neurofilament light chain (nfl), ultra-sensitive immunoassay, serum or cerebrospinal fluid
2026	0444U		20260101	N	\$2,919.60	Targeted genomic sequence analysis panel of 361 genes using DNA from	Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements , using dna from formalin-fixed paraffin-embedded (ffpe) tumor tissue, report of clinically significant variant(s)

2026	0445U		20260101	N	\$260.50	Electrochemiluminescent immunoassay (ECLIA) of cerebral spinal fluid for	B-amyloid (abeta42) and phospho tau (181p) (ptau181), electrochemiluminescent immunoassay (eclia), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
2026	0446U		20260101	N	\$840.65	Analysis of 10 cytokine soluble mediator biomarkers by immunoassay in plasma,	Autoimmune diseases (systemic lupus erythematosus [sle]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity

2026	0447U		20260101	N	\$840.65	Analysis of 11 cytokine soluble mediator biomarkers by immunoassay in plasma,	Autoimmune diseases (systemic lupus erythematosus [sle]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare
------	-------	--	----------	---	----------	---	--

2026	0449U		20260101	N	\$1,824.88	Genomic sequence analysis panel that must include analysis of 5 genes (CFTR,	Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (cftr, smn1, hbb, hba1, hba2)
------	-------	--	----------	---	------------	--	---

2026	0452U		20260101	N	\$192.00	Testing to detect methylated PENK DNA in urine, reported as likelihood of	Oncology (bladder), methylated penk dna detection by linear target enrichment-quantitative methylation-specific real-time pcr (lte-qmsp), urine, reported as likelihood of bladder cancer
2026	0453U		20260101	N	\$192.00	Testing for cell-free DNA in plasma, reported as the presence or absence of	Oncology (colorectal cancer), cellfree dna (cfdna), methylationbased quantitative pcr assay (septin9, ikzf1, bcat1, septin9-2, vav3, bcan), plasma, reported as presence or absence of circulating tumor dna (ctdna)

2026	0454U		20260101	N	\$1,263.53	Testing by optical genome mapping for constitutional/heritable disorders	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
------	-------	--	----------	---	------------	--	---

2026	0455U		20260101	N	\$142.63	Testing for sexually transmitted infections in vaginal, endocervical,	Infectious agents (sexually transmitted infection), chlamydia trachomatis, neisseria gonorrhoeae, and trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected
------	-------	--	----------	---	----------	---	---

2026	0457U		20260101	N	\$198.74	Testing for 9 perfluoroalkyl compounds in plasma or serum	Perfluoroalkyl substances (pfas) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 pfas compounds by lc-ms/ms, plasma or serum, quantitative
2026	0458U		20260101	N	\$260.50	Testing for S100A8 and S100A9 in tear fluid with age, reported as a risk score	Oncology (breast cancer), s100a8 and s100a9, by enzymelinked immunosorbent assay (elisa), tear fluid with age, algorithm reported as a risk score
2026	0459U		20260101	N	\$260.50	Testing for B-amyloid and total tau in spinal fluid, ratio reported as positive	B-amyloid (abeta42) and total tau (ttau), electrochemiluminescent immunoassay (elisa), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology

2026	0460U		20260101	N	\$917.08	DNA testing of 24 genes in whole blood or saliva in cancer	Oncology, whole blood or buccal, dna single-nucleotide polymorphism (snp) genotyping by real-time pcr of 24 genes, with variant analysis and reported phenotypes
2026	0461U		20260101	N	\$917.08	Analysis of 24 genes in whole blood or saliva for gene-drug interactions in	Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (snp) genotyping by real-time pcr of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes

2026	0462U		20260101	N	\$17.27	Screening testing of melatonin levels in saliva during sleep study	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (elisa), saliva, screening/preliminary
------	-------	--	----------	---	---------	--	---

2026	0463U		20260101	N	\$760.00	Gene expression profiling of high-risk HPV types in cervical cells, reported as	Oncology (cervix), mrna gene expression profiling of 14 biomarkers (e6 and e7 of the highest-risk human papillomavirus [hpv] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (nasba), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker
------	-------	--	----------	---	----------	---	---

2026	0464U		20260101	N	\$591.92	Screening test for DNA markers in stool reported as a positive or negative	Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated dna markers, including lass4, lrrc4 and ppp2r5c, a reference marker zdhhc1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result
2026	0465U		20260101	N	\$1,938.01	DNA testing for 2 genes reported as a positive or negative result for bladder	Oncology (urothelial carcinoma), dna, quantitative methylationspecific pcr of 2 genes (onecut2, vim), algorithmic analysis reported as positive or negative

2026	0466U		20260101	N	\$345.43	DNA genome study with patient lifestyle and clinical data, using saliva,	Cardiology (coronary artery disease [cad]), dna, genomewide association studies (564856 single-nucleotide polymorphisms [snps], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease
------	-------	--	----------	---	----------	--	--

2026	0467U		20260101	N	\$1,519.06	DNA sequencing of 60 genes in urine, results reported as minimal residual	Oncology (bladder), dna, nextgeneration sequencing (ngs) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (mrd) status positive or negative and quantitative disease burden
2026	0468U		20260101	N	\$251.70	Testing in serum and whole blood reported as a single score for nonalcoholic	Hepatology (nonalcoholic steatohepatitis [nash]), mir-34a5p, alpha 2-macroglobulin, ykl40, hba1c, serum and whole blood, algorithm reported as a single score for nash activity and fibrosis

2026	0469U		20260101	N	\$1,197.94	Whole genome sequencing in amniotic fluid, chorionic villus sample, or products	Rare diseases (constitutional/ heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (roh), inheritance pattern that indicate uniparental disomy (upd), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal
------	-------	--	----------	---	------------	---	--

2026	0470U		20260101	N	\$597.91	Next-generation sequencing of 8 DNA targets in plasma for detection of minimal	Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (ngs) based quantitative evaluation of 8 dna targets, cell-free hpv 16 and 18 dna from plasma
2026	0471U		20260101	N	\$760.00	Testing for 35 variants of KRAS and NRAS genes in tissue sample, reported as	Oncology (colorectal cancer), qualitative real-time pcr of 35 variants of kras and nras genes (exons 2, 3, 4), formalinixed paraffin-embedded (ffpe), predictive, identification of detected mutations

2026	0472U		20260101	N	\$27.90	Testing for proteins and antibodies in blood reported as predictive evidence of	Carbonic anhydrase vi (ca vi), parotid specific/secretory protein (psp) and salivary protein (sp1) igg, igm, and iga antibodies, enzyme-linked immunosorbent assay (elisa), semiquantitative, blood, reported as predictive evidence of early sjogren's syndrome
------	-------	--	----------	---	---------	---	--

2026	0473U		20260101	N	\$4,500.00	Next-generation sequencing of DNA from tissue sample of 648 genes with	Oncology (solid tumor), nextgeneration sequencing (ngs) of dna from formalin-fixed paraffinembedded (ffpe) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements , microsatellite instability, and tumor-mutation burden
------	-------	--	----------	---	------------	--	---

2026	0474U		20260101	N	\$1,303.95	Next-generation sequencing of 88 genes in blood or saliva, results reported as	Hereditary pancreatic cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using nextgeneration sequencing (ngs), sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene
------	-------	--	----------	---	------------	--	---

2026	0475U		20260101	N	\$1,303.95	Next-generation sequencing of 23 genes reported as pathologic mutations with a	Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (ngs), sanger sequencing, multiplex ligation-dependent probe amplification (mlpa), and array comparative genomic hybridization (cgh), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer
------	-------	--	----------	---	------------	--	--

2026	0476U		20260101	N	\$416.78	Pharmacogenomic genotyping of 14 genes including reported phenotypes to	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [adhd], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and cyp2d6 copy number variant analysis and reported phenotypes
------	-------	--	----------	---	----------	---	---

2026	0477U		20260101	N	\$416.78	Pharmacogenomic genotyping of 14 genes including gene-drug interactions and	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [adhd], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and cyp2d6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes
------	-------	--	----------	---	----------	---	--

2026	0478U		20260101	N	\$552.99	DNA and RNA analysis of 9 genes to determine therapy selection in non-small	Oncology (non-small cell lung cancer), dna and rna, digital pcr analysis of 9 genes (egfr, kras, braf, alk, ros1, ret, ntrk 1/2/3, erbb2, and met) in formalin-fixed paraffin-embedded (ffpe) tissue, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements , and reported as actionable detected variants for therapy selection
2026	0479U		20260101	N	\$17.27	Testing for phosphorylated tau	Tau, phosphorylated , ptau217

2026	0480U		20260101	N	\$2,126.20	DNA and RNA next generation sequencing for identifying pathogens in bacteria,	Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (csf), metagenomic next-generation sequencing (dna and rna), bioinformatic analysis, with positive pathogen identification
2026	0481U		20260101	N	\$674.24	Next-generation sequencing of genes in central nervous system tumors	Idh1 (isocitrate dehydrogenase 1 [nadp+]), idh2 (isocitrate dehydrogenase 2 [nadp+]), and tert (telomerase reverse transcriptase) promoter (eg, central nervous system [cns] tumors), next-generation sequencing (single-nucleotide variants [snv], deletions, and insertions)

2026	0482U		20260101	N	\$128.82	Testing of specific protein and factors to determine risk of progression of	Obstetrics (preeclampsia), biochemical assay of soluble fmslike tyrosine kinase 1 (sflt-1) and placental growth factor (plgf), serum, ratio reported for sflt1/plgf, with risk of progression for preeclampsia with severe features within 2 weeks
2026	0483U		20260101	N	\$35.09	Testing for probability of fluoroquinolone resistance in gonorrhea	Infectious disease (neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyra s91f point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance

2026	0484U		20260101	N	\$35.09	Testing for probability of macrolide resistance in in mycoplasma genitalium	Infectious disease (mycoplasma genitalium), macrolide sensitivity (23s rrna point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance
------	-------	--	----------	---	---------	---	---

2026	0485U		20260101	N	\$3,649.48	RNA next-generation sequencing in solid tumor cancer	Oncology (solid tumor), cell-free dna and rna by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden
------	-------	--	----------	---	------------	--	---

2026	0486U		20260101	N	\$1,644.25	DNA next-generation sequencing of tumor methylation markers present in	Oncology (pan-solid tumor), nextgeneration sequencing analysis of tumor methylation markers present in cell-free circulating tumor dna, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction
------	-------	--	----------	---	------------	--	--

2026	0487U		20260101	N	\$2,919.60	Genomic sequence analysis of 84 genes in solid tumors	Oncology (solid tumor), cell-free circulating dna, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidy corrected gene copy number amplifications and losses, gene rearrangements , and microsatellite instability
------	-------	--	----------	---	------------	---	---

2026	0488U		20260101	N	\$759.05	DNA sequence analysis for detection of fetal presence of antigen(s)	Obstetrics (fetal antigen noninvasive prenatal test), cellfree dna sequence analysis for detection of fetal presence or absence of 1 or more of the rh, c, c, d, e, duffy (fya), or kell (k) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected
------	-------	--	----------	---	----------	---	---

2026	0489U		20260101	N	\$1,153.62	Single-gene noninvasive prenatal test to determine fetal risk score for	Obstetrics (single-gene noninvasive prenatal test), cellfree dna sequence analysis of 1 or more targets (eg, cftr, smn1, hbb, hba1, hba2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)
------	-------	--	----------	---	------------	---	--

2026	0490U		20260101	N	\$2,435.00	Testing for antigen and protein biomarkers in melanoma(s)	Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential cd146, high molecular-weight melanomaassociated antigen, cd34 and cd45 protein biomarkers, peripheral blood
------	-------	--	----------	---	------------	---	--

2026	0491U		20260101	N	\$2,435.00	Testing for protein biomarkers and quantification of estrogen receptor protein	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (epcam), cytokeratins 8, 18, and 19, cd45 protein biomarkers, and quantification of estrogen receptor (er) protein biomarker-expressing cells, peripheral blood
------	-------	--	----------	---	------------	--	--

2026	0492U		20260101	N	\$2,435.00	Testing for protein biomarkers and quantification of PD-L1 protein biomarker	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (epcam), cytokeratins 8, 18, and 19, cd45 protein biomarkers, and quantification of pd-l1 protein biomarker expressing cells, peripheral blood
------	-------	--	----------	---	------------	--	---

2026	0493U		20260101	N	\$2,753.25	Testing of donor-derived cell-free DNA, reported as percentage of donor-derived	Transplantation medicine, quantification of donor-derived cell-free dna (cfdna) using nextgeneration sequencing, plasma, reported as percentage of donorderived cell-free dna
2026	0494U		20260101	N	\$759.05	Red blood cell antigen testing in pregnant individuals known to be RhD negative	Red blood cell antigen (fetal rhd gene analysis), next-generation sequencing of circulating cell-free dna (cfdna) of blood in pregnant individuals known to be rhd negative, reported as positive or negative

2026	0495U		20260101	N	\$760.00	Analysis of proteins to determine risk of clinically significant prostate cancer	Oncology (prostate), analysis of circulating plasma proteins (tpsa, fpsa, klk2, psp94, and gdf15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative prostate biopsy), algorithm reported as risk of likelihood of detecting clinically significant prostate cancer
------	-------	--	----------	---	----------	--	---

2026	0496U		20260101	N	\$485.86	Analysis of genes and proteins to determine risk of colorectal cancer or	Oncology (colorectal), cell-free dna, 8 genes for mutations, 7 genes for methylation by real-time rt-pcr, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk
------	-------	--	----------	---	----------	--	--

2026	0497U		20260101	N	\$3,873.00	mRNA gene-expression profiling of 6 genes to determine risk for prostate cancer	Oncology (prostate), mrna geneexpression profiling by real-time rt-pcr of 6 genes (foxm1, mcm3, mtus1, ttc21b, alas1, and ppp2ca), utilizing formalinixed paraffin-embedded (ffpe) tissue, algorithm reported as a risk score for prostate cancer
------	-------	--	----------	---	------------	---	---

2026	0498U		20260101	N	\$1,345.31	Next-generation sequencing for mutation detection in 43 genes and methylation	Oncology (colorectal), nextgeneration sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (ffpe) tissue, report of variants and methylation pattern with interpretation
2026	0499U		20260101	N	\$597.91	Next-generation sequencing for mutation detection in 8 genes in colorectal	Oncology (colorectal and lung), dna from formalin-fixed paraffinembedded (ffpe) tissue, nextgeneration sequencing of 8 genes (nras, egfr, cttnb1, pik3ca, apc, braf, kras, and tp53), mutation detection

2026	0500U		20260101	N	\$175.40	Testing for gene mutations in VEXAS syndrome	Autoinflammatory disease (vexas syndrome), dna, uba1 gene mutations, targeted variant analysis (m41t, m41v, m41l, c. 118-2a>c, c. 118-1g>c, c. 1189_118-2del, s56f, s621c)
2026	0501U		20260101	N	\$192.00	Measurement of cell-free DNA in colorectal cancer	Oncology (colorectal), blood, quantitative measurement of cellfree dna (cfdna)
2026	0502U		20260101	N	\$35.09	Testing for high-risk markers in human papillomavirus	Human papillomavirus (hpv), e6/e7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for hpv

2026	0503U		20260101	N	\$750.00	Testing for beta-amyloid and tau-protein to determine likelihood for amyloid	Neurology (alzheimer disease), beta amyloid (ab40, ab42, ab42/40 ratio) and tau-protein (ptau217, np-tau217, ptau217/nptau 217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (lc-ms/ms), algorithm score reported as likelihood of positive or negative for amyloid plaques
------	-------	--	----------	---	----------	--	---

2026	0504U		20260101	N	\$416.78	Testing for detection of 17 pathologic organism for urinary tract infection	Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, realtime pcr, reported as positive or negative for each organism
2026	0505U		20260101	N	\$679.77	Detection of 32 pathogenic organisms in vaginal infection	Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time pcr, reported as positive or negative for each organism

2026	0506U		20260101	N	\$1,938.01	Next-generation sequencing of at least 89 genomic regions to determine	Gastroenterology (barrett's esophagus), esophageal cells, dna methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for barrett's esophagus
2026	0507U		20260101	N	\$1,160.00	Whole-genome DNA sequencing for detection of ovarian cancer	Oncology (ovarian), dna, wholegenome sequencing with 5hydroxymethylcytosine (5hmc) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected

2026	0510U		20260101	N	\$473.91	Augmentative algorithmic analysis of 16 genes using previously sequenced RNA	Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced rna wholetranscriptome data, reported as probability of predicted molecular subtype
2026	0511U		20260101	N	\$3,033.86	Testing of tumor cell culture for a 36 or more drug panel to determine	Oncology (solid tumor), tumor cell culture in 3d microenvironm ent, 36 or more drug panel, reported as tumor-response prediction for each drug

2026	0512U		20260101	N	\$706.25	Augmentative algorithmic analysis of digitized whole-slide imaging of tissue	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (msi) status, formalin-fixed paraffinembedded (ffpe) tissue, reported as increased or decreased probability of msi-high (msi-h)
------	-------	--	----------	---	----------	--	---

2026	0513U		20260101	N	\$706.25	Augmentative algorithmic analysis of digitized whole-slide imaging of tissue	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (msi) and homologous recombination deficiency (hrd) status, formalin-fixed paraffin-embedded (ffpe) tissue, reported as increased or decreased probability of each biomarker
------	-------	--	----------	---	----------	--	--

2026	0514U		20260101	N	\$38.57	Testing for adalimumab levels in patients undergoing adalimumab therapy for	Gastroenterology (irritable bowel disease [ibd]), immunoassay for quantitative determination of adalimumab (adl) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (g/ml)
------	-------	--	----------	---	---------	---	--

2026	0515U		20260101	N	\$38.57	Testing for infliximab patients undergoing infliximab therapy for irritable	Gastroenterology (irritable bowel disease [ibd]), immunoassay for quantitative determination of infliximab (ifx) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (g/ml)
2026	0516U		20260101	N	\$416.78	Pharmacogenomic genotyping of 40 genes reported as metabolizer status for drug	Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and cyp2d6 copy number variant analysis, reported as metabolizer status

2026	0517U		20260101	N	\$246.92	Testing for 80 or more psychoactive drugs or substances, minimally and	Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, lc-ms/ms, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications
2026	0518U		20260101	N	\$246.92	Testing for 90 or more pain and mental health drugs or substances, minimally	Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, lc-ms/ms, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications

2026	0519U		20260101	N	\$246.92	Testing for 110 or more medications for pain, depression, and anxiety,	Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, lcms/ms, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation
2026	0520U		20260101	N	\$246.92	Testing for 200 or more drugs or substances, minimally effective range of	Therapeutic drug monitoring, 200 or more drugs or substances, lcms/ms, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications

2026	0521U		20260101	N	\$51.80	Test for markers of rheumatoid arthritis	Rheumatoid factor iga and igm, cyclic citrullinated peptide (ccp) antibodies, and scavenger receptor a (sr-a) by immunoassay, blood
2026	0522U		20260101	N	\$260.50	Test for markers of Sjogren's syndrome	Carbonic anhydrase vi, parotid specific/secretory protein and salivary protein 1 (sp1), igg, igm, and iga antibodies, chemiluminescence, semiquantitative, blood

2026	0523U		20260101	N	\$1,352.09	DNA next generation sequencing of 22 genes in solid tumor cancers	Oncology (solid tumor), dna, qualitative, next-generation sequencing (ngs) of single-nucleotide variants (snv) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location of mutation(s), nucleotide change, and amino acid change
2026	0524U		20260101	N	\$128.82	Test to predict preeclampsia	Obstetrics (preeclampsia), sflt-1/plgf ratio, immunoassay, utilizing serum or plasma, reported as a value

2026	0525U		20260101	N	\$3,033.86	Testing for 11 cancer drugs to predict response to each drug	Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug
2026	0526U		20260101	L	\$ -	Urine test for chemokines to monitor for potential kidney transplant rejection	Nephrology (renal transplant), quantification of cxcl10 chemokines, flow cytometry, urine, reported as pg/ml creatinine baseline and monitoring over time

2026	0527U		20260101	N	\$142.63	Amplified probe technique testing for Herpes simplex virus types 1 and 2 and	Herpes simplex virus (hsv) types 1 and 2 and varicella zoster virus (vzv), amplified probe technique, each pathogen reported as detected or not detected
2026	0528U		20260101	N	\$634.84	Amplified probe technique testing for infectious agents in lower respiratory	Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, including reverse transcription for rna targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria

2026	0529U		20260101	L	\$ -	Test for variants to determine risk for developing blood clots	Hematology (venous thromboembolism [vte]), genome-wide single-nucleotide polymorphism variants, including f2 and f5 gene analysis, and leiden variant, by microarray analysis, saliva, report as risk score for vte
------	-------	--	----------	---	------	--	---

2026	0530U		20260101	N	\$2,919.60	DNA next generation sequencing of 77 genes in pan-solid tumor cancers	Oncology (pan-solid tumor), ctDNA, utilizing plasma, next-generation sequencing (ngs) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy-number alterations, with therapy association
2026	0531U		20260101	L	\$ -	DNA next-generation sequencing of 673 infectious disease organisms	Infectious disease (acid-fast bacteria and invasive fungi), dna (673 organisms), nextgeneration sequencing, plasm

2026	0532U		20260101	N	\$5,031.20	Rapid whole genome and mitochondrial DNA sequencing for rare diseases	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome and mitochondrial dna sequencing for singlenucleotide variants, insertions/deletions, copy number variations, peripheral blood, buffy coat, saliva, buccal or tissue sample, results reported as positive or negative
------	-------	--	----------	---	------------	---	---

2026	0533U		20260101	N	\$416.78	Genotyping of 16 genes reported as metabolizer status and transporter function	Drug metabolism (adverse drug reactions and drug response), genotyping of 16 genes (ie, abcg2, cyp2b6, cyp2c9, cyp2c19, cyp2c, cyp2d6, cyp3a5, cyp4f2, dpyd, g6pd, ggcx, nudt15, slco1b1, tpmt, ugt1a1, vkorc1), reported as metabolizer status and transporter function
2026	0534U		20260101	L	\$ -	MicroRNA, single-nucleotide polymorphisms (SNPs) analysis of 32 variants	Oncology (prostate), microrna, single-nucleotide polymorphisms (snps) analysis by rt-pcr of 32 variants, using buccal swab algorithm reported as a risk score

2026	0535U		20260101	N	\$62.14	Testing for perfluoroalkyl substances (PFAS)	Perfluoroalkyl substances (pfas) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), by liquid chromatography with tandem mass spectrometry (lcms/ms), plasma or serum, quantitative
2026	0536U		20260101	N	\$192.00	Red blood cell antigen (fetal RhD) testing in pregnant individuals known to be	Red blood cell antigen (fetal rhd), pcr analysis of exon 4 of rhd gene and housekeeping control gene gapdh from whole blood in pregnant individuals at 10+ weeks gestation known to be rhd negative, reported as fetal rhd status

2026	0537U		20260101	N	\$1,495.00	DNA next-generation sequencing of more than 2500 differentially methylated	Oncology (colorectal cancer), analysis of cell-free dna for epigenomic patterns, nextgeneration sequencing, >2500 differentially methylated regions (dmrs), plasma, algorithm reported as positive or negative
------	-------	--	----------	---	------------	--	--

2026	0538U		20260101	N	\$2,989.55	DNA next generation sequencing of 600 genes, reported as actionable variant in	Oncology (solid tumor), nextgeneration targeted sequencing analysis, formalin-fixed paraffinembedded (ffpe) tumor tissue, dna analysis of 600 genes, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements , and copy number alterations, microsatellite instability, tumor mutation burden, reported as actionable variant
------	-------	--	----------	---	------------	--	---

2026	0539U		20260101	N	\$3,288.51	DNA next-generation sequencing of 152 genes reported as actionable variant in	Oncology (solid tumor), cellfree circulating tumor dna (ctdna), 152 genes, nextgeneration sequencing, interrogation for singlenucleotide variants, insertions/deletions, gene rearrangements , copy number alterations, and microsatellite instability, using whole-blood samples, mutations with clinical actionability reported as actionable variant
------	-------	--	----------	---	------------	---	---

2026	0540U		20260101	N	\$2,753.25	DNA next-generation sequencing reported as a percentage of donor-derived	Transplantation medicine, quantification of donor-derived cell-free dna using next-generation sequencing analysis of plasma, reported as percentage of donor-derived cell-free dna to determine probability of rejection
------	-------	--	----------	---	------------	--	--

2026	0541U		20260101	L	\$ -	Testing for 5 HDL-bound apolipoproteins reported as prediction of coronary	Cardiovascular disease (hdl reverse cholesterol transport), cholesterol efflux capacity, lc-ms/ms, quantitative measurement of 5 distinct hdl-bound apolipoproteins (apolipoproteins a1, c1, c2, c3, and c4), serum, algorithm reported as prediction of coronary artery disease (pcad) score
------	-------	--	----------	---	------	--	---

2026	0542U		20260101	L	\$ -	Nuclear magnetic resonance (NMR) spectroscopy measurement of 84 urinary	Nephrology (renal transplant), urine, nuclear magnetic resonance (nmr) spectroscopy measurement of 84 urinary metabolites, combined with patient data, quantification of bk virus (human polyomavirus 1) using real-time pcr and serum creatinine, algorithm reported as a probability score for allograft injury status
------	-------	--	----------	---	------	---	--

2026	0543U		20260101	N	\$2,989.55	DNA next-generation sequencing of 517 genes in solid tumor cancers	Oncology (solid tumor), nextgeneration sequencing of dna from formalin-fixed paraffin-embedded (ffpe) tissue of 517 genes, interrogation for single-nucleotide variants, multinucleotide variants, insertions and deletions from dna, fusions in 24 genes and splice variants in 1 gene from rna, and tumor mutation burden
2026	0545U		20260101	N	\$37.73	Testing for acetylcholine receptor (AChR) antibodies, reported as positive or	Acetylcholine receptor (achr), antibody identification by immunofluorescence, using live cells, reported as positive or negative

2026	0546U		20260101	N	\$37.73	Testing for low-density lipoprotein receptor-related protein 4 (Lrp4)	Low-density lipoprotein receptor-related protein 4 (Lrp4), antibody identification by immunofluorescence, using live cells, reported as positive or negative
2026	0547U		20260101	N	\$116.23	Testing for neurofilament light chain (NfL)	Neurofilament light chain (nfl), chemiluminescent enzyme immunoassay, plasma, quantitative
2026	0548U		20260101	N	\$116.23	Testing for glial fibrillary acidic protein (GFAP)	Glial fibrillary acidic protein (gfap), chemiluminescent enzyme immunoassay, using plasma

2026	0549U		20260101	N	\$760.00	DNA testing for biomarkers reported as probability index for bladder cancer	Oncology (urothelial), dna, quantitative methylated realtime pcr of trna-cys, sim2, and nkx1-1, using urine, diagnostic algorithm reported as a probability index for bladder cancer and/or upper tract urothelial carcinoma (utuc)
------	-------	--	----------	---	----------	---	---

2026	0552U		20260101	L	\$ -	Testing for genetic disorders from outer layer of embryo cells, reported as	Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophoctoderm biopsy, linkage analysis of disease-causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder
------	-------	--	----------	---	------	---	--

2026	0553U		20260101	N	\$759.05	Analysis of 24 chromosomes using DNA genomic sequence analysis of outer layer	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using dna genomic sequence analysis from embryonic trophoctoderm for structural rearrangements , aneuploidy, and a mitochondrial dna score, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, or mosaic, per embryo tested
------	-------	--	----------	---	----------	---	--

2026	0554U		20260101	N	\$759.05	Analysis of 24 chromosomes using DNA genomic sequence analysis of outer layer	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using dna genomic sequence analysis from trophoctoderm biopsy for aneuploidy, ploidy, a mitochondrial dna score, and embryo quality control, results reported as normal (euploidy), monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested
------	-------	--	----------	---	----------	---	---

2026	0555U		20260101	N	\$759.05	Analysis of 24 chromosomes using DNA genomic sequence analysis of outer layer	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using dna genomic sequence analysis from embryonic trophectoderm for structural rearrangements , aneuploidy, ploidy, a mitochondrial dna score, and embryo quality control, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when
------	-------	--	----------	---	----------	---	---

2026	0556U		20260101	N	\$142.63	Testing of pathogen-specific DNA and RNA by real-time PCR for 12 targets from	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific dna and rna by real-time pcr, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for rna targets, each analyte reported as detected or not detected
------	-------	--	----------	---	----------	---	---

2026	0557U		20260101	N	\$262.99	Real-time amplification testing for bacterial DNA markers in vaginal fluid	Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of dna markers for atobium vaginae, gardnerella vaginalis, megasphaera types 1 and 2, bacterial vaginosis associated bacteria-2 and -3 (bvab-2, bvab-3), mobiluncus species, trichomonas vaginalis, neisseria gonorrhoeae, candida species (c. albicans, c. tropicalis, c. parapsilosis, c. glabrata, c. krusei), herpes simplex viruses 1 and 2, vaginal fluid, reported as detected or not detected for each organism
------	-------	--	----------	---	----------	--	---

2026	0558U		20260101	N	\$20.81	Quantitative enzyme-linked immunosorbent assay (ELISA) for secreted colorectal	Oncology (colorectal), quantitative enzyme-linked immunosorbent assay (elisa) for secreted colorectal cancer protein marker (bf7 antigen), using serum, result reported as indicative of response/no response to therapy or disease progression/regression
------	-------	--	----------	---	---------	--	--

2026	0559U		20260101	N	\$20.81	Quantitative enzyme-linked immunosorbent assay (ELISA) for secreted breast	Oncology (breast), quantitative enzyme-linked immunosorbent assay (elisa) for secreted breast cancer protein marker (bf9 antigen), serum, result reported as indicative of response/no response to therapy or disease progression/regression
------	-------	--	----------	---	---------	--	--

2026	0560U		20260101	N	\$3,878.45	Genomic sequence analysis in cell-free DNA in whole blood and tumor tissue,	Oncology (minimal residual disease [mrd]), genomic sequence analysis, cell-free dna, whole blood and tumor tissue, baseline assessment for design and construction of a personalized variant panel to evaluate current mrd and for comparison to subsequent mrd assessments
------	-------	--	----------	---	------------	---	---

2026	0561U		20260101	N	\$794.49	Genomic sequence analysis in cell- free DNA in whole blood, subsequent	Oncology (minimal residual disease [mrd]), genomic sequence analysis, cell- free dna, whole blood, subsequent assessment with comparison to initial assessment to evaluate for mrd
------	-------	--	----------	---	----------	---	---

2026	0562U		20260101	N	\$597.91	Targeted genomic sequence analysis of 33 genes, detection of single-nucleotide	Oncology (solid tumor), targeted genomic sequence analysis, 33 genes, detection of single-nucleotide variants (snvs), insertions and deletions, copy-number amplifications, and translocations in human genomic circulating cell-free dna, plasma, reported as presence of actionable variants
------	-------	--	----------	---	----------	--	--

2026	0563U		20260101	N	\$416.78	Pathogen-specific nucleic acid DNA or RNA testing for 11 viral targets and 4	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (dna or rna), 11 viral targets and 4 bacterial targets, qualitative rt-pcr, upper respiratory specimen, each pathogen reported as positive or negative
------	-------	--	----------	---	----------	--	--

2026	0563U	QW	20260101	N	\$416.78	Pathogen-specific nucleic acid DNA or RNA testing for 11 viral targets and 4	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (dna or rna), 11 viral targets and 4 bacterial targets, qualitative rt-pcr, upper respiratory specimen, each pathogen reported as positive or negative
------	-------	----	----------	---	----------	--	--

2026	0564U		20260101	N	\$416.78	Pathogen-specific nucleic acid DNA or RNA testing for 10 viral targets and 4	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (dna or rna), 10 viral targets and 4 bacterial targets, qualitative rt-pcr, upper respiratory specimen, each pathogen reported as positive or negative
------	-------	--	----------	---	----------	--	--

2026	0564U	QW	20260101	N	\$416.78	Pathogen-specific nucleic acid DNA or RNA testing for 10 viral targets and 4	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (dna or rna), 10 viral targets and 4 bacterial targets, qualitative rt-pcr, upper respiratory specimen, each pathogen reported as positive or negative
------	-------	----	----------	---	----------	--	--

2026	0565U		20260101	N	\$1,160.00	Next-generation sequencing methylation pattern assay to detect 6626 epigenetic	Oncology (hepatocellular carcinoma), next-generation sequencing methylation pattern assay to detect 6626 epigenetic alterations, cell-free dna, plasma, algorithm reported as cancer signal detected or not detected
2026	0566U		20260101	N	\$416.78	qPCR-based analysis of 13 differentially methylated regions in pleural fluid,	Oncology (lung), qpcr-based analysis of 13 differentially methylated regions (ccdc181, hoxa7, lrrc8a, marchf11, mir129-2, ncor2, pantr1, prkcb, slc9a3, tbr1_2, trap1, vwc2, znf781), pleural fluid, algorithm reported as a qualitative result

2026	0567U		20260101	N	\$5,031.20	Whole-genome sequence analysis n blood, saliva, amniocentesis, chorionic villus	Rare diseases (constitutional/ heritable disorders), whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial dna sequence and deletions, short tandem repeat genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification
------	-------	--	----------	---	------------	---	--

2026	0568U		20260101	N	\$897.00	Testing for proteins by ultra high-sensitivity molecule array detection in	Neurology (dementia), beta amyloid (ab40, ab42, ab42/40 ratio), tau-protein phosphorylated at residue (eg, ptau217), neurofilament light chain (nfl), and glial fibrillary acidic protein (gfap), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for alzheimer pathology
------	-------	--	----------	---	----------	--	---

2026	0569U		20260101	L	\$ -	Next-generation sequencing analysis of tumor methylation markers present in	Oncology (solid tumor), next-generation sequencing analysis of tumor methylation markers (>20000 differentially methylated regions) present in cell-free circulating tumor dna (ctdna), whole blood, algorithm reported as presence or absence of ctdna with tumor fraction, if appropriate
------	-------	--	----------	---	------	---	---

2026	0570U		20260101	N	\$260.50	Testing for proteins in whole blood or plasma, individual components reported	Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (gfap) and ubiquitin carboxyl-terminal hydrolase I1 (uch-l1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison
------	-------	--	----------	---	----------	---	--

2026	0571U		20260101	N	\$2,919.60	Next-generation sequencing of DNA in 80 genes and RNA in 10 genes in plasma,	Oncology (solid tumor), dna (80 genes) and rna (10 genes), by next-generation sequencing, plasma, including single-nucleotide variants, insertions/deletions, copy-number alterations, microsatellite instability, and fusions, reported as clinically actionable variants
2026	0572U		20260101	L	\$ -	High-throughput telomere length quantification by FISH testing in whole blood,	Oncology (prostate), high-throughput telomere length quantification by fish, whole blood, diagnostic algorithm reported as risk of prostate cancer

2026	0573U		20260101	L	\$ -	Testing for 3 biomarkers in pancreatic cyst lesion fluid, algorithm reported as	Oncology (pancreas), 3 biomarkers (glucose, carcinoembryonic antigen, and gastrin), pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non-mucinous
2026	0574U		20260101	L	\$ -	Culture filtrate protein-10-kDa testing in serum or plasma for tuberculosis	Mycobacterium tuberculosis, culture filtrate protein-10-kDa (cfp-10), serum or plasma, liquid chromatography mass spectrometry (lc-ms)

2026	0575U		20260101	N	\$380.00	miRNA gene expression profiling by RT-PCR of 4 genes in serum reported as risk	Transplantation medicine (liver allograft rejection), mirna gene expression profiling by rt-pcr of 4 genes (mir-122, mir-885, mir-23a housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection
------	-------	--	----------	---	----------	--	---

2026	0576U		20260101	N	\$3,240.00	Whole genome next-generation sequencing in plasma and mRNA gene expression	Transplantation medicine (liver allograft rejection), quantitative donor-derived cell-free dna (cfdna) by whole genome nextgeneration sequencing, plasma and mrna gene expression profiling by multiplex real-time pcr of 56 genes, whole blood, combined algorithm reported as a rejection risk score
------	-------	--	----------	---	------------	--	--

2026	0577U		20260101	N	\$246.92	Analysis of proteins reported as likelihood of malignancy in ovarian cancer	Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (lc-ms/ms) in multiple reaction monitoring mode, reported as likelihood of malignancy
------	-------	--	----------	---	----------	---	--

2026	0578U		20260101	N	\$3,873.00	RNA gene expression profiling of 10 genes results reported as either low-risk	Oncology (cutaneous melanoma), rna, gene expression profiling by realtime qpcr of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence
------	-------	--	----------	---	------------	---	--

2026	0579U		20260101	N	\$390.75	Test for proteins in plasma combined with estimated glomerular filtration rate	Nephrology (diabetic chronic kidney disease), enzymelinked immunosorbent assay (elisa) of apolipoprotein a4 (apoa4), cd5 antigen-like (cd5l) combined with estimated glomerular filtration rate (gfr), age, plasma, algorithm reported as a risk score for kidney function decline
2026	0580U		20260101	N	\$17.21	Antibody detection test for borrelia	Borrelia burgdorferi (lyme disease), antibody detection of 31 recombinant protein groups, by immunoassay, igg

2026	0581U		20260101	N	\$325.80	Antibody test in blood, results reported as positive for antibodies tested in	Transplantation medicine, antibody to non-human leukocyte antigens (nonhla), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported
2026	0582U		20260101	N	\$7,582.20	Rapid whole genome sequence analysis of blood, saliva, tissue sample for	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome dna sequencing for single nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported

2026	0583U		20260101	N	\$3,791.10	Rapid whole genome comparator sequencing of blood, saliva, tissue sample for	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome comparator dna sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported with proband results (list separately in addition to code for primary procedure)
2026	0584U		20260101	N	\$540.99	Testing for protein to detect prion disease	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quakinginduced conformational conversion, qualitative

2026	0585U		20260101	N	\$2,919.60	Targeted genomic testing for solid organ cancer	Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free dna (cfdna) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements , and microsatellite instability, report shows identified mutations, including variants with clinical actionability
------	-------	--	----------	---	------------	---	--

2026	0586U		20260101	N	\$2,919.60	mRNA gene expression profiling of 216 genes in cancer	Oncology, mrna, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), rna expression analysis, formalinixed paraffin-embedded (ffpe) tissue, quantitative, reported as log2 ratio per gene
------	-------	--	----------	---	------------	---	---

2026	0587U		20260101	N	\$114.43	Testing for drug metabolites in urine and saliva reported as a risk score for	Therapeutic drug monitoring, 60-150 drugs and metabolites, urine, saliva, quantitative liquid chromatography with tandem mass spectrometry (lcms/ms), specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects
------	-------	--	----------	---	----------	---	--

2026	0588U		20260101	N	\$760.00	mRNA gene expression profiling of 32 genes in whole blood, reported as risk	Infectious disease (bacterial or viral), 32 genes (29 informative and 3 housekeeping), immune response mrna, gene expression profiling by splitwell multiplex reverse transcription loop-mediated isothermal amplification (rtlamp), whole blood, reported as continuous risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days
------	-------	--	----------	---	----------	---	--

2026	0589U		20260101	N	\$198.74	Testing of plasma or serum for 24 perfluoroalkyl substances (PFAS) compounds	Perfluoroalkyl substances (pfas) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 pfas compounds by high-performance liquid chromatography with tandem mass spectrometry (lcms/ms), plasma or serum, quantitative
2026	0590U		20260101	L	\$ -	Measurement of DNA of bacteria and fungi in urine	Infectious disease (bacterial and fungal), dna of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism

2026	0591U		20260101	N	\$760.00	Analysis of proteins in plasma reported as a probability score for prostate	Oncology (prostate cancer), biochemical analysis of 3 proteins (total psa, free psa, and he4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer
------	-------	--	----------	---	----------	---	--

2026	0592U		20260101	N	\$2,919.60	Targeted genomic testing for blood/lymph tumors	Oncology (hematolymphoid neoplasms), dna, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements , utilizing formalin-fixed paraffinembedded (ffpe) tumor tissue, results report clinically significant variant(s)
2026	0593U		20260101	N	\$634.84	Measurement of DNA of pathogens in urine, results reported as detected or not	Infectious disease (genitourinary pathogens), dna, 46 targets (28 pathogens, 18 resistance genes), rt-pcr amplified probe technique, urine, each analyte reported as detected or not detected

2026	0594U		20260101	L	\$ -	Measurement of protein in blood, reported as risk of blood infection	Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis
------	-------	--	----------	---	------	--	--

2026	0595U		20260101	N	\$262.99	Measurement of tropical fever pathogens in blood, results reported as detected	Infectious disease (tropical fever pathogens), vectorborne and zoonotic pathogens, including 2 viruses (chikungunya virus and dengue virus serotypes 1, 2, 3, and 4), 1 bacterium (leptospira species), and 1 parasite with species differentiation (plasmodium species, plasmodium falciparum, and plasmodium vivax/ovale), real-time rtPCR, whole blood, each pathogen reported as detected or not detected
------	-------	--	----------	---	----------	--	---

2026	0596U		20260101	L	\$ -	Measurement of peptides in plasma in Alzheimer disease reported as an	Neurology (alzheimer disease), plasma, 3 distinct isoform-specific peptides (apoe2, apoe3, and apoe4) by liquid chromatography with tandem mass spectrometry (lcms/ms), reported as an apoe prototype
------	-------	--	----------	---	------	---	---

2026	0597U		20260101	L	\$ -	RNA gene expression profiling of 329 genes and testing of 20 proteins to	Oncology (breast), rna expression profiling of 329 genes by targeted nextgeneration sequencing and 20 proteins by multiplex immunofluorescence, formalin-fixed paraffinembedded (ffpe) tissue, algorithmic analyses to determine tumor-recurrence risk score
2026	0598U		20260101	N	\$300.00	Testing for IgG antibodies to 18 food items in blood or serum, results reported	Gastroenterology (irritable bowel syndrome), igg antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels

2026	0599U		20260101	N	\$897.00	Testing for biomarkers for pancreatic cancer	Oncology (pancreatic cancer), multiplex immunoassay of icam1, timp1, ctcd, thbs1, and ca 19-9, serum, diagnostic algorithm reported as positive or negative
2026	0600U		20260101	L	\$ -	Infectious disease (wound infection), identification of 65 organisms and 30	Infectious disease (wound infection), identification of 65 organisms and 30 antibiotic resistance genes, wound swab, real-time pcr, reported as positive or negative for each organism

2026	0601U		20260101	L	\$ -	Infectious disease (periprosthetic joint infection), analysis of 11 biomarkers	Infectious disease (periprosthetic joint infection), analysis of 11 biomarkers (alpha defensins 1-3, creactive protein, microbial antigens for staphylococcus [spa, spb], enterococcus, candida, and c. acnes, total nucleated cell count, percent neutrophils, rbc count, and absorbance at 280 nm) using immunoassays, hematology, clinical chemistry, synovial fluid, and diagnostic algorithm reported as a probability score
------	-------	--	----------	---	------	--	---

2026	0602U		20260101	L	\$ -	Endocrinology (diabetes), insulin (ins) gene methylation using digital droplet	Endocrinology (diabetes), insulin (ins) gene methylation using digital droplet pcr, insulin, and cpeptide immunoassay, serum, hemoglobin a1c immunoassay, whole blood, algorithm reported as diabetes-risk score
2026	0603U		20260101	L	\$ -	Drug assay, presumptive, 77 drugs or metabolites, urine, liquid chromatography	Drug assay, presumptive, 77 drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (lc-ms/ms), results reported as positive or negative

2026	0604U		20260101	L	\$ -	Allergy and immunology (chronic recurrent angioedema), 4 bradykinin peptides,	Allergy and immunology (chronic recurrent angioedema), 4 bradykinin peptides, liquid chromatography and tandem mass spectrometry (lc-ms/ ms), whole blood, quantitative
2026	0605U		20260101	L	\$ -	Allergy and immunology (hereditary alpha tryptasemia), dna, analysis of tpsab1	Allergy and immunology (hereditary alpha tryptasemia), dna, analysis of tpsab1 gene copy number variation using digital pcr, whole blood, results reported with genotypespecific interpretation of alpha-tryptase copy number and algorithmic classification as normal or abnormal

2026	0606U		20260101	L	\$ -	Hematology (red cell membrane disorders), rbcs, osmotic gradient ektacytometry,	Hematology (red cell membrane disorders), rbcs, osmotic gradient ektacytometry, whole blood, quantitative
2026	0607U		20260101	L	\$ -	Reproductive medicine (endometrial microbiome assessment), real-time pcr	Reproductive medicine (endometrial microbiome assessment), real-time pcr analysis for 31 bacterial dna targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations

2026	0608U		20260101	L	\$ -	Reproductive medicine (endometrial microbiome assessment), real-time pcr	Reproductive medicine (endometrial microbiome assessment), real-time pcr analysis for 10 bacterial dna targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations
------	-------	--	----------	---	------	--	--

2026	0609U		20260101	L	\$ -	Oncology (prostate), immunoassay for total prostate-specific antigen (psa) and	Oncology (prostate), immunoassay for total prostate-specific antigen (psa) and free psa, serum or plasma, combined with clinical features, algorithm reported as a probability score for clinically significant prostate cancer
------	-------	--	----------	---	------	--	---

2026	0610U		20260101	L	\$ -	Infectious disease (antimicrobial susceptibility), phenotypic antimicrobial	Infectious disease (antimicrobial susceptibility), phenotypic antimicrobial susceptibility testing of positive blood culture using microfluidic sensor technology to quantify bacterial growth response to multiple antibiotic types, reporting categorical susceptibility (susceptible, susceptible dose dependent, intermediate, resistant), minimum inhibitory concentration, and interpretive comments
------	-------	--	----------	---	------	---	--

2026	0611U		20260101	L	\$ -	Oncology (liver), analysis of over 1,000 methylated regions, cell-free dna from	Oncology (liver), analysis of over 1,000 methylated regions, cell-free dna from plasma, algorithm reported as a quantitative result
2026	0612U		20260101	L	\$ -	Oncology (liver), analysis of over 1,000 methylated regions, cell-free dna from	Oncology (liver), analysis of over 1,000 methylated regions, cell-free dna from plasma, algorithm reported as a quantitative result

2026	0613U		20260101	L	\$ -	Oncology (urothelial carcinoma), dna methylation and mutation analysis of 6	Oncology (urothelial carcinoma), dna methylation and mutation analysis of 6 biomarkers (twist1, otx1, onecut2, fgfr3, hras, tert promoter region), methylation-specific pcr and targeted next-generation sequencing, urine, algorithm reported as a probability index for bladder cancer and upper tract urothelial carcinoma
------	-------	--	----------	---	------	---	---

2026	0614U		20260401	L	\$ -	Inborn error of metabolism (primary mitochondrial disease), mitochondrial	Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 4 enzyme complexes by stained blue native polyacrylamide gel electrophoresis (page), frozen tissue (muscle, liver, heart, cultured skin fibroblasts), diagnostic qualitative result
2026	0615U		20260401	L	\$ -	Borrelia burgdorferi (lyme disease), antibody detection of 26 recombinant	Borrelia burgdorferi (lyme disease), antibody detection of 26 recombinant protein groups, by immunoassay, igm

2026	0616U		20260401	L	\$ -	Neurology (dementia), dna methylation analysis of more than 30,000 sites, whole	Neurology (dementia), dna methylation analysis of more than 30,000 sites, whole blood, algorithm reported as positive or negative risk
2026	0617U		20260401	L	\$ -	Cardiovascular (atherosclerotic cardiovascular disease [ascvd]), dna	Cardiovascular (atherosclerotic cardiovascular disease [ascvd]), dna methylation analysis of more than 20,000 sites, whole blood, algorithm reported as positive or negative risk
2026	0618U		20260401	L	\$ -	Psychiatry (bipolar disorder), dna methylation analysis of more than 10,000	Psychiatry (bipolar disorder), dna methylation analysis of more than 10,000 sites, whole blood, algorithm reported as positive or negative risk

2026	0619U		20260401	L	\$ -	Pulmonary (chronic obstructive pulmonary disease [copd]), dna methylation	Pulmonary (chronic obstructive pulmonary disease [copd]), dna methylation analysis of more than 18,000 sites, whole blood, algorithm reported as positive or negative risk
2026	0620U		20260401	L	\$ -	Oncology (hepatocellular carcinoma), dna methylation analysis of more than	Oncology (hepatocellular carcinoma), dna methylation analysis of more than 5,000 sites, whole blood, algorithm reported as positive or negative risk

2026	0621U		20260401	L	\$ -	Infectious disease (lyme borreliosis), dna methylation analysis of more than	Infectious disease (lyme borreliosis), dna methylation analysis of more than 10,000 sites, whole blood, algorithm reported as positive or negative risk
2026	0622U		20260401	L	\$ -	Psychiatry (major depressive disorder), dna methylation analysis of more than	Psychiatry (major depressive disorder), dna methylation analysis of more than 20,000 sites, whole blood, algorithm reported as positive or negative risk
2026	0623U		20260401	L	\$ -	Autoimmune (multiple sclerosis), dna methylation analysis of more than 5,000	Autoimmune (multiple sclerosis), dna methylation analysis of more than 5,000 sites, whole blood, algorithm reported as positive or negative risk

2026	0624U		20260401	L	\$ -	Hepatology (nonalcoholic steatohepatitis [nash]), dna methylation analysis of	Hepatology (nonalcoholic steatohepatitis [nash]), dna methylation analysis of 5,000 sites, whole blood, algorithm reported as positive or negative risk
2026	0625U		20260401	L	\$ -	Endocrinology (osteoporosis), dna methylation analysis of more than 5,000	Endocrinology (osteoporosis), dna methylation analysis of more than 5,000 sites, whole blood, algorithm reported as positive or negative risk
2026	0626U		20260401	L	\$ -	Neurology (parkinson disease), dna methylation analysis of more than 20,000	Neurology (parkinson disease), dna methylation analysis of more than 20,000 sites, whole blood, algorithm reported as positive or negative risk

2026	0627U		20260401	L	\$ -	Psychiatry (schizophrenia), dna methylation analysis of more than 15,000 sites,	Psychiatry (schizophrenia), dna methylation analysis of more than 15,000 sites, whole blood, algorithm reported as positive or negative risk
2026	0628U		20260401	L	\$ -	Nephrology (kidney diseaserelated genetic conditions), genomic analysis, renal	Nephrology (kidney diseaserelated genetic conditions), genomic analysis, renal disease panel, saliva, dna, next-generation sequencing of 449 genes, reported as pathogenic or likely pathogenic variants of uncertain significance or risk alleles

2026	0629U		20260401	L	\$ -	Infectious disease (tuberculosis), dna, analysis of 1 target by pcr with	Infectious disease (tuberculosis), dna, analysis of 1 target by pcr with clustered regularly interspaced short palindromic repeat (crispr)-based probe detection, plasma or serum, qualitative report as detected or not detected
------	-------	--	----------	---	------	--	---

2026	0630U		20260401	L	\$ -	Oncology (breast), mrna, gene expression profiling by microarray of 80 genes	Oncology (breast), mrna, gene expression profiling by microarray of 80 genes (80 content and 465 housekeeping), utilizing formalin-fixed paraffinembedded tissue (ffpe), algorithm reported as an index that is diagnostic of a molecular subtype (luminal, basal, her2)
2026	36415		20260101	N	\$9.34	Insertion of needle into vein for collection of blood sample	Collection of venous blood by venipuncture
2026	78267		20260101	N	\$11.06	Nuclear medicine study to acquire exhaled breath samples	Urea breath test, c-14 (isotopic); acquisition for analysis
2026	78268		20260101	N	\$94.41	Nuclear medicine study to assess exhaled breath samples	Urea breath test, c-14 (isotopic); analysis

2026	80047		20260101	N	\$13.73	Blood test, basic group of blood chemicals (Calcium, ionized)	Basic metabolic panel (calcium, ionized) this panel must include the following: calcium, ionized (82330) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) potassium (84132) sodium (84295) urea nitrogen (bun) (84520)
------	-------	--	----------	---	---------	---	---

2026	80047	QW	20260101	N	\$13.73	Blood test, basic group of blood chemicals (Calcium, ionized)	Basic metabolic panel (calcium, ionized) this panel must include the following: calcium, ionized (82330) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) potassium (84132) sodium (84295) urea nitrogen (bun) (84520)
------	-------	----	----------	---	---------	---	---

2026	80048		20260101	N	\$8.46	Blood test, basic group of blood chemicals (Calcium, total)	Basic metabolic panel (calcium, total) this panel must include the following: calcium, total (82310) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) potassium (84132) sodium (84295) urea nitrogen (bun) (84520)
------	-------	--	----------	---	--------	--	---

2026	80048	QW	20260101	N	\$8.46	Blood test, basic group of blood chemicals (Calcium, total)	Basic metabolic panel (calcium, total) this panel must include the following: calcium, total (82310) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) potassium (84132) sodium (84295) urea nitrogen (bun) (84520)
2026	80051		20260101	N	\$7.01	Blood test panel for electrolytes (sodium potassium, chloride, carbon dioxide)	Electrolyte panel this panel must include the following: carbon dioxide (bicarbonate) (82374) chloride (82435) potassium (84132) sodium (84295)

2026	80051	QW	20260101	N	\$7.01	Blood test panel for electrolytes (sodium, potassium, chloride, carbon dioxide)	Electrolyte panel this panel must include the following: carbon dioxide (bicarbonate) (82374) chloride (82435) potassium (84132) sodium (84295)
------	-------	----	----------	---	--------	---	---

2026	80053		20260101	N	\$10.56	Blood test, comprehensive group of blood chemicals	Comprehensive metabolic panel this panel must include the following: albumin (82040) bilirubin, total (82247) calcium, total (82310) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) phosphatase, alkaline (84075) potassium (84132) protein, total (84155) sodium (84295) transferase, alanine amino (alt) (sgpt) (84460) transferase, aspartate amino (ast) (sgot) (84450) urea nitrogen (bun) (84520)
------	-------	--	----------	---	---------	--	---

2026	80053	QW	20260101	N	\$10.56	Blood test, comprehensive group of blood chemicals	Comprehensive metabolic panel this panel must include the following: albumin (82040) bilirubin, total (82247) calcium, total (82310) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) phosphatase, alkaline (84075) potassium (84132) protein, total (84155) sodium (84295) transferase, alanine amino (alt) (sgpt) (84460) transferase, aspartate amino (ast) (sgot) (84450) urea nitrogen (bun) (84520)
------	-------	----	----------	---	---------	--	---

2026	80055		20260101	N	\$47.81	Obstetric blood test panel	Obstetric panel this panel must include the following: blood count, complete (cbc), automated and automated differential wbc count (85025 or 85027 and 85004) or blood count, complete (cbc), automated (85027) and appropriate manual differential wbc count (85007 or 85009) hepatitis b surface antigen (hbsag) (87340) antibody, rubella (86762) syphilis test, non-treponemal antibody; qualitative (eg, vdrl, rpr, art) (86592) antibody screen, rbc, each serum technique (86850) blood typing, abo (86900) and blood typing, rh (d) (86901)
------	-------	--	----------	---	---------	----------------------------	---

2026	80061		20260101	N	\$13.39	Blood test, lipids (cholesterol and triglycerides)	Lipid panel this panel must include the following: cholesterol, serum, total (82465) lipoprotein, direct measurement, high density cholesterol (hdl cholesterol) (83718) triglycerides (84478)
2026	80061	QW	20260101	N	\$13.39	Blood test, lipids (cholesterol and triglycerides)	Lipid panel this panel must include the following: cholesterol, serum, total (82465) lipoprotein, direct measurement, high density cholesterol (hdl cholesterol) (83718) triglycerides (84478)

2026	80069		20260101	N	\$8.68	Kidney function blood test panel	Renal function panel this panel must include the following: albumin (82040) calcium, total (82310) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) phosphorus inorganic (phosphate) (84100) potassium (84132) sodium (84295) urea nitrogen (bun) (84520)
------	-------	--	----------	---	--------	--	---

2026	80069	QW	20260101	N	\$8.68	Kidney function blood test panel	Renal function panel this panel must include the following: albumin (82040) calcium, total (82310) carbon dioxide (bicarbonate) (82374) chloride (82435) creatinine (82565) glucose (82947) phosphorus inorganic (phosphate) (84100) potassium (84132) sodium (84295) urea nitrogen (bun) (84520)
------	-------	----	----------	---	--------	--	---

2026	80074		20260101	N	\$47.63	Acute hepatitis panel	Acute hepatitis panel this panel must include the following: hepatitis a antibody (haab), igm antibody (86709) hepatitis b core antibody (hbcab), igm antibody (86705) hepatitis b surface antigen (hbsag) (87340) hepatitis c antibody (86803)
------	-------	--	----------	---	---------	-----------------------	---

2026	80076		20260101	N	\$8.17	Liver function blood test panel	Hepatic function panel this panel must include the following: albumin (82040) bilirubin, total (82247) bilirubin, direct (82248) phosphatase, alkaline (84075) protein, total (84155) transferase, alanine amino (alt) (sgpt) (84460) transferase, aspartate amino (ast) (sgot) (84450)
------	-------	--	----------	---	--------	---------------------------------	---

2026	80081		20260101	N	\$74.86	Blood test panel for obstetrics (cbc, differential wbc count, hepatitis b,	Obstetric panel (includes hiv testing) this panel must include the following: blood count, complete (cbc), and automated differential wbc count (85025 or 85027 and 85004) or blood count, complete (cbc), automated (85027) and appropriate manual differential wbc count (85007 or 85009) hepatitis b surface antigen (hbsag) (87340) hiv-1 antigen(s), with hiv-1 and hiv-2 antibodies, single result (87389) antibody, rubella (86762) syphilis test, non-treponemal antibody; qualitative (eg, vdrl, rpr, art) (86592) antibody screen, rbc, each serum
------	-------	--	----------	---	---------	---	--

2026	80143		20260101	N	\$18.64	Measurement of acetaminophen	Acetaminophen
2026	80145		20260101	N	\$38.57	Measurement of adalimumab	Adalimumab
2026	80150		20260101	N	\$15.08	Amikacin (antibiotic) level	Amikacin
2026	80151		20260101	N	\$18.64	Measurement of amiodarone	Amiodarone
2026	80155		20260101	N	\$38.57	Caffeine level	Caffeine
2026	80156		20260101	N	\$14.57	Carbamazepine level, total	Carbamazepine ; total
2026	80157		20260101	N	\$13.25	Carbamazepine level, free	Carbamazepine ; free
2026	80158		20260101	N	\$18.05	Cyclosporine level	Cyclosporine
2026	80159		20260101	N	\$20.15	Clozapine level	Clozapine
2026	80161		20260101	N	\$18.64	Measurement of carbamazepine-10,11-epoxide	Carbamazepine ; -10,11-epoxide
2026	80162		20260101	N	\$13.28	Digoxin level, total	Digoxin; total
2026	80163		20260101	N	\$13.28	Digoxin level, free	Digoxin; free
2026	80164		20260101	N	\$13.54	Valproic acid level, total	Valproic acid (dipropylacetic acid); total
2026	80165		20260101	N	\$13.54	Valproic acid level, free	Valproic acid (dipropylacetic acid); free
2026	80167		20260101	N	\$18.64	Measurement of felbamate	Felbamate

2026	80168		20260101	N	\$16.34	Ethosuximide level	Ethosuximide
2026	80169		20260101	N	\$13.73	Everolimus level	Everolimus
2026	80170		20260101	N	\$16.38	Gentamicin (antibiotic) level	Gentamicin
2026	80171		20260101	N	\$21.67	Gabapentin level	Gabapentin, whole blood, serum, or plasma
2026	80173		20260101	N	\$15.78	Haloperidol level	Haloperidol
2026	80175		20260101	N	\$13.25	Lamotrigine level	Lamotrigine
2026	80176		20260101	N	\$14.69	Lidocaine level	Lidocaine
2026	80177		20260101	N	\$13.25	Levetiracetam level	Levetiracetam
2026	80178		20260101	N	\$6.61	Lithium level	Lithium
2026	80178	QW	20260101	N	\$6.61	Lithium level	Lithium
2026	80179		20260101	N	\$18.64	Measurement of salicylate	Salicylate
2026	80180		20260101	N	\$18.05	Mycophenolate (mycophenolic acid) level	Mycophenolate (mycophenolic acid)
2026	80181		20260101	N	\$18.64	Measurement of flecainide	Flecainide
2026	80183		20260101	N	\$13.25	Oxcarbazepine level	Oxcarbazepine
2026	80184		20260101	N	\$15.30	Phenobarbital level	Phenobarbital
2026	80185		20260101	N	\$13.25	Phenytoin level, total	Phenytoin; total

2026	80186		20260101	N	\$13.76	Phenytoin level, free	Phenytoin; free
2026	80187		20260101	N	\$27.11	Measurement of posaconazole	Posaconazole
2026	80188		20260101	N	\$16.59	Primidone level	Primidone
2026	80189		20260101	N	\$27.11	Measurement of itraconazole	Itraconazole
2026	80190		20260101	N	\$60.00	Procainamide level	Procainamide;
2026	80192		20260101	N	\$16.75	Procainamide level, with metabolites	Procainamide; with metabolites (eg, n-acetyl procainamide)
2026	80193		20260101	N	\$38.57	Measurement of leflunomide	Leflunomide
2026	80194		20260101	N	\$14.60	Quinidine level	Quinidine
2026	80195		20260101	N	\$13.73	Sirolimus level	Sirolimus
2026	80197		20260101	N	\$13.73	Tacrolimus level	Tacrolimus
2026	80198		20260101	N	\$14.14	Theophylline level	Theophylline
2026	80199		20260101	N	\$27.11	Tiagabine level	Tiagabine
2026	80200		20260101	N	\$16.13	Tobramycin (antibiotic) level	Tobramycin
2026	80201		20260101	N	\$11.92	Topiramate level	Topiramate
2026	80202		20260101	N	\$13.54	Vancomycin (antibiotic) level	Vancomycin
2026	80203		20260101	N	\$13.25	Zonisamide level	Zonisamide

2026	80204		20260101	N	\$38.57	Measurement of methotrexate	Methotrexate
2026	80210		20260101	N	\$27.11	Measurement of rufinamide	Rufinamide
2026	80220		20260101	N	\$18.64	Measurement of hydroxychloroquine	Hydroxychloroquine
2026	80230		20260101	N	\$38.57	Measurement of infliximab	Infliximab
2026	80235		20260101	N	\$27.11	Measurement of lacosamide	Lacosamide
2026	80280		20260101	N	\$38.57	Measurement of vedolizumab	Vedolizumab
2026	80285		20260101	N	\$27.11	Measurement of voriconazole	Voriconazole
2026	80299		20260101	N	\$18.64	Quantitation of therapeutic drug	Quantitation of therapeutic drug, not elsewhere specified

2026	80305		20260101	N	\$12.60	Testing for presence of drug, read by direct observation	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service
------	-------	--	----------	---	---------	--	--

2026	80305	QW	20260101	N	\$12.60	Testing for presence of drug, read by direct observation	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service
------	-------	----	----------	---	---------	--	--

2026	80306		20260101	N	\$17.14	Testing for presence of drug, read by instrument assisted observation	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service
------	-------	--	----------	---	---------	---	--

2026	80307		20260101	N	\$62.14	Testing for presence of drug, by chemistry analyzers	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, eia, elisa, emit, fpia, ia, kims, ria]), chromatography (eg, gc, hplc), and mass spectrometry either with or without chromatography, (eg, dart, desi, gc-ms, gc-ms/ms, lc-ms, lc-ms/ms, ltd, maldi, tof) includes sample validation when performed, per date of service
------	-------	--	----------	---	---------	--	---

2026	80400		20260101	N	\$32.62	Hormonal panel for adrenal gland assessment (adrenal gland insufficiency)	Acth stimulation panel; for adrenal insufficiency this panel must include the following: cortisol (82533 x 2)
2026	80402		20260101	N	\$86.96	Hormone panel for adrenal gland assessment (21 hydroxylase deficiency)	Acth stimulation panel; for 21 hydroxylase deficiency this panel must include the following: cortisol (82533 x 2) 17 hydroxyprogesterone (83498 x 2)

2026	80406		20260101	N	\$78.26	Hormone panel adrenal gland assessment (3 beta-hydroxydehydrogenase deficiency)	Acth stimulation panel; for 3 beta-hydroxydehydrogenase deficiency this panel must include the following: cortisol (82533 x 2) 17 hydroxypregnenolone (84143 x 2)
2026	80408		20260101	N	\$125.50	Aldosterone suppression evaluation panel	Aldosterone suppression evaluation panel (eg, saline infusion) this panel must include the following: aldosterone (82088 x 2) renin (84244 x 2)
2026	80410		20260101	N	\$80.37	Calcitonin stimulation panel	Calcitonin stimulation panel (eg, calcium, pentagastrin) this panel must include the following: calcitonin (82308 x 3)

2026	80412		20260101	N	\$801.62	Adrenal gland stimulation panel	Corticotropin releasing hormone (crh) stimulation panel this panel must include the following: cortisol (82533 x 6) adrenocorticotropic hormone (acth) (82024 x 6)
2026	80414		20260101	N	\$51.64	Reproductive hormone panel (testosterone)	Chorionic gonadotropin stimulation panel; testosterone response this panel must include the following: testosterone (84403 x 2 on 3 pooled blood samples)

2026	80415		20260101	N	\$55.89	Reproductive hormone panel (estradiol)	Chorionic gonadotropin stimulation panel; estradiol response this panel must include the following: estradiol, total (82670 x 2 on 3 pooled blood samples)
2026	80416		20260101	N	\$209.32	Renal vein renin (kidney enzyme) stimulation panel	Renal vein renin stimulation panel (eg, captopril) this panel must include the following: renin (84244 x 6)
2026	80417		20260101	N	\$43.99	Peripheral vein renin (kidney enzyme) stimulation panel	Peripheral vein renin stimulation panel (eg, captopril) this panel must include the following: renin (84244 x 2)

2026	80418		20260101	N	\$579.48	Anterior pituitary gland evaluation panel	Combined rapid anterior pituitary evaluation panel this panel must include the following: adrenocorticotr opic hormone (acth) (82024 x 4) luteinizing hormone (lh) (83002 x 4) follicle stimulating hormone (fsh) (83001 x 4) prolactin (84146 x 4) human growth hormone (hgh) (83003 x 4) cortisol (82533 x 4) thyroid stimulating hormone (tsh) (84443 x 4)
------	-------	--	----------	---	----------	--	---

2026	80420		20260101	N	\$161.88	Dexamethason e (steroid) suppression evaluation panel, 48 hour	Dexamethason e suppression panel, 48 hour this panel must include the following: free cortisol, urine (82530 x 2) cortisol (82533 x 2) volume measurement for timed collection (81050 x 2)
2026	80422		20260101	N	\$46.07	Glucagon (hormone) tolerance panel to evaluate for insulinoma (pancreatic tumor)	Glucagon tolerance panel; for insulinoma this panel must include the following: glucose (82947 x 3) insulin (83525 x 3)
2026	80424		20260101	N	\$50.50	Glucagon (hormone) tolerance panel to evaluate for pheochromocyt oma (adrenal	Glucagon tolerance panel; for pheochromocyt oma this panel must include the following: catecholamines , fractionated (82384 x 2)

2026	80426		20260101	N	\$148.41	Gonadotropin releasing hormone (reproductive hormone) panel	Gonadotropin releasing hormone stimulation panel this panel must include the following: follicle stimulating hormone (fsh) (83001 x 4) luteinizing hormone (lh) (83002 x 4)
2026	80428		20260101	N	\$66.70	Growth hormone stimulation panel	Growth hormone stimulation panel (eg, arginine infusion, l-dopa administration) this panel must include the following: human growth hormone (hgh) (83003 x 4)

2026	80430		20260101	N	\$129.33	Growth hormone suppression panel	Growth hormone suppression panel (glucose administration) this panel must include the following: glucose (82947 x 3) human growth hormone (hgh) (83003 x 4)
2026	80432		20260101	N	\$165.61	Insulin-induced C-peptide (protein) suppression panel	Insulin-induced c-peptide suppression panel this panel must include the following: insulin (83525) c-peptide (84681 x 5) glucose (82947 x 5)
2026	80434		20260101	N	\$285.03	Insulin tolerance panel for ACTH (adrenal gland hormone) insufficiency	Insulin tolerance panel; for acth insufficiency this panel must include the following: cortisol (82533 x 5) glucose (82947 x 5)

2026	80435		20260101	N	\$103.00	Insulin tolerance panel for growth hormone deficiency	Insulin tolerance panel; for growth hormone deficiency this panel must include the following: glucose (82947 x 5) human growth hormone (hgh) (83003 x 5)
2026	80436		20260101	N	\$91.16	Metyrapone (hormone antibody) panel	Metyrapone panel this panel must include the following: cortisol (82533 x 2) 11 deoxycortisol (82634 x 2)
2026	80438		20260101	N	\$50.41	Thyrotropin releasing hormone (TRH) (hypothalamus hormone) stimulation panel, 1	Thyrotropin releasing hormone (trh) stimulation panel; 1 hour this panel must include the following: thyroid stimulating hormone (tsh) (84443 x 3)

2026	80439		20260101	N	\$67.21	Thyrotropin releasing hormone (TRH) (hypothalamus hormone) stimulation panel, 2	Thyrotropin releasing hormone (trh) stimulation panel; 2 hour this panel must include the following: thyroid stimulating hormone (tsh) (84443 x 4)
2026	81000		20260101	N	\$4.02	Manual urinalysis test with examination using microscope, non-automated	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy

2026	81001		20260101	N	\$3.17	Manual urinalysis test with examination using microscope, automated	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy
2026	81002		20260101	N	\$3.48	Urinalysis, manual test	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy

2026	81003		20260101	N	\$2.25	Automated urinalysis test	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy
2026	81003	QW	20260101	N	\$2.25	Automated urinalysis test	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy

2026	81005		20260101	N	\$2.17	Analysis of urine, except immunoassays	Urinalysis; qualitative or semiquantitative, except immunoassays
2026	81007		20260101	N	\$29.98	Urinalysis for bacteria	Urinalysis; bacteriuria screen, except by culture or dipstick
2026	81007	QW	20260101	N	\$29.98	Urinalysis for bacteria	Urinalysis; bacteriuria screen, except by culture or dipstick
2026	81015		20260101	N	\$3.05	Urinalysis using microscope	Urinalysis; microscopic only
2026	81020		20260101	N	\$4.70	Urinalysis, 2 or 3 glass test	Urinalysis; 2 or 3 glass test
2026	81025		20260101	N	\$8.61	Urine pregnancy test	Urine pregnancy test, by visual color comparison methods
2026	81050		20260101	N	\$3.64	Urine volume measurement	Volume measurement for timed collection, each

2026	81105		20260101	N	\$122.22	Gene analysis (Human Platelet Antigen 1) for common variant	Human platelet antigen 1 genotyping (hpa-1), itgb3 (integrin, beta 3 [platelet glycoprotein iiia], antigen cd61 [gp11a]) (eg, neonatal alloimmune thrombocytopenia [nait], post-transfusion purpura), gene analysis, common variant, hpa-1a/b (l33p)
2026	81106		20260101	N	\$122.22	Gene analysis (Human Platelet Antigen 2) for common variant	Human platelet antigen 2 genotyping (hpa-2), gp1ba (glycoprotein ib [platelet], alpha polypeptide [gp1ba]) (eg, neonatal alloimmune thrombocytopenia [nait], post-transfusion purpura), gene analysis, common variant, hpa-2a/b (t145m)

2026	81107		20260101	N	\$122.22	Gene analysis (Human Platelet Antigen 3) for common variant	Human platelet antigen 3 genotyping (hpa-3), itga2b (integrin, alpha 2b [platelet glycoprotein iib of iib/iiia complex], antigen cd41 [gpiib]) (eg, neonatal alloimmune thrombocytopenia [nait], post-transfusion purpura), gene analysis, common variant, hpa-3a/b (i843s)
------	-------	--	----------	---	----------	---	---

2026	81108		20260101	N	\$122.22	Gene analysis (Human Platelet Antigen 4) for common variant	Human platelet antigen 4 genotyping (hpa-4), itgb3 (integrin, beta 3 [platelet glycoprotein iiia], antigen cd61 [gp111]) (eg, neonatal alloimmune thrombocytopenia [nait], post-transfusion purpura), gene analysis, common variant, hpa-4a/b (r143q)
------	-------	--	----------	---	----------	---	---

2026	81109		20260101	N	\$122.22	Gene analysis (Human Platelet Antigen 5) for common variant	Human platelet antigen 5 genotyping (hpa-5), itga2 (integrin, alpha 2 [cd49b, alpha 2 subunit of vla-2 receptor] [gpiia]) (eg, neonatal alloimmune thrombocytopenia [nait], post-transfusion purpura), gene analysis, common variant (eg, hpa-5a/b [k505e])
------	-------	--	----------	---	----------	---	---

2026	81110		20260101	N	\$122.22	Gene analysis (Human Platelet Antigen 6) for common variant	Human platelet antigen 6 genotyping (hpa-6w), itgb3 (integrin, beta 3 [platelet glycoprotein iiia, antigen cd61] [gpIIb/IIIa]) (eg, neonatal alloimmune thrombocytopenia [nait], post-transfusion purpura), gene analysis, common variant, hpa-6a/b (r489q)
------	-------	--	----------	---	----------	---	---

2026	81111		20260101	N	\$122.22	Gene analysis (Human Platelet Antigen 9) for common variant	Human platelet antigen 9 genotyping (hpa-9w), itga2b (integrin, alpha 2b [platelet glycoprotein iib of iib/iiia complex, antigen cd41] [gpiib]) (eg, neonatal alloimmune thrombocytopenia [nait], post-transfusion purpura), gene analysis, common variant, hpa-9a/b (v837m)
------	-------	--	----------	---	----------	---	--

2026	81112		20260101	N	\$122.22	Gene analysis (Human Platelet Antigen 15) for common variant	Human platelet antigen 15 genotyping (hpa-15), cd109 (cd109 molecule) (eg, neonatal alloimmune thrombocytopenia [nait], post-transfusion purpura), gene analysis, common variant, hpa-15a/b (s682y)
2026	81120		20260101	N	\$193.25	Gene analysis (isocitrate dehydrogenase 1 [NADP+], soluble) for common variants	Idh1 (isocitrate dehydrogenase 1 [nadp+], soluble) (eg, glioma), common variants (eg, r132h, r132c)
2026	81121		20260101	N	\$295.79	Gene analysis (isocitrate dehydrogenase 2 [NADP+], mitochondrial) for common	Idh2 (isocitrate dehydrogenase 2 [nadp+], mitochondrial) (eg, glioma), common variants (eg, r140w, r172m)

2026	81161		20260101	N	\$279.00	Gene analysis (dystrophin)	Dmd (dystrophin) (eg, duchenne/becker muscular dystrophy) deletion analysis, and duplication analysis, if performed
2026	81162		20260101	N	\$1,824.88	Gene analysis (breast cancer 1 and 2) of full sequence and analysis for	Brca1 (brca1, dna repair associated), brca2 (brca2, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (ie, detection of large gene rearrangements)

2026	81163		20260101	N	\$468.00	Gene analysis (breast cancer 1 and 2) of full sequence	Brca1 (brca1, dna repair associated), brca2 (brca2, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
2026	81164		20260101	N	\$584.23	Gene analysis (breast cancer 1 and 2) for duplication or deletion variants	Brca1 (brca1, dna repair associated), brca2 (brca2, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)

2026	81165		20260101	N	\$282.88	Gene analysis (breast cancer 1) of full sequence	Brca1 (brca1, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
2026	81166		20260101	N	\$301.35	Gene analysis (breast cancer 1) for duplication or deletion variants	Brca1 (brca1, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
2026	81167		20260101	N	\$282.88	Gene analysis (breast cancer 2) for duplication or deletion variants	Brca2 (brca2, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)

2026	81168		20260101	N	\$207.31	Gene analysis (CCND1/IGH (t(11;14))) translocation analysis	Ccnd1/igh (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed
2026	81170		20260101	N	\$300.00	Gene analysis (ABL proto-oncogene 1, non-receptor tyrosine kinase)	Abl1 (abl proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain
2026	81171		20260101	N	\$137.00	Gene analysis (fragile X intellectual disability 2) for detection of abnormal	Aff2 (alf transcription elongation factor 2 [fmr2]) (eg, fragile x intellectual disability 2 [fraxe]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles

2026	81172		20260101	N	\$274.83	Gene analysis (fragile X intellectual disability 2) for characterization of	Aff2 (alf transcription elongation factor 2 [fmr2]) (eg, fragile x intellectual disability 2 [fraxe]) gene analysis; characterization of alleles (eg, expanded size and methylation status)
2026	81173		20260101	N	\$301.35	Gene analysis (androgen receptor) of full sequence	Ar (androgen receptor) (eg, spinal and bulbar muscular atrophy, kennedy disease, x chromosome inactivation) gene analysis; full gene sequence

2026	81174		20260101	N	\$185.20	Gene analysis (androgen receptor) for known familial variant	Ar (androgen receptor) (eg, spinal and bulbar muscular atrophy, kennedy disease, x chromosome inactivation) gene analysis; known familial variant
2026	81175		20260101	N	\$676.50	Gene analysis (additional sex combs like 1, transcriptional regulator) full	Asx1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence

2026	81176		20260101	N	\$241.90	Gene analysis (additional sex combs like 1, transcriptional regulator) targeted	Asx1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12)
2026	81177		20260101	N	\$137.00	Gene analysis (atrophin 1) for abnormal alleles	Atn1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles

2026	81178		20260101	N	\$137.00	Gene analysis (ataxin 1) for abnormal alleles	Atxn1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
2026	81179		20260101	N	\$137.00	Gene analysis (ataxin 2) for abnormal alleles	Atxn2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
2026	81180		20260101	N	\$137.00	Gene analysis (ataxin 3) for abnormal alleles	Atxn3 (ataxin 3) (eg, spinocerebellar ataxia, machado-joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles

2026	81181		20260101	N	\$137.00	Gene analysis (ataxin 7) for abnormal alleles	Atxn7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
2026	81182		20260101	N	\$137.00	Gene analysis (ataxin 8 opposite strand [non-protein coding] for abnormal	Atxn8os (atxn8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
2026	81183		20260101	N	\$137.00	Gene analysis (ataxin 10) for abnormal alleles	Atxn10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles

2026	81184		20260101	N	\$137.00	Gene analysis (calcium voltage-gated channel subunit alpha1 A) for abnormal	Cacna1a (calcium voltage-gated channel subunit alpha1 a) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
2026	81185		20260101	N	\$846.27	Gene analysis (calcium voltage-gated channel subunit alpha1 A) of full sequence	Cacna1a (calcium voltage-gated channel subunit alpha1 a) (eg, spinocerebellar ataxia) gene analysis; full gene sequence
2026	81186		20260101	N	\$185.20	Gene analysis (calcium voltage-gated channel subunit alpha1 A) for known	Cacna1a (calcium voltage-gated channel subunit alpha1 a) (eg, spinocerebellar ataxia) gene analysis; known familial variant

2026	81187		20260101	N	\$137.00	Gene analysis (CCH-type zinc finger nucleic acid binding protein) for abnormal	Cnbp (cchc-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
2026	81188		20260101	N	\$137.00	Gene analysis (cystatin B) for abnormal alleles	Cstb (cystatin b) (eg, unverricht-lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
2026	81189		20260101	N	\$274.83	Gene analysis (cystatin B) of full sequence	Cstb (cystatin b) (eg, unverricht-lundborg disease) gene analysis; full gene sequence
2026	81190		20260101	N	\$185.20	Gene analysis (cystatin B) for known familial variants	Cstb (cystatin b) (eg, unverricht-lundborg disease) gene analysis; known familial variant (s)

2026	81191		20260101	N	\$207.31	Gene analysis (neurotrophic receptor tyrosine kinase 1) translocation analysis	Ntrk1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis
2026	81192		20260101	N	\$207.31	Gene analysis (neurotrophic receptor tyrosine kinase 2) translocation analysis	Ntrk2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis
2026	81193		20260101	N	\$207.31	Gene analysis (neurotrophic receptor tyrosine kinase 3) translocation analysis	Ntrk3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis
2026	81194		20260101	N	\$518.28	Gene analysis (neurotrophic receptor tyrosine kinase 1, 2, and 3) translocation	Ntrk (neurotrophic receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis

2026	81195		20260101	N	\$1,863.22	Optical genome mapping for hematologic malignancy	Cytogenomic (genome-wide) analysis, hematologic malignancy, structural variants and copy number variants, optical genome mapping (ogm)
2026	81200		20260101	N	\$47.25	Gene analysis (aspartoacylase)	Aspa (aspartoacylase) (eg, canavan disease) gene analysis, common variants (eg, e285a, y231x)
2026	81201		20260101	N	\$780.00	Gene analysis (adenomatous polyposis coli), full gene sequence	Apc (adenomatous polyposis coli) (eg, familial adenomatous polyposis [fap], attenuated fap) gene analysis; full gene sequence

2026	81202		20260101	N	\$280.00	Gene analysis (adenomatous polyposis coli), known familial variants	Apc (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [fap], attenuated fap) gene analysis; known familial variants
2026	81203		20260101	N	\$200.00	Gene analysis (adenomatous polyposis coli), duplication or deletion variants	Apc (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [fap], attenuated fap) gene analysis; duplication/deletion variants
2026	81204		20260101	N	\$137.00	Gene analysis (androgen receptor) for characterization of alleles	Ar (androgen receptor) (eg, spinal and bulbar muscular atrophy, kennedy disease, x chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)

2026	81205		20260101	N	\$94.99	Gene analysis (branched-chain keto acid dehydrogenase E1, beta polypeptide)	Bckdhb (branched-chain keto acid dehydrogenase e1, beta polypeptide) (eg, maple syrup urine disease) gene analysis, common variants (eg, r183p, g278s, e422x)
2026	81206		20260101	N	\$163.96	Translocation analysis (BCR/ABL1) major breakpoint	Bcr/abl1 (t(9; 22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative
2026	81207		20260101	N	\$144.84	Translocation analysis (BCR/ABL1) minor breakpoint	Bcr/abl1 (t(9; 22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative

2026	81208		20260101	N	\$214.62	Translocation analysis (BCR/ABL1) other breakpoint	Bcr/abl1 (t(9; 22)) (eg, chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative
2026	81209		20260101	N	\$39.31	Gene analysis (Bloom syndrome, RecQ helicase-like)	Blm (bloom syndrome, recq helicase-like) (eg, bloom syndrome) gene analysis, 2281del6ins7 variant
2026	81210		20260101	N	\$175.40	Gene analysis (v-raf murine sarcoma viral oncogene homolog B1)	Braf (b-raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, v600 variant(s)

2026	81212		20260101	N	\$440.00	Gene analysis (breast cancer 1 and 2) for 185delAG, 5385insC, 6174delT variants	Brca1 (brca1, dna repair associated), brca2 (brca2, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; 185delag, 5385insc, 6174delt variants
2026	81215		20260101	N	\$375.25	Gene analysis (breast cancer 1) for known familial variant	Brca1 (brca1, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
2026	81216		20260101	N	\$185.12	Gene analysis (breast cancer 2) of full sequence	Brca2 (brca2, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis

2026	81217		20260101	N	\$375.25	Gene analysis (breast cancer 2) for known familial variant	Brca2 (brca2, dna repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
2026	81218		20260101	N	\$241.90	Gene analysis (ccaat/enhancer binding protein [c/ebp], alpha) full gene sequence	Cebpa (ccaat/enhancer binding protein [c/ebp], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence
2026	81219		20260101	N	\$121.63	Gene analysis (calreticulin), common variants	Calr (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9

2026	81220		20260101	N	\$556.60	Gene analysis (cystic fibrosis transmembrane conductance regular) common	Cftr (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; common variants (eg, acmg/acog guidelines)
2026	81221		20260101	N	\$97.22	Gene analysis (cystic fibrosis transmembrane conductance regular) known	Cftr (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; known familial variants
2026	81222		20260101	N	\$435.07	Gene analysis (cystic fibrosis transmembrane conductance regular) duplication	Cftr (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; duplication/deletion variants

2026	81223		20260101	N	\$499.00	Gene analysis (cystic fibrosis transmembrane conductance regular) full gene	Cftr (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; full gene sequence
2026	81224		20260101	N	\$168.75	Gene analysis (cystic fibrosis transmembrane conductance regular) intron 8	Cftr (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; intron 8 poly-t analysis (eg, male infertility)
2026	81225		20260101	N	\$291.36	Gene analysis (cytochrome P450, family 2, subfamily C, polypeptide 19) common	Cyp2c19 (cytochrome p450, family 2, subfamily c, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)

2026	81226		20260101	N	\$450.91	Gene analysis (cytochrome P450, family 2, subfamily D, polypeptide 6) common	Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1xn, *2xn, *4xn)
2026	81227		20260101	N	\$174.81	Gene analysis (cytochrome P450, family 2, subfamily C, polypeptide 9) common	Cyp2c9 (cytochrome p450, family 2, subfamily c, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)

2026	81228		20260101	N	\$900.00	Genome-wide microarray analysis for copy number variants	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization [cgh] microarray analysis
2026	81229		20260101	N	\$1,160.00	Genome-wide microarray analysis for copy number and single nucleotide	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and single nucleotide polymorphism (snp) variants, comparative genomic hybridization (cgh) microarray analysis

2026	81230		20260101	N	\$174.81	Gene analysis (cytochrome P450 family 3 subfamily A member 4) for common variant	Cyp3a4 (cytochrome p450 family 3 subfamily a member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)
2026	81231		20260101	N	\$174.81	Gene analysis (cytochrome P450 family 3 subfamily A member 5) for common variant	Cyp3a5 (cytochrome p450 family 3 subfamily a member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)
2026	81232		20260101	N	\$174.81	Gene analysis (dihydropyrimidine dehydrogenase) for common variant	Dpyd (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-fu and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2a, *4, *5, *6)

2026	81233		20260101	N	\$175.40	Gene analysis (Bruton's tyrosine kinase) for common variants	Btk (bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, c481s, c481r, c481f)
2026	81234		20260101	N	\$137.00	Gene analysis (DM1 protein kinase) for abnormal alleles	Dmpk (dm1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles
2026	81235		20260101	N	\$324.58	Gene analysis (epidermal growth factor receptor), common variants	Egfr (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 lrea deletion, l858r, t790m, g719a, g719s, l861q)

2026	81236		20260101	N	\$282.88	Gene analysis (enhancer of zeste 2 polycomb repressive complex 2 subunit) of	Ezh2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence
2026	81237		20260101	N	\$175.40	Gene analysis (enhancer of zeste 2 polycomb repressive complex 2 subunit) for	Ezh2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large b-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)
2026	81238		20260101	N	\$600.00	Gene analysis (coagulation factor IX) full sequence analysis	F9 (coagulation factor ix) (eg, hemophilia b), full gene sequence

2026	81239		20260101	N	\$274.83	Gene analysis (DM1 protein kinase) for characterization of alleles	Dmpk (dm1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)
2026	81240		20260101	N	\$65.69	Gene analysis (prothrombin, coagulation factor II) A variant	F2 (prothrombin, coagulation factor ii) (eg, hereditary hypercoagulability) gene analysis, 20210g>a variant
2026	81241		20260101	N	\$73.37	Gene analysis (coagulation factor V) Leiden variant	F5 (coagulation factor v) (eg, hereditary hypercoagulability) gene analysis, leiden variant
2026	81242		20260101	N	\$36.62	Gene analysis (Fanconi anemia, complementation group C) common variant	Fancc (fanconi anemia, complementation group c) (eg, fanconi anemia, type c) gene analysis, common variant (eg, ivs4+4a>t)

2026	81243		20260101	N	\$57.04	Gene analysis (fragile X syndrome, X-linked intellectual disability) for	Fmr1 (fragile x messenger ribonucleoprotein 1) (eg, fragile x syndrome, x-linked intellectual disability [xlid]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
2026	81244		20260101	N	\$44.89	Gene analysis (fragile X syndrome, X-linked intellectual disability) for	Fmr1 (fragile x messenger ribonucleoprotein 1) (eg, fragile x syndrome, x-linked intellectual disability [xlid]) gene analysis; characterization of alleles (eg, expanded size and promoter methylation status)

2026	81245		20260101	N	\$165.51	Gene analysis (fms-related tyrosine kinase 3) internal tandem duplication	Flt3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; internal tandem duplication (itd) variants (ie, exons 14, 15)
2026	81246		20260101	N	\$83.00	Test for detecting genes associated with blood cancer	Flt3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (tkd) variants (eg, d835, i836)
2026	81247		20260101	N	\$174.81	Gene analysis (glucose-6-phosphate dehydrogenase) for common variant	G6pd (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, a, a-)

2026	81248		20260101	N	\$375.25	Gene analysis (glucose-6-phosphate dehydrogenase) for known familial variant	G6pd (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant (s)
2026	81249		20260101	N	\$600.00	Gene analysis (glucose-6-phosphate dehydrogenase) full sequence analysis	G6pd (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence
2026	81250		20260101	N	\$58.49	Gene analysis (glucose-6-phosphatase, catalytic subunit) common variants	G6pc (glucose-6-phosphatase, catalytic subunit) (eg, glycogen storage disease, type 1a, von gierke disease) gene analysis, common variants (eg, r83c, q347x)

2026	81251		20260101	N	\$47.25	Gene analysis (glucosidase, beta, acid) common variants	Gba (glucosidase, beta, acid) (eg, gaucher disease) gene analysis, common variants (eg, n370s, 84gg, l444p, ivs2+1g>a)
2026	81252		20260101	N	\$101.12	Gene analysis (gap junction protein, beta 2, 26kda, connexin 26), full gene	Gjb2 (gap junction protein, beta 2, 26kda, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence
2026	81253		20260101	N	\$61.52	Gene analysis (gap junction protein, beta 2, 26kda, connexin 26), known	Gjb2 (gap junction protein, beta 2, 26kda, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants

2026	81254		20260101	N	\$35.00	Gene analysis (gap junction protein, beta 6, 30kda, connexin 30), common	Gjb6 (gap junction protein, beta 6, 30kda, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del (gjb6-d13s1830)] and 232kb [del (gjb6-d13s1854)])
2026	81255		20260101	N	\$51.45	Gene analysis (hexosaminidase A) common variants	Hexa (hexosaminidase A [alpha polypeptide]) (eg, tay-sachs disease) gene analysis, common variants (eg, 1278instatc, 1421+1g>c, g269s)

2026	81256		20260101	N	\$65.36	Gene analysis (hemochromatosis) common variants	Hfe (hemochromatosis) (eg, hereditary hemochromatosis) gene analysis, common variants (eg, c282y, h63d)
2026	81257		20260101	N	\$102.26	Gene analysis (alpha globin 1 and alpha globin 2) for common deletions or	Hba1/hba2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, hb bart hydrops fetalis syndrome, hbh disease), gene analysis; common deletions or variant (eg, southeast asian, thai, filipino, mediterranean, alpha3.7, alpha4.2, alpha20.5, constant spring)

2026	81258		20260101	N	\$375.25	Gene analysis (alpha globin 1 and alpha globin 2) for known familial variant	Hba1/hba2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, hb bart hydrops fetalis syndrome, hbh disease), gene analysis; known familial variant
2026	81259		20260101	N	\$600.00	Gene analysis (alpha globin 1 and alpha globin 2) full sequence analysis	Hba1/hba2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, hb bart hydrops fetalis syndrome, hbh disease), gene analysis; full gene sequence

2026	81260		20260101	N	\$39.31	Gene analysis (inhibitor of kappa light polypeptide gene enhancer in B-cells,	Ikbkap (inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase complex-associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507+6t>c, r696p)
2026	81261		20260101	N	\$197.99	Gene rearrangement analysis (immunoglobulin heavy chain locus) to detect	Igh@ (immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, b-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)

2026	81262		20260101	N	\$68.55	Gene rearrangement analysis (immunoglobulin heavy chain locus) to detect	Igh@ (immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, b-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, southern blot)
2026	81263		20260101	N	\$294.52	Gene rearrangement analysis (immunoglobulin heavy chain locus), variable region	Igh@ (immunoglobulin heavy chain locus) (eg, leukemia and lymphoma, b-cell), variable region somatic mutation analysis

2026	81264		20260101	N	\$172.73	Gene rearrangement analysis (immunoglobulin kappa light chain locus) to detect	Igk@ (immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, b-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)
------	-------	--	----------	---	----------	--	--

2026	81265		20260101	N	\$233.07	Comparative analysis using Short Tandem Repeat (STR) markers of patient and	Comparative analysis using short tandem repeat (str) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells)
------	-------	--	----------	---	----------	---	--

2026	81266		20260101	N	\$304.81	Comparative analysis using Short Tandem Repeat (STR) markers of patient and	Comparative analysis using short tandem repeat (str) markers; each additional specimen (eg, additional cord blood donor, additional fetal samples from different cultures, or additional zygosity in multiple birth pregnancies) (list separately in addition to code for primary procedure)
2026	81267		20260101	N	\$207.46	Chimerism analysis post transplantation, without cell selection	Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline analyses; without cell selection

2026	81268		20260101	N	\$260.79	Chimerism analysis post transplantation, with cell selection	Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline analyses; with cell selection (eg, cd3, cd33), each cell type
2026	81269		20260101	N	\$202.40	Gene analysis (alpha globin 1 and alpha globin 2) for duplication/deletion	Hba1/hba2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, hb bart hydrops fetalis syndrome, hbh disease), gene analysis; duplication/deletion variants
2026	81270		20260101	N	\$91.66	Gene analysis (Janus kinase 2) variant	Jak2 (janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.val617phe (v617f) variant

2026	81271		20260101	N	\$137.00	Gene analysis (Huntingtin) for abnormal alleles	Htt (huntingtin) (eg, huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
2026	81272		20260101	N	\$329.51	Gene analysis (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog),	Kit (v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [gist], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)
2026	81273		20260101	N	\$124.87	Gene analysis (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog),	Kit (v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene analysis, d816 variant(s)

2026	81274		20260101	N	\$274.83	Gene analysis (Huntingtin) for characterization of alleles	Htt (huntingtin) (eg, huntington disease) gene analysis; characterization of alleles (eg, expanded size)
2026	81275		20260101	N	\$193.25	Gene analysis (v-Ki-ras2 Kirsten rat sarcoma viral oncogene) variants in codons	Kras (kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)
2026	81276		20260101	N	\$193.25	Gene analysis (Kirsten rat sarcoma viral oncogene homolog), additional variants	Kras (kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)

2026	81277		20260101	N	\$1,160.00	Cancer cytogenomic array gene analysis	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities
2026	81278		20260101	N	\$207.31	Gene analysis (IGH@/BCL2 (t(14;18)) translocation analysis	Igh@/bcl2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (mbr) and minor cluster region (mcr) breakpoints, qualitative or quantitative
2026	81279		20260101	N	\$185.20	Gene analysis (Janus kinase 2) targeted sequence analysis	Jak2 (janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)

2026	81283		20260101	N	\$73.37	Gene analysis (interferon, lambda 3) for rs12979860 variant	IfnI3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant
2026	81284		20260101	N	\$137.00	Gene analysis (frataxin) for abnormal alleles	Fxn (frataxin) (eg, friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles
2026	81285		20260101	N	\$274.83	Gene analysis (frataxin) for characterization of alleles	Fxn (frataxin) (eg, friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)
2026	81286		20260101	N	\$274.83	Gene analysis (frataxin) of full sequence	Fxn (frataxin) (eg, friedreich ataxia) gene analysis; full gene sequence

2026	81287		20260101	N	\$124.64	Gene analysis (O-6-methylguanine-DNA methyltransferase) for promoter methylation	Mgmt (o-6-methylguanine-dna methyltransferase) (eg, glioblastoma multiforme) promoter methylation analysis
2026	81288		20260101	N	\$192.32	Test for detecting genes associated with colon cancer, promoter methylation	Mlh1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; promoter methylation analysis
2026	81289		20260101	N	\$185.20	Gene analysis (frataxin) for known familial variants	Fxn (frataxin) (eg, friedreich ataxia) gene analysis; known familial variant (s)

2026	81290		20260101	N	\$39.31	Gene analysis (mucolipin 1) common variants	Mcoln1 (mucolipin 1) (eg, mucolipidosis, type iv) gene analysis, common variants (eg, ivs3-2a>g, del6.4kb)
2026	81291		20260101	N	\$65.34	Gene analysis (5, 10-methylenetetrahydrofolate reductase) common variants	Mthfr (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677t, 1298c)
2026	81292		20260101	N	\$675.40	Gene analysis (mutL homolog 1, colon cancer, nonpolyposis type 2) full sequence	Mlh1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis

2026	81293		20260101	N	\$331.00	Gene analysis (mutL homolog 1, colon cancer, nonpolyposis type 2) known	Mlh1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants
2026	81294		20260101	N	\$202.40	Gene analysis (mutL homolog 1, colon cancer, nonpolyposis type 2) duplication	Mlh1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants

2026	81295		20260101	N	\$381.70	Gene analysis (mutS homolog 2, colon cancer, nonpolyposis type 1) full sequence	Msh2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis
2026	81296		20260101	N	\$337.73	Gene analysis (mutS homolog 2, colon cancer, nonpolyposis type 1) known	Msh2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants

2026	81297		20260101	N	\$213.30	Gene analysis (mutS homolog 2, colon cancer, nonpolyposis type 1) duplication	Msh2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants
2026	81298		20260101	N	\$641.85	Gene analysis (mutS homolog 6 [E coli]) full sequence analysis	Msh6 (mutS homolog 6 [e. coli]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis
2026	81299		20260101	N	\$308.00	Gene analysis (mutS homolog 6 [E coli]) known familial variants	Msh6 (mutS homolog 6 [e. coli]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants

2026	81300		20260101	N	\$238.00	Gene analysis (mutS homolog 6 [E coli]) duplication or deletion variants	Msh6 (mutS homolog 6 [e. coli]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants
2026	81301		20260101	N	\$348.56	Microsatellite instability analysis	Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) of markers for mismatch repair deficiency (eg, bat25, bat26), includes comparison of neoplastic and normal tissue, if performed
2026	81302		20260101	N	\$527.87	Gene analysis (methyl CpG binding protein 2) full sequence analysis	Mecp2 (methyl cpg binding protein 2) (eg, rett syndrome) gene analysis; full sequence analysis

2026	81303		20260101	N	\$120.00	Gene analysis (methyl CpG binding protein 2) known familial variant	Mecp2 (methyl cpg binding protein 2) (eg, rett syndrome) gene analysis; known familial variant
2026	81304		20260101	N	\$150.00	Gene analysis (methyl CpG binding protein 2) duplication or deletion variants	Mecp2 (methyl cpg binding protein 2) (eg, rett syndrome) gene analysis; duplication/deletion variants
2026	81305		20260101	N	\$175.40	Gene analysis (myeloid differentiation primary response 88) for p.Leu265Pro	Myd88 (myeloid differentiation primary response 88) (eg, waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.leu265pro (l265p) variant
2026	81306		20260101	N	\$291.36	Gene analysis (nudix hydrolase 15) for common variants	Nudt15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)

2026	81307		20260101	N	\$676.50	Gene analysis (partner and localizer of BRCA2) full sequence analysis	Palb2 (partner and localizer of brca2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence
2026	81308		20260101	N	\$301.35	Gene analysis (partner and localizer of BRCA2) for detection of known familial	Palb2 (partner and localizer of brca2) (eg, breast and pancreatic cancer) gene analysis; known familial variant
2026	81309		20260101	N	\$274.83	Gene analysis (partner and localizer of BRCA2) targeted sequence analysis	Pik3ca (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)
2026	81310		20260101	N	\$246.52	Gene analysis (nucleophosmin) exon 12 variants	Npm1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants

2026	81311		20260101	N	\$295.79	Gene analysis for cancer (neuroblastoma)	Nras (neuroblastoma ras viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61)
2026	81312		20260101	N	\$137.00	Gene analysis (poly[A] binding protein nuclear 1) for abnormal alleles	Pabpn1 (poly[a] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles

2026	81313		20260101	N	\$255.05	Test for detecting genes associated with prostate cancer	Pca3/klk3 (prostate cancer antigen 3 [non-protein coding] /kallikrein-related peptidase 3 [prostate specific antigen]) ratio (eg, prostate cancer)
2026	81314		20260101	N	\$329.51	Gene analysis ((platelet-derived growth factor receptor, alpha polypeptide)	Pdgfra (platelet-derived growth factor receptor, alpha polypeptide) (eg, gastrointestinal stromal tumor [gist]), gene analysis, targeted sequence analysis (eg, exons 12, 18)

2026	81315		20260101	N	\$207.31	Translocation analysis (PML-RARA regulated adaptor molecule 1) common breakpoint	Pml/raralpha, (t (15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6), qualitative or quantitative
2026	81316		20260101	N	\$207.31	Translocation analysis (PML-RARA regulated adaptor molecule 1) single breakpoint	Pml/raralpha, (t (15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; single breakpoint (eg, intron 3, intron 6 or exon 6), qualitative or quantitative

2026	81317		20260101	N	\$676.50	Gene analysis (postmeiotic segregation increased 2 [<i>S cerevisiae</i>]) full	Pms2 (postmeiotic segregation increased 2 [<i>S. cerevisiae</i>]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis
2026	81318		20260101	N	\$331.00	Gene analysis (postmeiotic segregation increased 2 [<i>S cerevisiae</i>]) known	Pms2 (postmeiotic segregation increased 2 [<i>S. cerevisiae</i>]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants

2026	81319		20260101	N	\$203.50	Gene analysis (postmeiotic segregation increased 2 [S cerevisiae]) duplication	Pms2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants
2026	81320		20260101	N	\$291.36	Gene analysis (phospholipase C gamma 2) for common variants	Plcg2 (phospholipase c gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, r665w, s707f, l845f)
2026	81321		20260101	N	\$600.00	Gene analysis (phosphatase and tensin homolog), full sequence analysis	Pten (phosphatase and tensin homolog) (eg, cowden syndrome, pten hamartoma tumor syndrome) gene analysis; full sequence analysis

2026	81322		20260101	N	\$46.60	Gene analysis (phosphatase and tensin homolog), known familial variant	Pten (phosphatase and tensin homolog) (eg, cowden syndrome, pten hamartoma tumor syndrome) gene analysis; known familial variant
2026	81323		20260101	N	\$300.00	Gene analysis (phosphatase and tensin homolog), duplication or deletion variant	Pten (phosphatase and tensin homolog) (eg, cowden syndrome, pten hamartoma tumor syndrome) gene analysis; duplication/deletion variant

2026	81324		20260101	N	\$758.36	Gene analysis (peripheral myelin protein 22), duplication or deletion analysis	Pmp22 (peripheral myelin protein 22) (eg, charcot-marie-tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis
2026	81325		20260101	N	\$769.58	Gene analysis (peripheral myelin protein 22), full sequence analysis	Pmp22 (peripheral myelin protein 22) (eg, charcot-marie-tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis

2026	81326		20260101	N	\$46.60	Gene analysis (peripheral myelin protein 22), known familial variant	Pmp22 (peripheral myelin protein 22) (eg, charcot-marie-tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant
2026	81327		20260101	N	\$192.00	Gene analysis (Septin9) for promoter methylation	Sept9 (septin9) (eg, colorectal cancer) promoter methylation analysis
2026	81328		20260101	N	\$174.81	Gene analysis (solute carrier organic anion transporter family, member 1B1) for	Slco1b1 (solute carrier organic anion transporter family, member 1b1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)

2026	81329		20260101	N	\$137.00	Gene analysis (survival of motor neuron 1, telomeric) for dosage/deletion	Smn1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes smn2 (survival of motor neuron 2, centromeric) analysis, if performed
2026	81330		20260101	N	\$47.00	Gene analysis (sphingomyelin phosphodiesterase 1, acid lysosomal) common	Smpd1 (sphingomyelin phosphodiesterase 1, acid lysosomal) (eg, niemann-pick disease, type a) gene analysis, common variants (eg, r496l, l302p, fsp330)

2026	81331		20260101	N	\$51.07	Methylation analysis (small nuclear ribonucleoprotein polypeptide N and	Snrpn/ube3a (small nuclear ribonucleoprotein polypeptide n and ubiquitin protein ligase e3a) (eg, prader-willi syndrome and/or angelman syndrome), methylation analysis
2026	81332		20260101	N	\$43.65	Gene analysis (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase,	Serpina1 (serpin peptidase inhibitor, clade a, alpha-1 antiproteinase, antitrypsin, member 1) (eg, alpha-1-antitrypsin deficiency), gene analysis, common variants (eg, *s and *z)

2026	81333		20260101	N	\$137.00	Gene analysis (transforming growth factor beta-induced) for common variants	Tgfb1 (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, r124h, r124c, r124l, r555w, r555q)
2026	81334		20260101	N	\$329.51	Gene analysis (runt related transcription factor 1) targeted sequence analysis	Runx1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy) gene analysis, targeted sequence analysis (eg, exons 3-8)
2026	81335		20260101	N	\$174.81	Gene analysis (thiopurine S-methyltransferase) for common variant	Tpmt (thiopurine s-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)

2026	81336		20260101	N	\$301.35	Gene analysis (survival of motor neuron 1, telomeric) of full sequence	Smn1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence
2026	81337		20260101	N	\$185.20	Gene analysis (survival of motor neuron 1, telomeric) for known familial	Smn1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)
2026	81338		20260101	N	\$150.33	Gene analysis (MPL proto-oncogene, thrombopoietin receptor) for detection of	Mpl (mpl proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, w515a, w515k, w515l, w515r)

2026	81339		20260101	N	\$185.20	Gene analysis (MPL proto-oncogene, thrombopoietin receptor) sequence analysis	Mpl (mpl proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10
2026	81340		20260101	N	\$208.92	Gene analysis (T cell antigen receptor beta) amplification methodology	Trb@ (t cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)

2026	81341		20260101	N	\$49.59	Gene rearrangement analysis detection abnormal clonal population (T cell	Trb@ (t cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, southern blot)
2026	81342		20260101	N	\$201.50	Gene rearrangement analysis detection abnormal clonal population (T cell	Trg@ (t cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)

2026	81343		20260101	N	\$137.00	Gene analysis (protein phosphatase 2 regulatory subunit Bbeta) for abnormal	Ppp2r2b (protein phosphatase 2 regulatory subunit bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
2026	81344		20260101	N	\$137.00	Gene analysis (TATA box binding protein) for abnormal alleles	Tbp (tata box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles

2026	81345		20260101	N	\$185.20	Gene analysis (telomerase reverse transcriptase) targeted sequence analysis	Tert (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)
2026	81346		20260101	N	\$174.81	Gene analysis (thymidylate synthetase) for common variant	Tyms (thymidylate synthetase) (eg, 5-fluorouracil/5-fu drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)

2026	81347		20260101	N	\$193.25	Gene analysis (splicing factor [3b] subunit B1) for detection of common variants	Sf3b1 (splicing factor [3b] subunit b1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, a672t, e622d, l833f, r625c, r625l)
2026	81348		20260101	N	\$175.40	Gene analysis (serine and arginine-rich splicing factor 2) for detection of	Srsf2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, p95h, p95l)

2026	81349		20260101	N	\$1,197.94	Genome-wide microarray analysis for copy number and loss-of-heterozygosity	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis
2026	81350		20260101	N	\$234.00	Gene analysis (UDP glucuronosyltransferase 1 family, polypeptide A1) for	Ugt1a1 (udp glucuronosyltransferase 1 family, polypeptide a1) (eg, drug metabolism, hereditary unconjugated hyperbilirubemia [gilbert syndrome]) gene analysis, common variants (eg, *28, *36, *37)

2026	81351		20260101	N	\$641.85	Gene analysis (tumor protein 53) full sequence analysis	Tp53 (tumor protein 53) (eg, li-fraumeni syndrome) gene analysis; full gene sequence
2026	81352		20260101	N	\$329.51	Gene analysis (tumor protein 53) targeted sequence analysis	Tp53 (tumor protein 53) (eg, li-fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology)
2026	81353		20260101	N	\$308.00	Gene analysis (tumor protein 53) targeted sequence analysis for detection of	Tp53 (tumor protein 53) (eg, li-fraumeni syndrome) gene analysis; known familial variant
2026	81354		20260101	N	\$1,263.53	Detection of abnormalities associated with constitutional chromosomal	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of structural and copy number variants, optical genome mapping (ogm)

2026	81355		20260101	N	\$88.20	Gene analysis (vitamin K epoxide reductase complex subunit 1) common variants	Vkorc1 (vitamin k epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variant(s) (eg, -1639g>a, c. 173+1000c>t)
2026	81357		20260101	N	\$193.25	Gene analysis (U2 small nuclear RNA auxiliary factor 1) for detection of common	U2af1 (u2 small nuclear rna auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, s34f, s34y, q157r, q157p)

2026	81360		20260101	N	\$193.25	Gene analysis (zinc finger CCCH-type, RNA binding motif and	Zrsr2 (zinc finger ccch-type, rna binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, e65fs, e122fs, r448fs)
2026	81361		20260101	N	\$174.81	Gene analysis (hemoglobin, subunit beta) for common variant	Hbb (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); common variant(s) (eg, hbs, hbc, hbe)
2026	81362		20260101	N	\$375.25	Gene analysis (hemoglobin, subunit beta) for known familial variant	Hbb (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s)

2026	81363		20260101	N	\$202.40	Gene analysis (hemoglobin, subunit beta) for duplication/deletion variant	Hbb (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); duplication/deletion variant(s)
2026	81364		20260101	N	\$324.58	Gene analysis (hemoglobin, subunit beta) full sequence analysis	Hbb (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); full gene sequence
2026	81370		20260101	N	\$402.12	HLA class I and II typing low resolution HLA-A, -B, -C, -DRB1/3/4/5 and -DQB1	Hla class i and ii typing, low resolution (eg, antigen equivalents); hla-a, -b, -c, -drb1/3/4/5, and -dqb1
2026	81371		20260101	N	\$404.52	HLA class I and II typing, low resolution HLA-A, -B, and -DRB1	Hla class i and ii typing, low resolution (eg, antigen equivalents); hla-a, -b, and -drb1 (eg, verification typing)

2026	81372		20260101	N	\$403.59	HLA class I typing low resolution	Hla class i typing, low resolution (eg, antigen equivalents); complete (ie, hla-a, -b, and -c)
2026	81373		20260101	N	\$127.43	HLA class I typing low resolution one locus	Hla class i typing, low resolution (eg, antigen equivalents); one locus (eg, hla-a, -b, or -c), each
2026	81374		20260101	N	\$74.33	HLA class I typing, low resolution one antigen equivalent	Hla class i typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, b*27), each
2026	81375		20260101	N	\$220.74	HLA class II typing low resolution HLA-DRB1/3/4/5 and -DQB1	Hla class ii typing, low resolution (eg, antigen equivalents); hla-drb1/3/4/5 and -dqb1

2026	81376		20260101	N	\$122.22	HLA class II typing low resolution one locus	Hla class ii typing, low resolution (eg, antigen equivalents); one locus (eg, hla-drb1, -drb3/4/5, -dqb1, -dqa1, -dpb1, or -dpa1), each
2026	81377		20260101	N	\$94.74	HLA class II typing low resolution one antigen equivalent	Hla class ii typing, low resolution (eg, antigen equivalents); one antigen equivalent, each
2026	81378		20260101	N	\$345.57	HLA class I and II typing high resolution HLA-A, -B, -C, and -DRB1	Hla class i and ii typing, high resolution (ie, alleles or allele groups), hla-a, -b, -c, and -drb1
2026	81379		20260101	N	\$335.38	HLA Class I typing high resolution	Hla class i typing, high resolution (ie, alleles or allele groups); complete (ie, hla-a, -b, and -c)

2026	81380		20260101	N	\$177.25	HLA class I typing high resolution one locus	Hla class i typing, high resolution (ie, alleles or allele groups); one locus (eg, hla-a, -b, or -c), each
2026	81381		20260101	N	\$169.90	HLA class I typing high resolution one allele or allele group	Hla class i typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, b*57:01p), each
2026	81382		20260101	N	\$123.68	HLA class II typing high resolution one locus	Hla class ii typing, high resolution (ie, alleles or allele groups); one locus (eg, hla-drb1, -drb3/4/5, -dqb1, -dqa1, -dpb1, or -dpa1), each
2026	81383		20260101	N	\$109.13	HLA class II typing high resolution one allele or allele group	Hla class ii typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, hla-dqb1*06:02p), each

2026	81400		20260101	N	\$63.96	Molecular pathology procedure level 1	Molecular pathology procedure, level 1 (eg, identification of single germline variant [eg, snp] by techniques such as restriction enzyme digestion or melt curve analysis) acadm (acyl-coa dehydrogenase, c-4 to c-12 straight chain, mcad) (eg, medium chain acyl dehydrogenase deficiency), k304e variant ace (angiotensin converting enzyme) (eg, hereditary blood pressure regulation), insertion/deletion variant agtr1 (angiotensin ii receptor, type 1) (eg, essential hypertension), 1166a>c variant bckdha (branched chain keto acid dehydrogenase α1, alpha
------	-------	--	----------	---	---------	---------------------------------------	---

2026	81401		20260101	N	\$137.00	Molecular pathology procedure level 2	Molecular pathology procedure, level 2 (eg, 2-10 snps, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) abcc8 (atp-binding cassette, sub-family c [cftr/mrp], member 8) (eg, familial hyperinsulinism), common variants (eg, c. 3898-9g>a [c. 3992-9g>a], f1388del) abl1 (abl proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance), t315i variant acadm (acyl-coa dehydrogenase, c-4 to c-12 straight chain, mcad) (eg, medium chain
------	-------	--	----------	---	----------	---------------------------------------	--

2026	81402		20260101	N	\$150.33	Molecular pathology procedure level 3	Molecular pathology procedure, level 3 (eg, >10 snps, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and t-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [loh], uniparental disomy [upd]) chromosome 1p-/19q- (eg, glial tumors), deletion analysis chromosome 18q- (eg, d18s55, d18s58, d18s61, d18s64, and d18s69) (eg, colon cancer), allelic imbalance assessment (ie, loss of
------	-------	--	----------	---	----------	---------------------------------------	--

2026	81403		20260101	N	\$185.20	Molecular pathology procedure level 4 genetic analysis	Molecular pathology procedure, level 4 (eg, analysis of single exon by dna sequence analysis, analysis of >10 amplicons using multiplex pcr in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ang (angiogenin, ribonuclease, rnaase a family, 5) (eg, amyotrophic lateral sclerosis), full gene sequence arx (aristaless related homeobox) (eg, x-linked lissencephaly with ambiguous genitalia, x-linked intellectual disability), duplication/deletion analysis cel (carboxyl ester lipase [bile salt
------	-------	--	----------	---	----------	--	--

2026	81404		20260101	N	\$274.83	Molecular pathology procedure level 5 genetic analysis	Molecular pathology procedure, level 5 (eg, analysis of 2-5 exons by dna sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by southern blot analysis) acads (acyl-coa dehydrogenase, c-2 to c-3 short chain) (eg, short chain acyl-coa dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) aqp2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes insipidus), full gene sequence arx (aristaless related
------	-------	--	----------	---	----------	--	---

2026	81405		20260101	N	\$301.35	Molecular pathology procedure level 6 genetic analysis	Molecular pathology procedure, level 6 (eg, analysis of 6-10 exons by dna sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis) abcd1 (atp-binding cassette, sub-family d [ald], member 1) (eg, adrenoleukodystrophy), full gene sequence acads (acyl-coa dehydrogenase, c-2 to c-3 short chain) (eg, short chain acyl-coa dehydrogenase deficiency), full gene sequence acta2 (actin, alpha 2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence
------	-------	--	----------	---	----------	--	--

2026	81406		20260101	N	\$282.88	Molecular pathology procedure level 7 genetic analysis	Molecular pathology procedure, level 7 (eg, analysis of 11-25 exons by dna sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons) acadvl (acyl-coa dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme a dehydrogenase deficiency), full gene sequence actn4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence afg3l2 (afg3 atpase family gene 3-like 2 [s. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence aire (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence
------	-------	--	----------	---	----------	--	---

2026	81407		20260101	N	\$846.27	Molecular pathology procedure level 8 genetic analysis	Molecular pathology procedure, level 8 (eg, analysis of 26-50 exons by dna sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) abcc8 (atp-binding cassette, sub-family c [cftr/mrp], member 8) (eg, familial hyperinsulinism), full gene sequence agl (amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase) (eg, glycogen storage disease type iii), full gene sequence ahi1 (abelson helper integration site 1) (eg, joubert syndrome), full gene sequence anob
------	-------	--	----------	---	----------	--	--

2026	81408		20260101	N	\$2,000.00	Molecular pathology procedure level 9 genetic analysis	Molecular pathology procedure, level 9 (eg, analysis of >50 exons in a single gene by dna sequence analysis) abca4 (atp-binding cassette, sub-family a [abc1], member 4) (eg, stargardt disease, age-related macular degeneration), full gene sequence atm (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence cdh23 (cadherin-related 23) (eg, usher syndrome, type 1), full gene sequence cep290 (centrosomal protein 290kda) (eg, joubert syndrome), full gene sequence col1a1 (collagen, type i, alpha 1) (eg, osteogenesis
------	-------	--	----------	---	------------	--	---

2026	81410		20260101	N	\$504.00	Test for detecting genes associated with heart disease, genomic sequence	Aortic dysfunction or dilation (eg, marfan syndrome, loeys dietz syndrome, ehler danlos syndrome type iv, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including fbn1, tgfr1, tgfr2, col3a1, myh11, acta2, slc2a10, smad3, and mylk
------	-------	--	----------	---	----------	--	---

2026	81411		20260101	N	\$1,350.19	Test for detecting genes associated with heart disease, duplication/deletion	Aortic dysfunction or dilation (eg, marfan syndrome, loeys dietz syndrome, ehler danlos syndrome type iv, arterial tortuosity syndrome); duplication/deletion analysis panel, must include analyses for tgfr1, tgfr2, myh11, and col3a1
------	-------	--	----------	---	------------	--	---

2026	81412		20260101	N	\$2,448.56	Test for detecting genes for disorders related to Ashkenazi Jews, genomic	Ashkenazi jewish associated disorders (eg, bloom syndrome, canavan disease, cystic fibrosis, familial dysautonomia, fanconi anemia group c, gaucher disease, tay-sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including aspa, blm, cftr, fanc, gba, hexa, ikbkap, mcoln1, and smpd1
------	-------	--	----------	---	------------	---	--

2026	81413		20260101	N	\$584.90	Test for detecting genes associated with heart disease, genomic sequence	Cardiac ion channelopathies (eg, brugada syndrome, long qt syndrome, short qt syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ank2, casq2, cav3, kcne1, kcne2, kcnh2, kcnj2, kcnq1, ryr2, and scn5a
------	-------	--	----------	---	----------	--	--

2026	81414		20260101	N	\$584.90	Test for detecting genes associated with heart disease, duplication/deletion	Cardiac ion channelopathies (eg, brugada syndrome, long qt syndrome, short qt syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including kcnh2 and kcnq1
2026	81415		20260101	N	\$4,780.00	Test for detecting exome, sequence analysis	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis

2026	81416		20260101	N	\$12,000.00	Test for detecting exome, sequence analysis, each comparator exome	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (list separately in addition to code for primary procedure)
2026	81417		20260101	N	\$320.00	Reevaluation test of previously obtained exome sequence	Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)

2026	81418		20260101	N	\$917.08	Genomic sequence analysis panel of at least 6 genes associated with drug	Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including cyp2c19, cyp2d6, and cyp2d6 duplication/deletion analysis
2026	81419		20260101	N	\$2,448.56	Gene analysis panel for evaluation of genes associated with epilepsy	Epilepsy genomic sequence analysis panel, must include analyses for aldh7a1, cacna1a, cdkl5, chd2, gabrg2, grin2a, kcnq2, mecp2, pcdh19, polg, prrt2, scn1a, scn1b, scn2a, scn8a, slc2a1, slc9a6, stxbp1, syngap1, tcf4, tpp1, tsc1, tsc2, and zeb2

2026	81420		20260101	N	\$759.05	Test for detecting genes associated with fetal disease, aneuploidy genomic	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy x) genomic sequence analysis panel, circulating cell-free fetal dna in maternal blood, must include analysis of chromosomes 13, 18, and 21
2026	81422		20260101	N	\$759.05	Test for detecting genes associated with fetal disease, microdeletion (s)	Fetal chromosomal microdeletion (s) genomic sequence analysis (eg, digeorge syndrome, cri-du-chat syndrome), circulating cell-free fetal dna in maternal blood
2026	81425		20260101	N	\$5,031.20	Test for detecting genes associated with disease, genome sequence analysis	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis

2026	81426		20260101	N	\$2,709.95	Test for detecting genes associated with disease, genome sequence analysis,	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (list separately in addition to code for primary procedure)
2026	81427		20260101	N	\$2,337.65	Reevaluation test of previously obtained genome sequence	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)

2026	81430		20260101	N	\$1,625.00	Test for detecting genes causing hearing loss genomic sequence analysis panel,	Hearing loss (eg, nonsyndromic hearing loss, usher syndrome, pendred syndrome); genomic sequence analysis panel, must include sequencing of at least 60 genes, including cdh23, clrn1, gjb2, gpr98, mtrnr1, myo7a, myo15a, pcdh15, otof, slc26a4, tmc1, tmpRSS3, ush1c, ush1g, ush2a, and wfs1
------	-------	--	----------	---	------------	--	--

2026	81431		20260101	N	\$679.57	Test for detecting genes causing hearing loss, duplication/deletion analysis	Hearing loss (eg, nonsyndromic hearing loss, usher syndrome, pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for strc and dfnb1 deletions in gjb2 and gjb6 genes
------	-------	--	----------	---	----------	--	--

2026	81432		20260101	N	\$1,303.95	Test for detecting genes associated with inherited breast cancer-related	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer, hereditary pancreatic cancer, hereditary prostate cancer), genomic sequence analysis panel, 5 or more genes, interrogation for sequence variants and copy number variants
------	-------	--	----------	---	------------	--	---

2026	81434		20260101	N	\$597.91	Gene analysis (retinal disorders), genomic sequence	Hereditary retinal disorders (eg, retinitis pigmentosa, leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including abca4, cnga1, crb1, eys, pde6a, pde6b, prpf31, prph2, rdh12, rho, rp1, rp2, rpe65, rpgr, and ush2a
------	-------	--	----------	---	----------	---	--

2026	81435		20260101	N	\$1,303.95	Test for detecting genes associated with inherited colon cancer-related	Hereditary colon cancer-related disorders (eg, lynch syndrome, pten hamartoma syndrome, cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel, 5 or more genes, interrogation for sequence variants and copy number variants
------	-------	--	----------	---	------------	---	---

2026	81437		20260101	N	\$1,303.95	Test for detecting genes associated with inherited neuroendocrine tumor-related	Hereditary neuroendocrine tumor-related disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma) , genomic sequence analysis panel, 5 or more genes, interrogation for sequence variants and copy number variants
------	-------	--	----------	---	------------	---	--

2026	81439		20260101	N	\$584.90	Test for detecting genes associated with inherited disease of heart muscle	Hereditary cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), genomic sequence analysis panel, must include sequencing of at least 5 cardiomyopathy-related genes (eg, <i>dsg2</i> , <i>mybpc3</i> , <i>myh7</i> , <i>pkp2</i> , <i>ttn</i>)
------	-------	--	----------	---	----------	--	---

2026	81440		20260101	N	\$3,324.00	Test for detecting genes	Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including bcs1l, c10orf2, coq2, cox10, dguok, mpv17, opa1, pdss2, polg, polg2, rrm2b, sco1, sco2, slc25a4, sucla2, suclg1, taz, tk2, and tymp
------	-------	--	----------	---	------------	--------------------------	--

2026	81441		20260101	N	\$2,448.56	Gene sequence analysis panel at least 30 genes associated with inherited bone	Inherited bone marrow failure syndromes (ibmfs) (eg, fanconi anemia, dyskeratosis congenita, diamond-blackfan anemia, shwachman-diamond syndrome, gata2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including brca2, brip1, dkc1, fanca, fancb, fanc, fancd2, fance, fancf, fancg, fanci, fanci, gata1, gata2, mpl, nhp2, nop10, palb2, rad51c, rpl11, rpl35a, rpl5, rps10, rps19, rps24, rps26, rps7, sbds, tert, and tinf2
------	-------	--	----------	---	------------	---	---

2026	81442		20260101	N	\$2,143.60	Gene analysis (noonan syndrome) genomic sequence analysis	Noonan spectrum disorders (eg, noonan syndrome, cardio-facio-cutaneous syndrome, costello syndrome, leopard syndrome, noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including braf, cbl, hras, kras, map2k1, map2k2, nras, ptpn11, raf1, rit1, shoc2, and sos1
------	-------	--	----------	---	------------	---	--

2026	81445		20260101	N	\$597.91	Genomic sequence analysis panel of DNA or combined DNA and RNA of 5-50 genes	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements , if performed; dna analysis or combined dna and rna analysis
2026	81448		20260101	N	\$584.90	Gene analysis panel for hereditary disorders of the peripheral nervous system	Hereditary peripheral neuropathies (eg, charcot-marie-tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (eg, bscl2, gjb1, mfn2, mpz, reep1, spast, spg11, sptlc1)

2026	81449		20260101	N	\$597.91	Genomic sequence analysis panel of RNA of 5-50 genes associated with solid	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements , if performed; rna analysis
2026	81450		20260101	N	\$759.53	Genomic sequence analysis panel of DNA or combined DNA and RNA of 5-50 genes	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements , or isoform expression or mrna expression levels, if performed; dna analysis or combined dna and rna analysis

2026	81451		20260101	N	\$759.53	Genomic sequence analysis panel of RNA of 5-50 genes associated with blood and	Hematolymphoi d neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements , or isoform expression or mrna expression levels, if performed; rna analysis
------	-------	--	----------	---	----------	--	---

2026	81455		20260101	N	\$2,919.60	Genomic sequence analysis panel of DNA or combined DNA and RNA of 51 or more	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements , or isoform expression or mrna expression levels, if performed; dna analysis or combined dna and rna analysis
------	-------	--	----------	---	------------	--	---

2026	81456		20260101	N	\$2,919.60	Genomic sequence analysis panel of RNA of 51 or more genes associated with	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements , or isoform expression or mrna expression levels, if performed; rna analysis
2026	81457		20260101	N	\$896.87	Genomic sequence analysis panel of DNA for microsatellite instability in solid	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; dna analysis, microsatellite instability

2026	81458		20260101	N	\$1,046.35	Genomic sequence analysis panel of DNA for microsatellite instability and copy	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; dna analysis, copy number variants and microsatellite instability
2026	81459		20260101	N	\$2,989.55	Genomic sequence analysis panel of DNA or combined DNA and RNA for copy number	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; dna analysis or combined dna and rna analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements

2026	81460		20260101	N	\$1,287.00	Test for detecting genes associated with disease, genomic sequence, must	Whole mitochondrial genome (eg, leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [melas], myoclonic epilepsy with ragged-red fibers [merff], neuropathy, ataxia, and retinitis pigmentosa [narp], leber hereditary optic neuropathy [lhon]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection
------	-------	--	----------	---	------------	--	--

2026	81462		20260101	N	\$1,195.83	Genomic sequence analysis of DNA or combined DNA and RNA in plasma for copy	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; dna analysis or combined dna and rna analysis, copy number variants and rearrangements
2026	81463		20260101	N	\$1,345.31	Genomic sequence analysis of DNA in plasma for copy number variants and	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; dna analysis, copy number variants, and microsatellite instability

2026	81464		20260101	N	\$3,288.51	Genomic sequence analysis of DNA or combined DNA and RNA in plasma for copy	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; dna analysis or combined dna and rna analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements
------	-------	--	----------	---	------------	---	---

2026	81465		20260101	N	\$936.00	Test for detecting genes associated with disease, whole mitochondrial genome	Whole mitochondrial genome large deletion analysis panel (eg, kearns-sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed
2026	81470		20260101	N	\$914.00	Test for detecting genes associated with intellectual disability, genomic	X-linked intellectual disability (xlid) (eg, syndromic and non-syndromic xlid); genomic sequence analysis panel, must include sequencing of at least 60 genes, including arx, atrx, cdkl5, fgd1, fmr1, huwe1, il1rapl, kdm5c, l1cam, mecp2, med12, mid1, ocr1, rps6ka3, and slc16a2

2026	81471		20260101	N	\$914.00	Test for detecting genes associated with intellectual disability,	X-linked intellectual disability (xlid) (eg, syndromic and non-syndromic xlid); duplication/deletion gene analysis, must include analysis of at least 60 genes, including arx, atrx, cdkl5, fgd1, fmr1, huwe1, il1rapl, kdm5c, l1cam, mecp2, med12, mid1, ocr1, rps6ka3, and slc16a2
2026	81490		20260101	N	\$840.65	Test for detecting genes associated with rheumatoid arthritis using immunoassay	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score

2026	81493		20260101	N	\$1,050.00	Test for detecting genes associated with heart vessels diseases	Coronary artery disease, mrna, gene expression profiling by real-time rt-pcr of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score
2026	81500		20260101	N	\$260.50	Genetic profiling on oncology biopsy of ovarian lesions, assays of two proteins	Oncology (ovarian), biochemical assays of two proteins (ca-125 and he4), utilizing serum, with menopausal status, algorithm reported as a risk score

2026	81503		20260101	N	\$897.00	Genetic profiling on oncology biopsy of ovarian lesions, assays of five proteins	Oncology (ovarian), biochemical assays of five proteins (ca-125, apolipoprotein a1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score
2026	81504		20260101	N	\$520.00	Genetic profiling on oncology biopsy lesions	Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores

2026	81506		20260101	N	\$68.92	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose,	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, hba1c, insulin, hs-crp, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score
2026	81507		20260101	N	\$795.00	DNA analysis using maternal plasma	Fetal aneuploidy (trisomy 21, 18, and 13) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

2026	81508		20260101	N	\$54.30	Fetal congenital abnormalities, biochemical assays of two proteins (papp-a, hcg	Fetal congenital abnormalities, biochemical assays of two proteins (papp-a, hcg [any form]), utilizing maternal serum, algorithm reported as a risk score
2026	81509		20260101	N	\$1,487.37	Fetal congenital abnormalities, biochemical assays of three proteins (papp-a,	Fetal congenital abnormalities, biochemical assays of three proteins (papp-a, hcg [any form], dia), utilizing maternal serum, algorithm reported as a risk score
2026	81510		20260101	N	\$55.54	Fetal congenital abnormalities, biochemical assays of three analytes (afp, ue3,	Fetal congenital abnormalities, biochemical assays of three analytes (afp, ue3, hcg [any form]), utilizing maternal serum, algorithm reported as a risk score

2026	81511		20260101	N	\$153.50	Fetal congenital abnormalities, biochemical assays of four analytes (afp, ue3,	Fetal congenital abnormalities, biochemical assays of four analytes (afp, ue3, hcg [any form], dia) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)
2026	81512		20260101	N	\$69.52	Fetal congenital abnormalities, biochemical assays of five analytes (afp, ue3,	Fetal congenital abnormalities, biochemical assays of five analytes (afp, ue3, total hcg, hyperglycosylated hcg, dia) utilizing maternal serum, algorithm reported as a risk score

2026	81513		20260101	N	\$142.63	Measurement of RNA of bacteria in vaginal fluid specimen	Infectious disease, bacterial vaginosis, quantitative real-time amplification of rna markers for atobium vaginae, gardnerella vaginalis, and lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis
------	-------	--	----------	---	----------	--	--

2026	81514		20260101	N	\$262.99	Measurement of DNA of bacteria in vaginal fluid specimen	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of dna markers for gardnerella vaginalis, atopobium vaginae, megasphaera type 1, bacterial vaginosis associated bacteria-2 (bvab-2), and lactobacillus species (l. crispatus and l. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of trichomonas vaginalis and/or candida species (c. albicans, c. tropicalis, c. parapsilosis, c. dubliniensis), candida
------	-------	--	----------	---	----------	--	--

2026	81514	QW	20260101	N	\$262.99	Measurement of DNA of bacteria in vaginal fluid specimen	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of dna markers for gardnerella vaginalis, atopobium vaginae, megasphaera type 1, bacterial vaginosis associated bacteria-2 (bvab-2), and lactobacillus species (l. crispatus and l. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of trichomonas vaginalis and/or candida species (c. albicans, c. tropicalis, c. parapsilosis, c. dubliniensis), candida
------	-------	----	----------	---	----------	--	--

2026	81515		20260101	N	\$262.99	Test for detection of bacteria causing vaginosis and vaginitis	Infectious disease, bacterial vaginosis and vaginitis, real-time pcr amplification of dna markers for atopobium vaginae, atopobium species, megasphaera type 1, and bacterial vaginosis associated bacteria-2 (bvab-2), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, includes separate detection of trichomonas vaginalis and candida species (c. albicans, c. tropicalis, c. parapsilosis, c. dubliniensis), candida glabrata/candida krusei, when reported
------	-------	--	----------	---	----------	--	---

2026	81515	QW	20260101	N	\$262.99	Test for detection of bacteria causing vaginosis and vaginitis	Infectious disease, bacterial vaginosis and vaginitis, real-time pcr amplification of dna markers for atopobium vaginae, atopobium species, megasphaera type 1, and bacterial vaginosis associated bacteria-2 (bvab-2), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, includes separate detection of trichomonas vaginalis and candida species (c. albicans, c. tropicalis, c. parapsilosis, c. dubliniensis), candida glabrata/candida krusei, when reported
------	-------	----	----------	---	----------	--	---

2026	81517		20260101	N	\$176.19	Test for detecting 3 biomarkers associated with risk for liver disease	Liver disease, analysis of 3 biomarkers (hyaluronic acid [ha], procollagen iii amino terminal peptide [piiinp], tissue inhibitor of metalloproteinase 1 [timp-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years
------	-------	--	----------	---	----------	--	---

2026	81518		20260101	N	\$3,873.00	mRNA gene analysis of 11 genes in breast tumor tissue	Oncology (breast), mrna, gene expression profiling by real-time rt-pcr of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy
------	-------	--	----------	---	------------	---	--

2026	81519		20260101	N	\$3,873.00	Test for detecting genes associated with breast cancer	Oncology (breast), mrna, gene expression profiling by real-time rt-pcr of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score
2026	81520		20260101	N	\$2,510.21	Gene analysis of breast tumor tissue, profiling by hybrid capture of 58 genes	Oncology (breast), mrna gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score

2026	81521		20260101	N	\$3,873.00	Gene analysis of breast tumor tissue, profiling of 70 content genes and 465	Oncology (breast), mrna, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis
------	-------	--	----------	---	------------	---	--

2026	81522		20260101	N	\$3,873.00	mRNA gene expression analysis of 12 genes in breast tumor tissue	Oncology (breast), mrna, gene expression profiling by rt-pcr of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score
------	-------	--	----------	---	------------	--	---

2026	81523		20260101	N	\$3,873.00	Next-generation sequencing of breast cancer profiling 70 content genes and 31	Oncology (breast), mrna, next-generation sequencing gene expression profiling of 70 content genes and 31 housekeeping genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk to distant metastasis
------	-------	--	----------	---	------------	---	---

2026	81524		20260101	L	\$ -	DNA methylation analysis of at least 10,000 methylation sites using DNA,	Oncology (central nervous system tumor), dna methylation analysis of at least 10,000 methylation sites, utilizing dna extracted from formalin-fixed tumor tissue, algorithm(s) reported as probability of matching a reference tumor family and class, and mgmt (o-6-methylguanine-dna methyltransferase) promoter methylation status, if performed
------	-------	--	----------	---	------	--	---

2026	81525		20260101	N	\$3,116.00	Gene analysis (colon related cancer)	Oncology (colon), mrna, gene expression profiling by real-time rt-pcr of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score
------	-------	--	----------	---	------------	--------------------------------------	---

2026	81528		20260101	N	\$508.87	Gene analysis (colorectal cancer)	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 dna markers (kras mutations, promoter methylation of ndrg4 and bmp3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result
------	-------	--	----------	---	----------	-----------------------------------	---

2026	81529		20260101	N	\$7,193.00	mRNA gene analysis of 31 genes in skin melanoma tissue specimen	Oncology (cutaneous melanoma), mrna, gene expression profiling by real-time rt-pcr of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis
------	-------	--	----------	---	------------	---	--

2026	81535		20260101	N	\$579.46	Culture of live tumor cells and chemotherapy drug response by staining, first	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by dapi stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination
------	-------	--	----------	---	----------	---	---

2026	81536		20260101	N	\$177.56	Culture of live tumor cells and chemotherapy drug response by staining, each	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by dapi stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (list separately in addition to code for primary procedure)
2026	81538		20260101	N	\$2,871.00	Testing of lung tumor cells for prediction of survival	Oncology (lung), mass spectrometric 8-protein signature, including amyloid a, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival

2026	81539		20260101	N	\$760.00	Measurement of proteins associated with prostate cancer	Oncology (high-grade prostate cancer), biochemical assay of four proteins (total psa, free psa, intact psa, and human kallikrein-2 [hk2]), utilizing plasma or serum, prognostic algorithm reported as a probability score
------	-------	--	----------	---	----------	---	--

2026	81540		20260101	N	\$3,750.00	Gene analysis (cancer)	Oncology (tumor of unknown origin), mrna, gene expression profiling by real-time rt-pcr of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype
------	-------	--	----------	---	------------	------------------------	---

2026	81541		20260101	N	\$3,873.00	Gene analysis of prostate tumor tissue, profiling by real-time RT-PCR of 46	Oncology (prostate), mrna gene expression profiling by real-time rt-pcr of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score
2026	81542		20260101	N	\$3,873.00	mRNA gene expression analysis of 22 genes in prostate tumor tissue	Oncology (prostate), mrna, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score

2026	81546		20260101	N	\$3,600.00	mRNA gene analysis of 10,196 genes in fine needle aspiration thyroid specimen,	Oncology (thyroid), mrna, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)
2026	81551		20260101	N	\$2,030.00	Gene analysis of prostate tumor tissue, profiling by real-time PCR of 3 genes	Oncology (prostate), promoter methylation profiling by real-time pcr of 3 genes (gstp1, apc, rassf1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy

2026	81552		20260101	N	\$7,776.00	mRNA gene expression analysis of 15 genes in eye melanoma o tissue or fine	Oncology (uveal melanoma), mrna, gene expression profiling by real-time rt-pcr of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis
------	-------	--	----------	---	------------	--	---

2026	81554		20260101	N	\$5,409.60	mRNA gene analysis of 190 genes associated with lung disease (idiopathic	Pulmonary disease (idiopathic pulmonary fibrosis [ipf]), mrna, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [uip])
------	-------	--	----------	---	------------	--	--

2026	81558		20260101	N	\$3,240.00	Test for detecting 139 genes associated with kidney transplant rejection	Transplantation medicine (allograft rejection, kidney), mrna, gene expression profiling by quantitative polymerase chain reaction (qpcr) of 139 genes, utilizing whole blood, algorithm reported as a binary categorization as transplant excellence, which indicates immune quiescence, or not transplant excellence, indicating subclinical rejection
------	-------	--	----------	---	------------	--	---

2026	81560		20260101	N	\$640.73	Measurement of donor and third-party memory cells for transplantation medicine	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced cd154+t-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score
------	-------	--	----------	---	----------	--	--

2026	81595		20260101	N	\$3,240.00	Test for detecting genes associated with heart diseases	Cardiology (heart transplant), mrna, gene expression profiling by real-time quantitative pcr of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score
------	-------	--	----------	---	------------	---	---

2026	81596		20260101	N	\$72.19	Biochemical assays for evaluation of chronic Hepatitis C virus infection	Infectious disease, chronic hepatitis c virus (hcv) infection, six biochemical assays (alt, a2-macroglobulin, apolipoprotein a-1, total bilirubin, ggt, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
2026	82009		20260101	N	\$4.52	Ketone bodies analysis, qualitative	Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate); qualitative
2026	82010		20260101	N	\$8.17	Ketone bodies analysis, quantitative	Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate); quantitative

2026	82010	QW	20260101	N	\$8.17	Ketone bodies analysis, quantitative	Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate); quantitative
2026	82013		20260101	N	\$12.29	Acetylcholinesterase (enzyme) level	Acetylcholinesterase
2026	82016		20260101	N	\$16.49	Chemical analysis for genetic disorder	Acylcarnitines; qualitative, each specimen
2026	82017		20260101	N	\$16.87	Chemical test for genetic disorder	Acylcarnitines; quantitative, each specimen
2026	82024		20260101	N	\$38.62	Adrenocorticotropic hormone (ACTH) level	Adrenocorticotropic hormone (acth)
2026	82030		20260101	N	\$25.80	Adenosine, 5-monophosphate, cyclic (cyclic AMP) level	Adenosine, 5-monophosphate, cyclic (cyclic amp)
2026	82040		20260101	N	\$4.95	Albumin (protein) level	Albumin; serum, plasma or whole blood
2026	82040	QW	20260101	N	\$4.95	Albumin (protein) level	Albumin; serum, plasma or whole blood
2026	82042		20260101	N	\$7.78	Cerebrospinal fluid, or amniotic fluid albumin (protein) level	Albumin; other source, quantitative, each specimen

2026	82042	QW	20260101	N	\$7.78	Cerebrospinal fluid, or amniotic fluid albumin (protein) level	Albumin; other source, quantitative, each specimen
2026	82043		20260101	N	\$5.78	Urine microalbumin (protein) level	Albumin; urine (eg, microalbumin), quantitative
2026	82043	QW	20260101	N	\$5.78	Urine microalbumin (protein) level	Albumin; urine (eg, microalbumin), quantitative
2026	82044		20260101	N	\$6.23	Urine microalbumin (protein) analysis	Albumin; urine (eg, microalbumin), semiquantitative (eg, reagent strip assay)
2026	82044	QW	20260101	N	\$6.23	Urine microalbumin (protein) analysis	Albumin; urine (eg, microalbumin), semiquantitative (eg, reagent strip assay)
2026	82045		20260101	N	\$33.94	Albumin (protein) level related to restricted heart blood flow	Albumin; ischemia modified
2026	82075		20260101	N	\$30.00	Measurement of alcohol level in breath specimen	Alcohol (ethanol); breath

2026	82077		20260101	N	\$17.27	Measurement of alcohol level in specimen other than breath or urine	Alcohol (ethanol); any specimen except urine and breath, immunoassay (eg, ia, eia, elisa, ria, emit, fpia) and enzymatic methods (eg, alcohol dehydrogenase)
2026	82085		20260101	N	\$9.71	Aldolase (enzyme) level	Aldolase
2026	82088		20260101	N	\$40.75	Aldosterone hormone level	Aldosterone
2026	82103		20260101	N	\$13.44	Alpha-1-antitrypsin (protein) blood test, total	Alpha-1-antitrypsin; total
2026	82104		20260101	N	\$14.46	Alpha-1-antitrypsin (protein) blood test, phenotype	Alpha-1-antitrypsin; phenotype
2026	82105		20260101	N	\$16.77	Alpha-fetoprotein (AFP) level, serum	Alpha-fetoprotein (afp); serum
2026	82106		20260101	N	\$17.00	Alpha-fetoprotein (AFP) level, amniotic fluid	Alpha-fetoprotein (afp); amniotic fluid

2026	82107		20260101	N	\$64.41	Alpha-fetoprotein (AFP) analysis	Alpha-fetoprotein (afp); afp-l3 fraction isoform and total afp (including ratio)
2026	82108		20260101	N	\$25.48	Aluminum level	Aluminum
2026	82120		20260101	N	\$5.99	Vaginal fluid chemical analysis for bacteria	Amines, vaginal fluid, qualitative
2026	82120	QW	20260101	N	\$5.99	Vaginal fluid chemical analysis for bacteria	Amines, vaginal fluid, qualitative
2026	82127		20260101	N	\$14.18	Amino acid analysis, qualitative, each specimen	Amino acids; single, qualitative, each specimen
2026	82128		20260101	N	\$13.87	Amino acid analysis, multiple amino acids, qualitative, each specimen	Amino acids; multiple, qualitative, each specimen
2026	82131		20260101	N	\$22.98	Amino acid analysis, quantitative, each specimen	Amino acids; single, quantitative, each specimen
2026	82135		20260101	N	\$16.45	Aminolevulinic acid (protein) level	Aminolevulinic acid, delta (ala)

2026	82136		20260101	N	\$19.61	Amino acid level, 2 to 5 amino acids, quantitative, each specimen	Amino acids, 2 to 5 amino acids, quantitative, each specimen
2026	82139		20260101	N	\$16.87	Amino acid level, 6 or more amino acids, quantitative, each specimen	Amino acids, 6 or more amino acids, quantitative, each specimen
2026	82140		20260101	N	\$14.57	Ammonia level	Ammonia
2026	82143		20260101	N	\$9.35	Amniotic fluid scan	Amniotic fluid scan (spectrophotometric)
2026	82150		20260101	N	\$6.48	Amylase (enzyme) level	Amylase
2026	82150	QW	20260101	N	\$6.48	Amylase (enzyme) level	Amylase
2026	82154		20260101	N	\$28.83	Androstenediol glucuronide (hormone) level	Androstenediol glucuronide
2026	82157		20260101	N	\$29.28	Androstenedione (hormone) level	Androstenedione
2026	82160		20260101	N	\$25.55	Androsterone (hormone) level	Androsterone
2026	82163		20260101	N	\$20.52	Angiotensin II (protein) level	Angiotensin ii
2026	82164		20260101	N	\$14.60	Angiotensin I - converting enzyme (ACE) level	Angiotensin i - converting enzyme (ace)

2026	82166		20260101	N	\$38.62	Test for anti-mullerian hormone	Anti-mullerian hormone (amh)
2026	82172		20260101	N	\$21.09	Apolipoprotein level	Apolipoprotein, each
2026	82175		20260101	N	\$18.97	Arsenic level	Arsenic
2026	82180		20260101	N	\$9.89	Ascorbic acid (Vitamin C) level, blood	Ascorbic acid (vitamin c), blood
2026	82190		20260101	N	\$15.90	Measurement of substance using spectroscopy (light)	Atomic absorption spectroscopy, each analyte
2026	82232		20260101	N	\$16.18	Beta-2 microglobulin (protein) level	Beta-2 microglobulin
2026	82233		20260101	N	\$128.92	Test for beta-amyloid 1-40	Beta-amyloid; 1-40 (abeta 40)
2026	82234		20260101	N	\$128.92	Test for beta-amyloid 1-42	Beta-amyloid; 1-42 (abeta 42)
2026	82239		20260101	N	\$17.12	Bile acids level, total	Bile acids; total
2026	82240		20260101	N	\$26.58	Bile acids level, cholyglycine	Bile acids; cholyglycine
2026	82247		20260101	N	\$5.02	Bilirubin level, total	Bilirubin; total
2026	82247	QW	20260101	N	\$5.02	Bilirubin level, total	Bilirubin; total
2026	82248		20260101	N	\$5.02	Bilirubin level, direct	Bilirubin; direct
2026	82252		20260101	N	\$4.56	Stool analysis for bilirubin	Bilirubin; feces, qualitative

2026	82261		20260101	N	\$16.87	Biotinidase (enzyme) level	Biotinidase, each specimen
2026	82270		20260101	N	\$4.38	Stool analysis for blood to screen for colon tumors	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection)
2026	82271		20260101	N	\$5.32	Specimen analysis for blood	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources
2026	82271	QW	20260101	N	\$5.32	Specimen analysis for blood	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources

2026	82272		20260101	N	\$4.23	Stool analysis for blood, by peroxidase activity	Blood, occult, by peroxidase activity (eg, guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening
2026	82274		20260101	N	\$15.92	Stool analysis for blood, by fecal hemoglobin determination by immunoassay	Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations
2026	82274	QW	20260101	N	\$15.92	Stool analysis for blood, by fecal hemoglobin determination by immunoassay	Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations
2026	82286		20260101	N	\$5.16	Bradykinin (protein) level	Bradykinin
2026	82300		20260101	N	\$23.64	Cadmium level	Cadmium

2026	82306		20260101	N	\$29.60	Vitamin D-3 level	Vitamin d; 25 hydroxy, includes fraction(s), if performed
2026	82308		20260101	N	\$26.79	Calcitonin (hormone) level	Calcitonin
2026	82310		20260101	N	\$5.16	Calcium level, total	Calcium; total
2026	82310	QW	20260101	N	\$5.16	Calcium level, total	Calcium; total
2026	82330		20260101	N	\$13.68	Calcium level, ionized	Calcium; ionized
2026	82330	QW	20260101	N	\$13.68	Calcium level, ionized	Calcium; ionized
2026	82331		20260101	N	\$13.34	Calcium level, after calcium infusion test	Calcium; after calcium infusion test
2026	82340		20260101	N	\$6.03	Urine calcium level	Calcium; urine quantitative, timed specimen
2026	82355		20260101	N	\$11.58	Analysis of stone	Calculus; qualitative analysis
2026	82360		20260101	N	\$12.87	Chemical analysis of stone	Calculus; quantitative analysis, chemical
2026	82365		20260101	N	\$12.90	Infrared analysis of stone	Calculus; infrared spectroscopy
2026	82370		20260101	N	\$12.52	X-ray analysis of stone	Calculus; x-ray diffraction

2026	82373		20260101	N	\$18.06	Carbohydrate deficient transferrin (protein) level	Carbohydrate deficient transferrin
2026	82374		20260101	N	\$4.88	Carbon dioxide (bicarbonate) level	Carbon dioxide (bicarbonate)
2026	82374	QW	20260101	N	\$4.88	Carbon dioxide (bicarbonate) level	Carbon dioxide (bicarbonate)
2026	82375		20260101	N	\$12.32	Carboxyhemoglobin (protein) level	Carboxyhemoglobin; quantitative
2026	82376		20260101	N	\$14.07	Carboxyhemoglobin (protein) analysis	Carboxyhemoglobin; qualitative
2026	82378		20260101	N	\$18.96	Carcinoembryonic antigen (CEA) protein level	Carcinoembryonic antigen (cea)
2026	82379		20260101	N	\$16.87	Carnitine level	Carnitine (total and free), quantitative, each specimen
2026	82380		20260101	N	\$9.22	Carotene level	Carotene
2026	82382		20260101	N	\$27.30	Catecholamines (organic nitrogen) urine level	Catecholamines ; total urine
2026	82383		20260101	N	\$29.08	Catecholamines organic nitrogen blood level	Catecholamines ; blood

2026	82384		20260101	N	\$25.25	Catecholamines (organic nitrogen) level	Catecholamines ; fractionated
2026	82387		20260101	N	\$18.06	Cathepsin-D (enzyme) level	Cathepsin-d
2026	82390		20260101	N	\$10.74	Ceruloplasmin (protein) level	Ceruloplasmin
2026	82397		20260101	N	\$14.12	Analysis using chemiluminescent technique (light and chemical) reaction	Chemiluminescent assay
2026	82415		20260101	N	\$12.67	Chloramphenicol level	Chloramphenicol
2026	82435		20260101	N	\$4.60	Blood chloride level	Chloride; blood
2026	82435	QW	20260101	N	\$4.60	Blood chloride level	Chloride; blood
2026	82436		20260101	N	\$5.75	Urine chloride level	Chloride; urine
2026	82438		20260101	N	\$5.00	Chloride level	Chloride; other source
2026	82441		20260101	N	\$6.01	Screening test for chlorinated hydrocarbons	Chlorinated hydrocarbons, screen
2026	82465		20260101	N	\$4.35	Cholesterol level	Cholesterol, serum or whole blood, total
2026	82465	QW	20260101	N	\$4.35	Cholesterol level	Cholesterol, serum or whole blood, total

2026	82480		20260101	N	\$7.87	Cholinesterase (enzyme) level, to test for exposure to chemical or liver disease	Cholinesterase; serum
2026	82482		20260101	N	\$9.81	Cholinesterase (enzyme) level	Cholinesterase; rbc
2026	82485		20260101	N	\$20.65	Chondroitin B sulfate (protein) level	Chondroitin b sulfate, quantitative
2026	82495		20260101	N	\$20.28	Chromium level to test for poisoning or deficiency	Chromium
2026	82507		20260101	N	\$27.80	Citrate level	Citrate
2026	82523		20260101	N	\$18.68	Collagen cross links test, (urine test to evaluate bone health)	Collagen cross links, any method
2026	82523	QW	20260101	N	\$18.68	Collagen cross links test, (urine test to evaluate bone health)	Collagen cross links, any method
2026	82525		20260101	N	\$12.41	Copper level	Copper
2026	82528		20260101	N	\$22.52	Corticosterone (hormone) level	Corticosterone
2026	82530		20260101	N	\$16.71	Cortisol (hormone) measurement, free	Cortisol; free
2026	82533		20260101	N	\$16.30	Cortisol (hormone) measurement, total	Cortisol; total

2026	82540		20260101	N	\$4.64	Creatine measurement	Creatine
2026	82542		20260101	N	\$24.09	Chemical analysis using chromatography technique	Column chromatography, includes mass spectrometry, if performed (eg, hplc, lc, lc/ms, lc/ms-ms, gc, gc/ms-ms, gc/ms, hplc/ms), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
2026	82550		20260101	N	\$6.51	Creatine kinase (cardiac enzyme) level, total	Creatine kinase (ck), (cpk); total
2026	82550	QW	20260101	N	\$6.51	Creatine kinase (cardiac enzyme) level, total	Creatine kinase (ck), (cpk); total
2026	82552		20260101	N	\$13.39	Creatine kinase (cardiac enzyme) level, isoenzymes	Creatine kinase (ck), (cpk); isoenzymes
2026	82553		20260101	N	\$11.55	Creatine kinase (cardiac enzyme) level, MB fraction only	Creatine kinase (ck), (cpk); mb fraction only

2026	82554		20260101	N	\$11.87	Creatine kinase (cardiac enzyme) level, isoforms	Creatine kinase (ck), (cpk); isoforms
2026	82565		20260101	N	\$5.12	Blood creatinine level	Creatinine; blood
2026	82565	QW	20260101	N	\$5.12	Blood creatinine level	Creatinine; blood
2026	82570		20260101	N	\$5.18	Creatinine level to test for kidney function or muscle injury	Creatinine; other source
2026	82570	QW	20260101	N	\$5.18	Creatinine level to test for kidney function or muscle injury	Creatinine; other source
2026	82575		20260101	N	\$9.46	Creatinine clearance measurement to test for kidney function	Creatinine; clearance
2026	82585		20260101	N	\$14.14	Cryofibrinogen (protein) level	Cryofibrinogen
2026	82595		20260101	N	\$6.47	Cryoglobulin (protein) measurement	Cryoglobulin, qualitative or semi-quantitative (eg, cryocrit)
2026	82600		20260101	N	\$19.40	Cyanide measurement	Cyanide
2026	82607		20260101	N	\$15.08	Cyanocobalamin (vitamin B-12) level	Cyanocobalamin (vitamin b-12);

2026	82608		20260101	N	\$14.32	Cyanocobalamin (vitamin B-12) level, unsaturated binding capacity	Cyanocobalamin (vitamin b-12); unsaturated binding capacity
2026	82610		20260101	N	\$18.52	Cystatin C (enzyme inhibitor) level	Cystatin c
2026	82615		20260101	N	\$9.55	Cystine and homocystine (amino acids) analysis	Cystine and homocystine, urine, qualitative
2026	82626		20260101	N	\$25.27	Dehydroepiandrosterone (DHEA) hormone level	Dehydroepiandrosterone (dhea)
2026	82627		20260101	N	\$22.23	Dehydroepiandrosterone (DHEA-S) hormone level	Dehydroepiandrosterone-sulfate (dhea-s)
2026	82633		20260101	N	\$30.98	Desoxycorticosterone, 11 (hormone) level	Desoxycorticosterone, 11-
2026	82634		20260101	N	\$29.28	Deoxycortisol, 11 (hormone) level	Deoxycortisol, 11-
2026	82638		20260101	N	\$12.25	Dibucaine number (enzyme) measurement	Dibucaine number
2026	82642		20260101	N	\$29.28	Measurement of dihydrotestosterone	Dihydrotestosterone (dht)

2026	82652		20260101	N	\$38.50	Dihydroxyvitamin D, 1, 25 level	Vitamin d; 1, 25 dihydroxy, includes fraction(s), if performed
2026	82653		20260101	N	\$22.97	Measurement of pancreatic elastase (enzyme) in stool	Elastase, pancreatic (el-1), fecal; quantitative
2026	82656		20260101	N	\$11.53	Detection of pancreatic elastase (enzyme) in stool	Elastase, pancreatic (el-1), fecal; qualitative or semi-quantitative
2026	82657		20260101	N	\$22.17	Enzyme activity measurement, nonradioactive substrate	Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen
2026	82658		20260101	N	\$44.03	Enzyme activity measurement, radioactive substrate	Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; radioactive substrate, each specimen

2026	82664		20260101	N	\$61.50	Electrophoresis, laboratory testing technique	Electrophoretic technique, not elsewhere specified
2026	82668		20260101	N	\$18.79	Erythropoietin (protein) level	Erythropoietin
2026	82670		20260101	N	\$27.94	Measurement of total estradiol (hormone)	Estradiol; total
2026	82671		20260101	N	\$32.30	Estrogen analysis, fractionated	Estrogens; fractionated
2026	82672		20260101	N	\$21.70	Estrogen analysis, total	Estrogens; total
2026	82677		20260101	N	\$24.18	Estriol (hormone) level	Estriol
2026	82679		20260101	N	\$24.95	Estrone (hormone) level	Estrone
2026	82679	QW	20260101	N	\$24.95	Estrone (hormone) level	Estrone
2026	82681		20260101	N	\$27.94	Direct measurement of free estradiol (hormone)	Estradiol; free, direct measurement (eg, equilibrium dialysis)
2026	82693		20260101	N	\$14.90	Ethylene glycol (antifreeze) measurement	Ethylene glycol
2026	82696		20260101	N	\$26.24	Etiocholanolone (testosterone byproduct) level	Etiocholanolone

2026	82705		20260101	N	\$5.10	Stool fat or lipids analysis, qualitative	Fat or lipids, feces; qualitative
2026	82710		20260101	N	\$16.80	Stool fat or lipids analysis, quantitative	Fat or lipids, feces; quantitative
2026	82715		20260101	N	\$22.97	Stool fat differential measurement, quantitative	Fat differential, feces, quantitative
2026	82725		20260101	N	\$18.77	Fatty acids measurement	Fatty acids, nonesterified
2026	82726		20260101	N	\$19.75	Very long chain fatty acids level	Very long chain fatty acids
2026	82728		20260101	N	\$13.63	Ferritin (blood protein) level	Ferritin
2026	82731		20260101	N	\$64.41	Fetal fibronectin (protein) analysis	Fetal fibronectin, cervicovaginal secretions, semi-quantitative
2026	82735		20260101	N	\$18.54	Fluoride level	Fluoride
2026	82746		20260101	N	\$14.70	Folic acid level, serum	Folic acid; serum
2026	82747		20260101	N	\$17.65	Folic acid level, RBC	Folic acid; rbc
2026	82757		20260101	N	\$17.34	Semen fructose (carbohydrate) level	Fructose, semen
2026	82759		20260101	N	\$21.48	Galactokinase (enzyme) level	Galactokinase, rbc

2026	82760		20260101	N	\$11.20	Galactose (carbohydrate) level	Galactose
2026	82775		20260101	N	\$21.07	Galactose-1-phosphate uridyl transferase (enzyme) level	Galactose-1-phosphate uridyl transferase; quantitative
2026	82776		20260101	N	\$11.74	Galactose-1-phosphate uridyl transferase screening test	Galactose-1-phosphate uridyl transferase; screen
2026	82777		20260101	N	\$44.25	Galectin-3 level	Galectin-3
2026	82784		20260101	N	\$9.30	Gammaglobulin (immune system protein) measurement	Gammaglobulin (immunoglobulin); iga, igd, igg, igm, each
2026	82785		20260101	N	\$16.46	IgE (immune system protein) level	Gammaglobulin (immunoglobulin); ige
2026	82787		20260101	N	\$8.02	Gammaglobulin (immune system protein) measurement, immunoglobulin subclasses	Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, igg1, 2, 3, or 4), each
2026	82800		20260101	N	\$11.00	Blood pH level	Gases, blood, ph only

2026	82803		20260101	N	\$26.07	Blood gases measurement	Gases, blood, any combination of ph, pco2, po2, co2, hco3 (including calculated o2 saturation);
2026	82805		20260101	N	\$78.77	Blood gases measurement, with O2 saturation	Gases, blood, any combination of ph, pco2, po2, co2, hco3 (including calculated o2 saturation); with o2 saturation, by direct measurement, except pulse oximetry
2026	82810		20260101	N	\$9.77	Blood gas, oxygen saturation measurement	Gases, blood, o2 saturation only, by direct measurement, except pulse oximetry
2026	82820		20260101	N	\$13.34	Hemoglobin-oxygen affinity measurement	Hemoglobin-oxygen affinity (po2 for 50% hemoglobin saturation with oxygen)

2026	82930		20260101	N	\$6.71	Gastric acid analysis	Gastric acid analysis, includes ph if performed, each specimen
2026	82938		20260101	N	\$17.69	Gastrin (GI tract hormone) level, after secretin stimulation	Gastrin after secretin stimulation
2026	82941		20260101	N	\$17.63	Gastrin (GI tract hormone) level	Gastrin
2026	82943		20260101	N	\$14.29	Glucagon (pancreatic hormone) level	Glucagon
2026	82945		20260101	N	\$3.93	Glucose (sugar) level on body fluid	Glucose, body fluid, other than blood
2026	82946		20260101	N	\$17.77	Glucagon (pancreatic hormone) tolerance test	Glucagon tolerance test
2026	82947		20260101	N	\$3.93	Blood glucose (sugar) level	Glucose; quantitative, blood (except reagent strip)
2026	82947	QW	20260101	N	\$3.93	Blood glucose (sugar) level	Glucose; quantitative, blood (except reagent strip)
2026	82948		20260101	N	\$5.04	Blood glucose (sugar) measurement using reagent strip	Glucose; blood, reagent strip

2026	82950		20260101	N	\$4.75	Blood glucose (sugar) level after receiving dose of glucose	Glucose; post glucose dose (includes glucose)
2026	82950	QW	20260101	N	\$4.75	Blood glucose (sugar) level after receiving dose of glucose	Glucose; post glucose dose (includes glucose)
2026	82951		20260101	N	\$12.87	Blood glucose (sugar) tolerance test, 3 specimens	Glucose; tolerance test (gtt), 3 specimens (includes glucose)
2026	82951	QW	20260101	N	\$12.87	Blood glucose (sugar) tolerance test, 3 specimens	Glucose; tolerance test (gtt), 3 specimens (includes glucose)
2026	82952		20260101	N	\$3.92	Blood glucose (sugar) tolerance test, each additional beyond 3 specimens	Glucose; tolerance test, each additional beyond 3 specimens (list separately in addition to code for primary procedure)

2026	82952	QW	20260101	N	\$3.92	Blood glucose (sugar) tolerance test, each additional beyond 3 specimens	Glucose; tolerance test, each additional beyond 3 specimens (list separately in addition to code for primary procedure)
2026	82955		20260101	N	\$9.70	G6PD (enzyme) level	Glucose-6-phosphate dehydrogenase (g6pd); quantitative
2026	82960		20260101	N	\$6.05	G6PD (enzyme) screening test	Glucose-6-phosphate dehydrogenase (g6pd); screen
2026	82962		20260101	N	\$3.28	Blood glucose (sugar) test performed by hand-held instrument	Glucose, blood by glucose monitoring device(s) cleared by the fda specifically for home use
2026	82963		20260101	N	\$21.48	Glucosidase (sugar enzyme) measurement	Glucosidase, beta
2026	82965		20260101	N	\$13.15	Glutamate dehydrogenase (enzyme) measurement	Glutamate dehydrogenase
2026	82977		20260101	N	\$7.20	Glutamyltransferase (liver enzyme) level	Glutamyltransferase, gamma (ggt)

2026	82977	QW	20260101	N	\$7.20	Glutamyltransfe rase (liver enzyme) level	Glutamyltransfe rase, gamma (ggt)
2026	82978		20260101	N	\$15.45	Glutathione (protein) level	Glutathione
2026	82979		20260101	N	\$9.44	Glutathione reductase (enzyme) level	Glutathione reductase, rbc
2026	82985		20260101	N	\$16.76	Glycated protein level	Glycated protein
2026	82985	QW	20260101	N	\$16.76	Glycated protein level	Glycated protein
2026	83001		20260101	N	\$18.58	Gonadotropin, follicle stimulating (reproductive hormone) level	Gonadotropin; follicle stimulating hormone (fsh)
2026	83001	QW	20260101	N	\$18.58	Gonadotropin, follicle stimulating (reproductive hormone) level	Gonadotropin; follicle stimulating hormone (fsh)
2026	83002		20260101	N	\$18.52	Gonadotropin, luteinizing (reproductive hormone) level	Gonadotropin; luteinizing hormone (lh)
2026	83002	QW	20260101	N	\$18.52	Gonadotropin, luteinizing (reproductive hormone) level	Gonadotropin; luteinizing hormone (lh)
2026	83003		20260101	N	\$16.67	Human growth hormone level	Growth hormone, human (hgh) (somatotropin)

2026	83006		20260101	N	\$75.60	Test for detecting genes associated with growth stimulation	Growth stimulation expressed gene 2 (st2, interleukin 1 receptor like-1)
2026	83009		20260101	N	\$67.36	Blood test analysis for helicobacter pylori	Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (eg, c-13)
2026	83010		20260101	N	\$12.58	Haptoglobin (serum protein) level	Haptoglobin; quantitative
2026	83012		20260101	N	\$26.89	Haptoglobin (serum protein) measurement	Haptoglobin; phenotypes
2026	83013		20260101	N	\$67.36	Breath test analysis for helicobacter pylori	Helicobacter pylori; breath test analysis for urease activity, non-radioactive isotope (eg, c-13)
2026	83014		20260101	N	\$7.86	Administration of drug for helicobacter pylori	Helicobacter pylori; drug administration

2026	83015		20260101	N	\$20.94	Heavy metal screening test	Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury); qualitative, any number of analytes
2026	83018		20260101	N	\$21.96	Heavy metal level	Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury); quantitative, each, not elsewhere specified
2026	83020		20260101	N	\$12.87	Hemoglobin analysis and measurement, electrophoresis	Hemoglobin fractionation and quantitation; electrophoresis (eg, a2, s, c, and/or f)
2026	83021		20260101	N	\$18.06	Hemoglobin analysis and measurement, chromatography	Hemoglobin fractionation and quantitation; chromatography (eg, a2, s, c, and/or f)

2026	83026		20260101	N	\$4.01	Hemoglobin level	Hemoglobin; by copper sulfate method, non-automated
2026	83030		20260101	N	\$10.74	Fetal hemoglobin level	Hemoglobin; f (fetal), chemical
2026	83033		20260101	N	\$8.00	Fetal hemoglobin analysis	Hemoglobin; f (fetal), qualitative
2026	83036		20260101	N	\$9.71	Hemoglobin A1C level	Hemoglobin; glycosylated (a1c)
2026	83036	QW	20260101	N	\$9.71	Hemoglobin A1C level	Hemoglobin; glycosylated (a1c)
2026	83037		20260101	N	\$9.71	Hemoglobin A1C level, by device for home use	Hemoglobin; glycosylated (a1c) by device cleared by fda for home use
2026	83037	QW	20260101	N	\$9.71	Hemoglobin A1C level, by device for home use	Hemoglobin; glycosylated (a1c) by device cleared by fda for home use
2026	83045		20260101	N	\$6.49	Methemoglobin (hemoglobin) analysis, qualitative	Hemoglobin; methemoglobin, qualitative
2026	83050		20260101	N	\$8.20	Methemoglobin (hemoglobin) analysis, quantitative	Hemoglobin; methemoglobin, quantitative

2026	83051		20260101	N	\$7.31	Plasma hemoglobin level	Hemoglobin; plasma
2026	83060		20260101	N	\$8.80	Sulfhemoglobin (hemoglobin) level	Hemoglobin; sulfhemoglobin, quantitative
2026	83065		20260101	N	\$9.00	Thermolabile (heat sensitive) hemoglobin level	Hemoglobin; thermolabile
2026	83068		20260101	N	\$9.47	Screening test for unstable hemoglobin	Hemoglobin; unstable, screen
2026	83069		20260101	N	\$3.95	Urine hemoglobin level	Hemoglobin; urine
2026	83070		20260101	N	\$4.75	Hemosiderin (hemoglobin breakdown product) analysis	Hemosiderin, qualitative
2026	83080		20260101	N	\$16.87	b-Hexosaminidase (enzyme) level	B-hexosaminidase, each assay
2026	83088		20260101	N	\$29.53	Histamine (immune system substance) level	Histamine
2026	83090		20260101	N	\$17.92	Homocysteine (amino acid) level	Homocysteine
2026	83150		20260101	N	\$22.41	Homovanillic acid (organic acid) level	Homovanillic acid (hva)

2026	83491		20260101	N	\$17.90	Hydroxycorticosteroids, 17 (adrenal gland hormone) level	Hydroxycorticosteroids, 17- (17-ohcs)
2026	83497		20260101	N	\$12.90	Hydroxyindolacetic acid (product of metabolism) level	Hydroxyindolacetic acid, 5- (hiaa)
2026	83498		20260101	N	\$27.17	Hydroxyprogesterone, 17-D (synthetic hormone) level	Hydroxyprogesterone, 17-d
2026	83500		20260101	N	\$22.65	Hydroxyproline (amino acid) measurement, free	Hydroxyproline; free
2026	83505		20260101	N	\$24.30	Hydroxyproline (amino acid) measurement, total	Hydroxyproline; total
2026	83516		20260101	N	\$11.53	Analysis of substance using immunoassay technique, multiple step method	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method

2026	83516	QW	20260101	N	\$11.53	Analysis of substance using immunoassay technique, multiple step method	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method
2026	83518		20260101	N	\$9.64	Analysis of substance using immunoassay technique, single step method	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, single step method (eg, reagent strip)
2026	83518	QW	20260101	N	\$9.64	Analysis of substance using immunoassay technique, single step method	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, single step method (eg, reagent strip)

2026	83519		20260101	N	\$18.40	Measurement of substance using immunoassay technique, by radioimmunoassay	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, ria)
2026	83520		20260101	N	\$17.27	Measurement of substance using immunoassay technique	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
2026	83520	QW	20260101	N	\$17.27	Measurement of substance using immunoassay technique	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
2026	83521		20260101	N	\$17.27	Measurement of immunoglobulin light chains	Immunoglobulin light chains (ie, kappa, lambda), free, each

2026	83525		20260101	N	\$11.43	Insulin measurement, total	Insulin; total
2026	83527		20260101	N	\$12.95	Insulin measurement, free	Insulin; free
2026	83528		20260101	N	\$19.82	Intrinsic factor (stomach protein) level	Intrinsic factor
2026	83529		20260101	N	\$17.27	Measurement of interleukin-6	Interleukin-6 (il-6)
2026	83540		20260101	N	\$6.47	Iron level	Iron
2026	83550		20260101	N	\$8.74	Iron binding capacity	Iron binding capacity
2026	83570		20260101	N	\$8.85	Isocitric dehydrogenase (enzyme) level	Isocitric dehydrogenase (idh)
2026	83582		20260101	N	\$15.47	Ketogenic steroids (hormone) measurement	Ketogenic steroids, fractionation
2026	83586		20260101	N	\$12.80	Ketosteroids, 17 (hormone) measurement, total	Ketosteroids, 17- (17-ks); total
2026	83593		20260101	N	\$28.50	Ketosteroids, 17 (hormone) measurement, fractionation	Ketosteroids, 17- (17-ks); fractionation
2026	83605		20260101	N	\$11.57	Lactic acid level	Lactate (lactic acid)
2026	83605	QW	20260101	N	\$11.57	Lactic acid level	Lactate (lactic acid)

2026	83615		20260101	N	\$6.04	Lactate dehydrogenase (enzyme) level	Lactate dehydrogenase (ld), (ldh);
2026	83625		20260101	N	\$12.79	Lactate dehydrogenase (enzyme) measurement	Lactate dehydrogenase (ld), (ldh); isoenzymes, separation and quantitation
2026	83630		20260101	N	\$19.70	Stool lactoferrin (immune system protein) analysis	Lactoferrin, fecal; qualitative
2026	83631		20260101	N	\$19.63	Stool lactoferrin (immune system protein) level	Lactoferrin, fecal; quantitative
2026	83632		20260101	N	\$20.22	Human placental lactogen (placental hormone) level	Lactogen, human placental (hpl) human chorionic somatomammotropin
2026	83633		20260101	N	\$11.25	Urine lactose (carbohydrate) analysis	Lactose, urine, qualitative
2026	83655		20260101	N	\$12.11	Lead level	Lead
2026	83655	QW	20260101	N	\$12.11	Lead level	Lead
2026	83661		20260101	N	\$21.99	Fetal lung maturity assessment, lecithin sphingomyelin (L/S) ratio	Fetal lung maturity assessment; lecithin sphingomyelin (l/s) ratio

2026	83662		20260101	N	\$18.91	Fetal lung maturity assessment, foam stability test	Fetal lung maturity assessment; foam stability test
2026	83663		20260101	N	\$18.91	Fetal lung maturity assessment, fluorescence polarization	Fetal lung maturity assessment; fluorescence polarization
2026	83664		20260101	N	\$19.32	Fetal lung maturity assessment, lamellar body density	Fetal lung maturity assessment; lamellar body density
2026	83670		20260101	N	\$9.81	Leucine aminopeptidase (enzyme) level	Leucine aminopeptidase (lap)
2026	83690		20260101	N	\$6.89	Lipase (fat enzyme) level	Lipase
2026	83695		20260101	N	\$14.32	Lipoprotein (A) level	Lipoprotein (a)
2026	83698		20260101	N	\$46.31	Lipoprotein-associated phospholipase A2 (enzyme) level	Lipoprotein-associated phospholipase a2 (lp-pla2)
2026	83700		20260101	N	\$11.26	Lipoprotein level, electrophoretic separation and quantitation	Lipoprotein, blood; electrophoretic separation and quantitation

2026	83701		20260101	N	\$33.86	Lipoprotein measurement	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation)
2026	83704		20260101	N	\$34.19	Lipoprotein level, quantitation of lipoprotein particle number (s)	Lipoprotein, blood; quantitation of lipoprotein particle number (s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed
2026	83718		20260101	N	\$8.19	HDL cholesterol level	Lipoprotein, direct measurement; high density cholesterol (hdl cholesterol)

2026	83718	QW	20260101	N	\$8.19	HDL cholesterol level	Lipoprotein, direct measurement; high density cholesterol (hdl cholesterol)
2026	83719		20260101	N	\$12.75	VLDL cholesterol level	Lipoprotein, direct measurement; vldl cholesterol
2026	83721		20260101	N	\$10.50	LDL cholesterol level	Lipoprotein, direct measurement; ldl cholesterol
2026	83721	QW	20260101	N	\$10.50	LDL cholesterol level	Lipoprotein, direct measurement; ldl cholesterol
2026	83722		20260101	N	\$34.19	Measurement of small dense low density lipoprotein cholesterol	Lipoprotein, direct measurement; small dense ldl cholesterol
2026	83727		20260101	N	\$17.19	Luteinizing releasing factor (reproductive hormone) level	Luteinizing releasing factor (lrh)
2026	83735		20260101	N	\$6.70	Magnesium level	Magnesium
2026	83775		20260101	N	\$7.37	Malate dehydrogenase (enzyme) level	Malate dehydrogenase
2026	83785		20260101	N	\$26.65	Manganese (heavy metal) level	Manganese

2026	83789		20260101	N	\$24.11	Mass spectrometry (laboratory testing method)	Mass spectrometry and tandem mass spectrometry (eg, ms, ms/ms, maldi, ms-tof, qtof), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
2026	83825		20260101	N	\$16.26	Mercury level	Mercury, quantitative
2026	83835		20260101	N	\$16.94	Metanephrines level	Metanephrines
2026	83857		20260101	N	\$10.74	Methemalbumin (protein) level	Methemalbumin
2026	83861		20260101	N	\$22.48	Microfluid analysis of tears	Microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity
2026	83861	QW	20260101	N	\$22.48	Microfluid analysis of tears	Microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity
2026	83864		20260101	N	\$28.50	Mucopolysaccharides (protein) level	Mucopolysaccharides, acid, quantitative

2026	83872		20260101	N	\$5.86	Joint fluid diagnostic test	Mucin, synovial fluid (ropes test)
2026	83873		20260101	N	\$17.20	Myelin basic protein (nerve protein) level, spinal fluid	Myelin basic protein, cerebrospinal fluid
2026	83874		20260101	N	\$12.92	Myoglobin (muscle protein) level	Myoglobin
2026	83876		20260101	N	\$50.86	Myeloperoxidase (white blood cell enzyme) measurement	Myeloperoxidase (mpo)
2026	83880		20260101	N	\$39.26	Natriuretic peptide (heart and blood vessel protein) level	Natriuretic peptide
2026	83880	QW	20260101	N	\$39.26	Natriuretic peptide (heart and blood vessel protein) level	Natriuretic peptide
2026	83883		20260101	N	\$13.60	Nephelometry, test method using light	Nephelometry, each analyte not elsewhere specified
2026	83884		20260101	N	\$116.23	Test for neurofilament light chain	Neurofilament light chain (nfl)
2026	83885		20260101	N	\$24.51	Nickel level	Nickel
2026	83915		20260101	N	\$11.15	Nucleotidase 5' (enzyme) level	Nucleotidase 5'-

2026	83916		20260101	N	\$27.39	Measurement of immune substance (oligoclonal bands)	Oligoclonal immune (oligoclonal bands)
2026	83918		20260101	N	\$23.60	Organic acids level	Organic acids; total, quantitative, each specimen
2026	83919		20260101	N	\$16.45	Organic acids analysis	Organic acids; qualitative, each specimen
2026	83921		20260101	N	\$21.21	Organic acid level	Organic acid, single, quantitative
2026	83930		20260101	N	\$6.61	Blood osmolality (concentration) measurement	Osmolality; blood
2026	83935		20260101	N	\$6.82	Urine osmolality (concentration) measurement	Osmolality; urine
2026	83937		20260101	N	\$29.85	Osteocalcin (bone protein) level	Osteocalcin (bone g1a protein)
2026	83945		20260101	N	\$14.45	Oxalate level	Oxalate
2026	83950		20260101	N	\$64.41	HER-2 oncoprotein (cancer related gene) measurement	Oncoprotein; her-2/neu

2026	83951		20260101	N	\$64.41	Oncoprotein (cancer related gene) measurement	Oncoprotein; des-gamma-carboxy-prothrombin (dcp)
2026	83970		20260101	N	\$41.28	Parathormone (parathyroid hormone) level	Parathormone (parathyroid hormone)
2026	83986		20260101	N	\$3.58	Body fluid pH level	Ph; body fluid, not otherwise specified
2026	83986	QW	20260101	N	\$3.58	Body fluid pH level	Ph; body fluid, not otherwise specified
2026	83987		20260101	N	\$3.58	pH exhaled breath	Ph; exhaled breath condensate
2026	83993		20260101	N	\$19.63	Stool calprotectin (protein) level	Calprotectin, fecal
2026	84030		20260101	N	\$5.50	Phenylalanine, PKU (amino acid) level	Phenylalanine (pku), blood
2026	84035		20260101	N	\$3.98	Phenylketones (ketone) analysis	Phenylketones, qualitative
2026	84060		20260101	N	\$7.64	Phosphatase (enzyme) measurement, acid, total	Phosphatase, acid; total
2026	84066		20260101	N	\$9.66	Phosphatase, prostatic (prostate enzyme) level	Phosphatase, acid; prostatic

2026	84075		20260101	N	\$5.18	Phosphatase (enzyme) level, alkaline	Phosphatase, alkaline;
2026	84075	QW	20260101	N	\$5.18	Phosphatase (enzyme) level, alkaline	Phosphatase, alkaline;
2026	84078		20260101	N	\$8.26	Phosphatase (enzyme) level, alkaline, heat stable	Phosphatase, alkaline; heat stable (total not included)
2026	84080		20260101	N	\$14.78	Phosphatase (enzyme) measurement, alkaline, isoenzymes	Phosphatase, alkaline; isoenzymes
2026	84081		20260101	N	\$16.52	Phosphatidylglycerol (amniotic fluid organic acid) level	Phosphatidylglycerol
2026	84085		20260101	N	\$9.44	Phosphogluconate, 6-, dehydrogenase (enzyme) level	Phosphogluconate, 6-, dehydrogenase, rbc
2026	84087		20260101	N	\$10.73	Phosphohexose isomerase (enzyme) level	Phosphohexose isomerase
2026	84100		20260101	N	\$4.74	Phosphate level	Phosphorus inorganic (phosphate);
2026	84105		20260101	N	\$5.78	Urine phosphate level	Phosphorus inorganic (phosphate); urine

2026	84106		20260101	N	\$5.82	Urine porphobilinogen (metabolism substance) analysis	Porphobilinogen, urine; qualitative
2026	84110		20260101	N	\$8.44	Urine porphobilinogen (metabolism substance) level	Porphobilinogen, urine; quantitative
2026	84112		20260101	N	\$98.11	Cervicovaginal secretion of placenta protein	Evaluation of cervicovaginal fluid for specific amniotic fluid protein(s) (eg, placental alpha microglobulin-1 [pamg-1], placental protein 12 [pp12], alpha-fetoprotein), qualitative, each specimen
2026	84119		20260101	N	\$13.36	Urine porphyrins (metabolism substance) analysis	Porphyrins, urine; qualitative
2026	84120		20260101	N	\$14.71	Urine porphyrins (metabolism substance) measurement	Porphyrins, urine; quantitation and fractionation

2026	84126		20260101	N	\$39.11	Stool porphyrins (metabolism substance) level	Porphyrins, feces, quantitative
2026	84132		20260101	N	\$4.76	Blood potassium level	Potassium; serum, plasma or whole blood
2026	84132	QW	20260101	N	\$4.76	Blood potassium level	Potassium; serum, plasma or whole blood
2026	84133		20260101	N	\$4.73	Urine potassium level	Potassium; urine
2026	84134		20260101	N	\$14.59	Prealbumin (protein) level	Prealbumin
2026	84135		20260101	N	\$21.27	Pregnanediol (reproductive hormone) level	Pregnanediol
2026	84138		20260101	N	\$21.05	Pregnanetriol (reproductive hormone) level	Pregnanetriol
2026	84140		20260101	N	\$20.67	Pregnenolone (reproductive hormone) level	Pregnenolone
2026	84143		20260101	N	\$22.81	17-hydroxypregnenolone (hormone) level	17-hydroxypregnenolone
2026	84144		20260101	N	\$20.86	Progesterone (reproductive hormone) level	Progesterone
2026	84145		20260101	N	\$27.22	Procalcitonin (hormone) level	Procalcitonin (pct)
2026	84146		20260101	N	\$19.38	Prolactin (milk producing hormone) level	Prolactin

2026	84150		20260101	N	\$41.77	Prostaglandin (hormone) level	Prostaglandin, each
2026	84152		20260101	N	\$18.39	PSA (prostate specific antigen) measurement, complexed	Prostate specific antigen (psa); complexed (direct measurement)
2026	84153		20260101	N	\$18.39	PSA (prostate specific antigen) measurement, total	Prostate specific antigen (psa); total
2026	84154		20260101	N	\$18.39	PSA (prostate specific antigen) measurement, free	Prostate specific antigen (psa); free
2026	84155		20260101	N	\$3.67	Total protein level, blood	Protein, total, except by refractometry; serum, plasma or whole blood
2026	84155	QW	20260101	N	\$3.67	Total protein level, blood	Protein, total, except by refractometry; serum, plasma or whole blood
2026	84156		20260101	N	\$3.67	Total protein level, urine	Protein, total, except by refractometry; urine

2026	84157		20260101	N	\$4.00	Total protein level, body fluid	Protein, total, except by refractometry; other source (eg, synovial fluid, cerebrospinal fluid)
2026	84157	QW	20260101	N	\$4.00	Total protein level, body fluid	Protein, total, except by refractometry; other source (eg, synovial fluid, cerebrospinal fluid)
2026	84160		20260101	N	\$5.61	Total protein level	Protein, total, by refractometry, any source
2026	84163		20260101	N	\$15.05	Pregnancy-associated plasma protein-A level	Pregnancy-associated plasma protein-a (papp-a)
2026	84165		20260101	N	\$10.74	Protein measurement, serum	Protein; electrophoretic fractionation and quantitation, serum

2026	84166		20260101	N	\$17.83	Protein measurement, body fluid	Protein; electrophoretic fractionation and quantitation, other fluids with concentration (eg, urine, csf)
2026	84181		20260101	N	\$17.03	Protein measurement	Protein; western blot, with interpretation and report, blood or other body fluid
2026	84182		20260101	N	\$29.21	Protein measurement, immunological probe for band identification	Protein; western blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each
2026	84202		20260101	N	\$14.35	Protoporphyrin (metabolism substance) level	Protoporphyrin, rbc; quantitative
2026	84203		20260101	N	\$9.74	Protoporphyrin (metabolism substance) screening test	Protoporphyrin, rbc; screen

2026	84206		20260101	N	\$26.69	Proinsulin (pancreatic hormone) level	Proinsulin
2026	84207		20260101	N	\$28.10	Vitamin B-6 level	Pyridoxal phosphate (vitamin b-6)
2026	84210		20260101	N	\$14.48	Pyruvate (organic acid) level	Pyruvate
2026	84220		20260101	N	\$9.44	Pyruvate kinase (enzyme) level	Pyruvate kinase
2026	84228		20260101	N	\$11.63	Quinine (drug) level	Quinine
2026	84233		20260101	N	\$87.88	Estrogen receptor analysis	Receptor assay; estrogen
2026	84234		20260101	N	\$64.88	Progesterone (reproductive hormone) receptor analysis	Receptor assay; progesterone
2026	84235		20260101	N	\$71.23	Hormone receptor analysis	Receptor assay; endocrine, other than estrogen or progesterone (specify hormone)
2026	84238		20260101	N	\$36.57	Chemical receptor analysis	Receptor assay; non-endocrine (specify receptor)
2026	84244		20260101	N	\$21.99	Renin (kidney enzyme) level	Renin

2026	84252		20260101	N	\$20.24	Vitamin B-2 (riboflavin) level	Riboflavin (vitamin b-2)
2026	84255		20260101	N	\$25.53	Selenium (vitamin) level	Selenium
2026	84260		20260101	N	\$30.98	Serotonin (hormone) level	Serotonin
2026	84270		20260101	N	\$21.73	Sex hormone binding globulin (protein) level	Sex hormone binding globulin (shbg)
2026	84275		20260101	N	\$13.44	Sialic acid (organic acid) level	Sialic acid
2026	84285		20260101	N	\$25.21	Silica (silicon) level	Silica
2026	84295		20260101	N	\$4.81	Blood sodium level	Sodium; serum, plasma or whole blood
2026	84295	QW	20260101	N	\$4.81	Blood sodium level	Sodium; serum, plasma or whole blood
2026	84300		20260101	N	\$5.06	Urine sodium level	Sodium; urine
2026	84302		20260101	N	\$4.86	Sodium level	Sodium; other source
2026	84305		20260101	N	\$21.26	Somatomedin (growth factor) level	Somatomedin
2026	84307		20260101	N	\$18.28	Somatostatin (growth hormone inhibitor) level	Somatostatin

2026	84311		20260101	N	\$8.10	Chemical analysis using spectrophotometry (light)	Spectrophotometry, analyte not elsewhere specified
2026	84315		20260101	N	\$3.28	Specific gravity (liquid weight) measurement	Specific gravity (except urine)
2026	84375		20260101	N	\$39.00	Carbohydrate (sugar) analysis	Sugars, chromatographic, tlc or paper chromatography
2026	84376		20260101	N	\$5.50	Carbohydrate analysis, single qualitative	Sugars (mono-, di-, and oligosaccharides); single qualitative, each specimen
2026	84377		20260101	N	\$5.50	Carbohydrate analysis, multiple qualitative	Sugars (mono-, di-, and oligosaccharides); multiple qualitative, each specimen
2026	84378		20260101	N	\$11.53	Carbohydrate analysis, single quantitative	Sugars (mono-, di-, and oligosaccharides); single quantitative, each specimen
2026	84379		20260101	N	\$11.53	Carbohydrate analysis, multiple quantitative	Sugars (mono-, di-, and oligosaccharides); multiple quantitative, each specimen

2026	84392		20260101	N	\$5.49	Urine sulfate (acid) level	Sulfate, urine
2026	84393		20260101	N	\$128.92	Test for phosphorylated Tau protein	Tau, phosphorylated (eg, ptau 181, ptau 217), each
2026	84394		20260101	N	\$128.92	Test for total Tau protein	Tau, total (ttau)
2026	84402		20260101	N	\$25.47	Testosterone (hormone) level, free	Testosterone; free
2026	84403		20260101	N	\$25.81	Testosterone (hormone) level, total	Testosterone; total
2026	84410		20260101	N	\$51.28	Testosterone level	Testosterone; bioavailable, direct measurement (eg, differential precipitation)
2026	84425		20260101	N	\$21.23	Vitamin B-1 (thiamine) level	Thiamine (vitamin b-1)
2026	84430		20260101	N	\$11.63	Thiocyanate (organic sulfur substance) level	Thiocyanate
2026	84431		20260101	N	\$35.11	Urine analysis for thromboxane (lipid)	Thromboxane metabolite(s), including thromboxane if performed, urine
2026	84432		20260101	N	\$16.06	Thyroglobulin (thyroid related hormone) level	Thyroglobulin

2026	84433		20260101	N	\$22.17	Evaluation of thiopurine S-methyltransferase (TPMT)	Thiopurine s-methyltransferase (tpmt)
2026	84436		20260101	N	\$6.87	Thyroxine (thyroid chemical), total	Thyroxine; total
2026	84437		20260101	N	\$6.47	Thyroxine (thyroid chemical), requiring elution	Thyroxine; requiring elution (eg, neonatal)
2026	84439		20260101	N	\$9.02	Thyroxine (thyroid chemical), free	Thyroxine; free
2026	84442		20260101	N	\$14.78	Thyroxine binding globulin (thyroid related protein) level	Thyroxine binding globulin (tbg)
2026	84443		20260101	N	\$16.80	Blood test, thyroid stimulating hormone (TSH)	Thyroid stimulating hormone (tsh)
2026	84443	QW	20260101	N	\$16.80	Blood test, thyroid stimulating hormone (TSH)	Thyroid stimulating hormone (tsh)
2026	84445		20260101	N	\$50.86	Thyroid stimulating immune globulins (thyroid related protein) level	Thyroid stimulating immune globulins (tsi)

2026	84446		20260101	N	\$14.18	Vitamin E level	Tocopherol alpha (vitamin e)
2026	84449		20260101	N	\$18.00	Transcortin (cortisol binding protein) level	Transcortin (cortisol binding globulin)
2026	84450		20260101	N	\$5.18	Liver enzyme (SGOT), level	Transferase; aspartate amino (ast) (sgot)
2026	84450	QW	20260101	N	\$5.18	Liver enzyme (SGOT), level	Transferase; aspartate amino (ast) (sgot)
2026	84460		20260101	N	\$5.30	Liver enzyme (SGPT), level	Transferase; alanine amino (alt) (sgpt)
2026	84460	QW	20260101	N	\$5.30	Liver enzyme (SGPT), level	Transferase; alanine amino (alt) (sgpt)
2026	84466		20260101	N	\$12.76	Transferrin (iron binding protein) level	Transferrin
2026	84478		20260101	N	\$5.74	Triglycerides level	Triglycerides
2026	84478	QW	20260101	N	\$5.74	Triglycerides level	Triglycerides
2026	84479		20260101	N	\$6.47	Thyroid hormone evaluation	Thyroid hormone (t3 or t4) uptake or thyroid hormone binding ratio (thbr)

2026	84480		20260101	N	\$14.18	Thyroid hormone, T3 measurement, total	Triiodothyronine t3; total (tt-3)
2026	84481		20260101	N	\$16.94	Thyroid hormone, T3 measurement, free	Triiodothyronine t3; free
2026	84482		20260101	N	\$15.76	Thyroid hormone, T3 measurement, reverse	Triiodothyronine t3; reverse
2026	84484		20260101	N	\$12.47	Troponin (protein) analysis, quantitative	Troponin, quantitative
2026	84485		20260101	N	\$7.20	Trypsin (pancreatic enzyme) measurement, intestinal fluid	Trypsin; duodenal fluid
2026	84488		20260101	N	\$7.30	Trypsin (pancreatic enzyme) analysis, stool	Trypsin; feces, qualitative
2026	84490		20260101	N	\$9.93	Stool trypsin (pancreatic enzyme) analysis, 24-hour collection	Trypsin; feces, quantitative, 24-hour collection
2026	84510		20260101	N	\$10.63	Tyrosine (amino acid) level	Tyrosine

2026	84512		20260101	N	\$10.09	Troponin (protein) analysis, qualitative	Troponin, qualitative
2026	84520		20260101	N	\$3.95	Urea nitrogen level to assess kidney function, quantitative	Urea nitrogen; quantitative
2026	84520	QW	20260101	N	\$3.95	Urea nitrogen level to assess kidney function, quantitative	Urea nitrogen; quantitative
2026	84525		20260101	N	\$5.13	Urea nitrogen level to assess kidney function, semiquantitative	Urea nitrogen; semiquantitative (eg, reagent strip test)
2026	84540		20260101	N	\$5.56	Urea nitrogen level to assess kidney function, urine	Urea nitrogen, urine
2026	84545		20260101	N	\$7.20	Urea nitrogen level to assess kidney function, clearance	Urea nitrogen, clearance
2026	84550		20260101	N	\$4.52	Uric acid level, blood	Uric acid; blood
2026	84550	QW	20260101	N	\$4.52	Uric acid level, blood	Uric acid; blood
2026	84560		20260101	N	\$5.08	Uric acid level	Uric acid; other source
2026	84577		20260101	N	\$16.80	Urobilinogen (metabolism substance) level, stool	Urobilinogen, feces, quantitative

2026	84578		20260101	N	\$4.47	Urobilinogen (metabolism substance) analysis, urine	Urobilinogen, urine; qualitative
2026	84580		20260101	N	\$9.55	Urobilinogen (metabolism substance) level, urine	Urobilinogen, urine; quantitative, timed specimen
2026	84583		20260101	N	\$6.05	Urobilinogen (metabolism substance) measurement, urine	Urobilinogen, urine; semiquantitative
2026	84585		20260101	N	\$15.50	Urine vanillylmandelic acid	Vanillylmandelic acid (vma), urine
2026	84586		20260101	N	\$35.33	Vasoactive intestinal peptide (intestinal hormone) level	Vasoactive intestinal peptide (vip)
2026	84588		20260101	N	\$33.94	ADH (antidiuretic hormone) level	Vasopressin (antidiuretic hormone, adh)
2026	84590		20260101	N	\$11.61	Vitamin A level	Vitamin a
2026	84591		20260101	N	\$17.06	Vitamin measurement	Vitamin, not otherwise specified
2026	84597		20260101	N	\$13.72	Vitamin K level	Vitamin k
2026	84600		20260101	N	\$17.11	Volatile chemical measurement	Volatiles (eg, acetic anhydride, diethylether)

2026	84620		20260101	N	\$12.91	Xylose (carbohydrate) absorption test of blood and/or urine	Xylose absorption test, blood and/or urine
2026	84630		20260101	N	\$11.39	Zinc level	Zinc
2026	84681		20260101	N	\$20.81	C-peptide (protein) level	C-peptide
2026	84702		20260101	N	\$15.05	Gonadotropin, chorionic (reproductive hormone) level	Gonadotropin, chorionic (hcg); quantitative
2026	84703		20260101	N	\$7.52	Gonadotropin (reproductive hormone) analysis	Gonadotropin, chorionic (hcg); qualitative
2026	84703	QW	20260101	N	\$7.52	Gonadotropin (reproductive hormone) analysis	Gonadotropin, chorionic (hcg); qualitative
2026	84704		20260101	N	\$15.29	Gonadotropin, chorionic (reproductive hormone) measurement	Gonadotropin, chorionic (hcg); free beta chain
2026	84830		20260101	N	\$12.70	Ovulation tests	Ovulation tests, by visual color comparison methods for human luteinizing hormone
2026	85002		20260101	N	\$4.82	Bleeding time	Bleeding time

2026	85004		20260101	N	\$6.47	White blood cell count	Blood count; automated differential wbc count
2026	85007		20260101	N	\$3.80	Microscopic examination for white blood cells with manual cell count	Blood count; blood smear, microscopic examination with manual differential wbc count
2026	85008		20260101	N	\$3.43	Microscopic examination for white blood cells	Blood count; blood smear, microscopic examination without manual differential wbc count
2026	85009		20260101	N	\$5.07	Manual white blood cell count and evaluation	Blood count; manual differential wbc count, buffy coat
2026	85013		20260101	N	\$7.00	Red blood cell hemoglobin concentration	Blood count; spun microhematocrit
2026	85014		20260101	N	\$2.37	Red blood cell concentration measurement	Blood count; hematocrit (hct)
2026	85014	QW	20260101	N	\$2.37	Red blood cell concentration measurement	Blood count; hematocrit (hct)
2026	85018		20260101	N	\$2.37	Blood count, hemoglobin	Blood count; hemoglobin (hgb)

2026	85018	QW	20260101	N	\$2.37	Blood count, hemoglobin	Blood count; hemoglobin (hgb)
2026	85025		20260101	N	\$7.77	Complete blood cell count (red cells, white blood cell, platelets), automated	Blood count; complete (cbc), automated (hgb, hct, rbc, wbc and platelet count) and automated differential wbc count
2026	85025	QW	20260101	N	\$7.77	Complete blood cell count (red cells, white blood cell, platelets), automated	Blood count; complete (cbc), automated (hgb, hct, rbc, wbc and platelet count) and automated differential wbc count
2026	85027		20260101	N	\$6.47	Complete blood cell count (red cells, white blood cell, platelets), automated	Blood count; complete (cbc), automated (hgb, hct, rbc, wbc and platelet count)
2026	85032		20260101	N	\$4.31	Manual blood cell count	Blood count; manual cell count (erythrocyte, leukocyte, or platelet) each

2026	85041		20260101	N	\$3.02	Red blood cell count, automated test	Blood count; red blood cell (rbc), automated
2026	85044		20260101	N	\$4.31	Red blood count, manual test	Blood count; reticulocyte, manual
2026	85045		20260101	N	\$3.99	Red blood count, automated test	Blood count; reticulocyte, automated
2026	85046		20260101	N	\$5.57	Red blood count automated, with additional calculations	Blood count; reticulocytes, automated, including 1 or more cellular parameters (eg, reticulocyte hemoglobin content [chr], immature reticulocyte fraction [irf], reticulocyte volume [mrv], rna content), direct measurement
2026	85048		20260101	N	\$2.54	Automated white blood cell count	Blood count; leukocyte (wbc), automated
2026	85049		20260101	N	\$4.48	Platelet count, automated test	Blood count; platelet, automated

2026	85055		20260101	N	\$35.74	Reticulated (young) platelet measurement	Reticulated platelet assay
2026	85130		20260101	N	\$11.89	Assessment of blood clotting function	Chromogenic substrate assay
2026	85170		20260101	N	\$16.30	Blood clot evaluation, (retraction time)	Clot retraction
2026	85175		20260101	N	\$20.37	Blood clot evaluation, (clot dissolving time)	Clot lysis time, whole blood dilution
2026	85210		20260101	N	\$12.98	Clotting factor II prothrombin, measurement	Clotting; factor ii, prothrombin, specific
2026	85220		20260101	N	\$17.65	Clotting factor V (AcG or proaccelerin) measurement	Clotting; factor v (acg or proaccelerin), labile factor
2026	85230		20260101	N	\$17.90	Clotting factor VII (proconvertin, stable factor)	Clotting; factor vii (proconvertin, stable factor)
2026	85240		20260101	N	\$17.90	Clotting factor VIII (AHG) measurement	Clotting; factor viii (ahg), 1-stage
2026	85244		20260101	N	\$20.42	Clotting factor VIII related antigen measurement	Clotting; factor viii related antigen
2026	85245		20260101	N	\$22.94	Clotting factor VIII (VW factor) measurement	Clotting; factor viii, vw factor, ristocetin cofactor

2026	85246		20260101	N	\$22.94	Clotting factor VIII (VW factor) antigen	Clotting; factor viii, vw factor antigen
2026	85247		20260101	N	\$22.94	Clotting factor VIII (von Willebrand factor) measurement	Clotting; factor viii, von willebrand factor, multimeric analysis
2026	85250		20260101	N	\$19.04	Clotting factor IX (PTC or Christmas) measurement	Clotting; factor ix (ptc or christmas)
2026	85260		20260101	N	\$17.90	Clotting factor X (Stuart-Prower) measurement	Clotting; factor x (stuart-prower)
2026	85270		20260101	N	\$17.90	Clotting factor XI (PTA) measurement	Clotting; factor xi (pta)
2026	85280		20260101	N	\$19.35	Clotting factor XII (Hageman) measurement	Clotting; factor xii (hageman)
2026	85290		20260101	N	\$16.34	Clotting factor XIII (fibrin stabilizing) measurement	Clotting; factor xiii (fibrin stabilizing)
2026	85291		20260101	N	\$9.11	Clotting factor XIII (fibrin stabilizing) screening test	Clotting; factor xiii (fibrin stabilizing), screen solubility
2026	85292		20260101	N	\$18.93	Fletcher factor (clotting factor) measurement	Clotting; prekallikrein assay (fletcher factor assay)

2026	85293		20260101	N	\$18.93	Fitzgerald factor (clotting factor) measurement	Clotting; high molecular weight kininogen assay (fitzgerald factor assay)
2026	85300		20260101	N	\$11.85	Antithrombin III antigen (clotting inhibitor) activity	Clotting inhibitors or anticoagulants; antithrombin iii, activity
2026	85301		20260101	N	\$10.81	Antithrombin III antigen (clotting inhibitor) level	Clotting inhibitors or anticoagulants; antithrombin iii, antigen assay
2026	85302		20260101	N	\$12.01	Protein C, (clotting inhibitor) activity	Clotting inhibitors or anticoagulants; protein c, antigen
2026	85303		20260101	N	\$13.84	Protein C antigen (clotting inhibitor) measurement	Clotting inhibitors or anticoagulants; protein c, activity
2026	85305		20260101	N	\$11.61	Protein S (clotting inhibitor) level	Clotting inhibitors or anticoagulants; protein s, total
2026	85306		20260101	N	\$15.32	Protein S (clotting inhibitor) measurement	Clotting inhibitors or anticoagulants; protein s, free

2026	85307		20260101	N	\$15.32	Activated protein resistance assay	Activated protein c (apc) resistance assay
2026	85335		20260101	N	\$12.87	Clotting factor inhibitor test	Factor inhibitor test
2026	85337		20260101	N	\$17.27	Thrombomodulin (coagulation protein) measurement	Thrombomodulin
2026	85345		20260101	N	\$4.69	Coagulation time measurement, Lee and White	Coagulation time; lee and white
2026	85347		20260101	N	\$4.28	Coagulation time measurement, activated	Coagulation time; activated
2026	85348		20260101	N	\$4.49	Coagulation time measurement, other methods	Coagulation time; other methods
2026	85360		20260101	N	\$8.41	Euglobulin lysis (clot dissolving) measurement	Euglobulin lysis
2026	85362		20260101	N	\$6.89	Coagulation function analysis, agglutination slide, semiquantitative	Fibrin(ogen) degradation (split) products (fdp) (fsp); agglutination slide, semiquantitative

2026	85366		20260101	N	\$80.46	Coagulation function measurement, paracoagulation	Fibrin(ogen) degradation (split) products (fdp) (fsp); paracoagulation
2026	85370		20260101	N	\$12.43	Coagulation function measurement, quantitative	Fibrin(ogen) degradation (split) products (fdp) (fsp); quantitative
2026	85378		20260101	N	\$9.72	Coagulation function measurement, qualitative or semiquantitative	Fibrin degradation products, d-dimer; qualitative or semiquantitative
2026	85379		20260101	N	\$10.18	Coagulation function measurement, D-dimer; quantitative	Fibrin degradation products, d-dimer; quantitative
2026	85380		20260101	N	\$10.18	Coagulation function measurement, ultrasensitive, qualitative or	Fibrin degradation products, d-dimer; ultrasensitive (eg, for evaluation for venous thromboembolism), qualitative or semiquantitative

2026	85384		20260101	N	\$9.72	Fibrinogen (factor 1) activity measurement	Fibrinogen; activity
2026	85385		20260101	N	\$14.46	Fibrinogen (factor 1) antigen detection	Fibrinogen; antigen
2026	85390		20260101	N	\$15.48	Coagulation function screening test with interpretation and report	Fibrinolysins or coagulopathy screen, interpretation and report
2026	85397		20260101	N	\$30.86	Measurement of blood coagulation and fibrinolysis (clot dissolving) function	Coagulation and fibrinolysis, functional activity, not otherwise specified (eg, adams-13), each analyte
2026	85400		20260101	N	\$7.71	Plasmin (fibrinolytic factor) measurement	Fibrinolytic factors and inhibitors; plasmin
2026	85410		20260101	N	\$7.71	Alpha-2 antiplasmin (factor inhibitor) measurement	Fibrinolytic factors and inhibitors; alpha-2 antiplasmin
2026	85415		20260101	N	\$17.19	Plasminogen activator (fibrinolytic factor) measurement	Fibrinolytic factors and inhibitors; plasminogen activator

2026	85420		20260101	N	\$6.53	Plasminogen (fibrinolytic factor) measurement	Fibrinolytic factors and inhibitors; plasminogen, except antigenic assay
2026	85421		20260101	N	\$10.18	Plasminogen antigenic (factor inhibitor) measurement	Fibrinolytic factors and inhibitors; plasminogen, antigenic assay
2026	85441		20260101	N	\$4.20	Evaluation of red blood cell defect (Heinz bodies), direct	Heinz bodies; direct
2026	85445		20260101	N	\$6.82	Evaluation of red blood cell defect (Heinz bodies), induced	Heinz bodies; induced, acetyl phenylhydrazine
2026	85460		20260101	N	\$7.73	Fetal hemoglobin or red blood cells measurement for assessment of	Hemoglobin or rbc, fetal, for fetomaternal hemorrhage; differential lysis (kleihauer-betke)
2026	85461		20260101	N	\$9.36	Fetal hemoglobin or red blood cells measurement for assessment of	Hemoglobin or rbc, fetal, for fetomaternal hemorrhage; rosette

2026	85475		20260101	N	\$8.87	Measurement of hemolysin (red blood cell destructive substance)	Hemolysin, acid
2026	85520		20260101	N	\$13.09	Heparin assay	Heparin assay
2026	85525		20260101	N	\$11.84	Heparin neutralization test	Heparin neutralization test
2026	85530		20260101	N	\$13.09	Heparin therapy assessment	Heparin-protamine tolerance test
2026	85536		20260101	N	\$6.88	Blood smear for iron	Iron stain, peripheral blood
2026	85540		20260101	N	\$8.60	White blood cell alkaline phosphatase (enzyme) measurement with cell count	Leukocyte alkaline phosphatase with count
2026	85547		20260101	N	\$8.60	Red blood cell fragility measurement	Mechanical fragility, rbc
2026	85549		20260101	N	\$18.75	White blood cell enzyme activity measurement	Muramidase
2026	85555		20260101	N	\$7.47	Red blood cell fragility measurement, unincubated	Osmotic fragility, rbc; unincubated

2026	85557		20260101	N	\$13.36	Red blood cell fragility measurement, incubated	Osmotic fragility, rbc; incubated
2026	85576		20260101	N	\$24.91	Platelet aggregation function test	Platelet, aggregation (in vitro), each agent
2026	85576	QW	20260101	N	\$24.91	Platelet aggregation function test	Platelet, aggregation (in vitro), each agent
2026	85597		20260101	N	\$17.98	Platelet function test	Phospholipid neutralization; platelet
2026	85598		20260101	N	\$17.98	Phospholipid test	Phospholipid neutralization; hexagonal phospholipid
2026	85610		20260101	N	\$4.29	Blood test, clotting time	Prothrombin time;
2026	85610	QW	20260101	N	\$4.29	Blood test, clotting time	Prothrombin time;
2026	85611		20260101	N	\$3.94	Blood test, clotting time, substitution	Prothrombin time; substitution, plasma fractions, each
2026	85612		20260101	N	\$17.49	Clotting factor X assessment test, undiluted	Russell viper venom time (includes venom); undiluted

2026	85613		20260101	N	\$9.58	Clotting factor X assessment test, diluted	Russell viper venom time (includes venom); diluted
2026	85635		20260101	N	\$9.85	Blood coagulation screening test	Reptilase test
2026	85651		20260101	N	\$4.27	Red blood cell sedimentation rate, to detect inflammation, non-automated	Sedimentation rate, erythrocyte; non-automated
2026	85652		20260101	N	\$2.70	Red blood cell sedimentation rate, to detect inflammation, automated	Sedimentation rate, erythrocyte; automated
2026	85660		20260101	N	\$5.51	Red blood cell sickling measurement	Sickling of rbc, reduction
2026	85670		20260101	N	\$5.77	Thrombin time, fibrinogen screening test, plasma	Thrombin time; plasma
2026	85675		20260101	N	\$6.85	Thrombin time, fibrinogen screening test, titer	Thrombin time; titer
2026	85705		20260101	N	\$9.63	Thromboplastin inhibition (circulating anticoagulant) measurement	Thromboplastin inhibition, tissue

2026	85730		20260101	N	\$6.01	Coagulation assessment blood test, plasma or whole blood	Thromboplastin time, partial (ptt); plasma or whole blood
2026	85732		20260101	N	\$6.47	Coagulation assessment blood test, substitution, plasma fractions	Thromboplastin time, partial (ptt); substitution, plasma fractions, each
2026	85810		20260101	N	\$11.67	Blood viscosity measurement	Viscosity
2026	86000		20260101	N	\$6.98	Measurement of antibody to infectious organism	Agglutinins, febrile (eg, brucella, francisella, murine typhus, q fever, rocky mountain spotted fever, scrub typhus), each antigen
2026	86001		20260101	N	\$7.82	Measurement of antibody (IgG) to allergic substance, each allergen	Allergen specific igg quantitative or semiquantitative, each allergen
2026	86003		20260101	N	\$5.22	Measurement of antibody (IgE) to allergic substance, crude allergen extract,	Allergen specific ige; quantitative or semiquantitative, crude allergen extract, each

2026	86005		20260101	N	\$7.97	Measurement of antibody (IgE) to allergic substance, multiallergen screen	Allergen specific ige; qualitative, multiallergen screen (eg, disk, sponge, card)
2026	86008		20260101	N	\$17.93	Measurement of antibody (IgE) to allergic substance, recombinant or purified	Allergen specific ige; quantitative or semiquantitative, recombinant or purified component, each
2026	86015		20260101	N	\$12.05	Measurement of Actin (smooth muscle) antibody	Actin (smooth muscle) antibody (asma), each
2026	86021		20260101	N	\$15.05	Antibody identification test for white blood cell antibodies	Antibody identification; leukocyte antibodies
2026	86022		20260101	N	\$18.37	Antibody identification test, platelet antibodies	Antibody identification; platelet antibodies
2026	86023		20260101	N	\$12.46	Antibody identification test, platelet associated immunoglobulin assay	Antibody identification; platelet associated immunoglobulin assay

2026	86036		20260101	N	\$12.05	Screening test for antineutrophil cytoplasmic antibody	Antineutrophil cytoplasmic antibody (anca); screen, each antibody
2026	86037		20260101	N	\$12.05	Antineutrophil cytoplasmic antibody titer	Antineutrophil cytoplasmic antibody (anca); titer, each antibody
2026	86038		20260101	N	\$12.09	Screening test for autoimmune disorder	Antinuclear antibodies (ana);
2026	86039		20260101	N	\$11.16	Measurement of antibody for assessment of autoimmune disorder, titer	Antinuclear antibodies (ana); titer
2026	86041		20260101	N	\$18.40	Test for acetylcholine receptor binding antibody	Acetylcholine receptor (achr); binding antibody
2026	86042		20260101	N	\$18.40	Test for acetylcholine receptor blocking antibody	Acetylcholine receptor (achr); blocking antibody
2026	86043		20260101	N	\$12.05	Test for acetylcholine receptor modulating antibody	Acetylcholine receptor (achr); modulating antibody

2026	86051		20260101	N	\$11.53	ELISA detection of aquaporin-4 (neuromyelitis optica [NMO]) antibody	Aquaporin-4 (neuromyelitis optica [nmo]) antibody; enzyme-linked immunosorbent immunoassay (elisa)
2026	86052		20260101	N	\$12.05	Cell-based immunofluorescence (CBA) detection of aquaporin-4 (neuromyelitis	Aquaporin-4 (neuromyelitis optica [nmo]) antibody; cell-based immunofluorescence assay (cba), each
2026	86053		20260101	N	\$37.73	Flow cytometry detection of aquaporin-4 (neuromyelitis optica [NMO]) antibody	Aquaporin-4 (neuromyelitis optica [nmo]) antibody; flow cytometry (ie, fluorescence-activated cell sorting [facs]), each
2026	86060		20260101	N	\$7.30	Measurement for Strep antibody (strep throat)	Antistreptolysin O; titer
2026	86063		20260101	N	\$5.77	Screening test for Strep antibody (strep throat)	Antistreptolysin O; screen

2026	86140		20260101	N	\$5.18	Measurement C-reactive protein for detection of infection or inflammation	C-reactive protein;
2026	86141		20260101	N	\$12.95	Measurement C-reactive protein for detection of infection or inflammation, high	C-reactive protein; high sensitivity (hscrp)
2026	86146		20260101	N	\$25.45	Beta 2 glycoprotein 1 antibody (autoantibody) measurement	Beta 2 glycoprotein i antibody, each
2026	86147		20260101	N	\$25.45	Cardiolipin antibody (tissue antibody) measurement	Cardiolipin (phospholipid) antibody, each ig class
2026	86148		20260101	N	\$16.07	Phospholipid antibody (autoimmune antibody) measurement	Anti- phosphatidylser ine (phospholipid) antibody

2026	86152		20260101	N	\$250.78	Cell enumeration using immunologic selection and identification in fluid	Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood);
2026	86155		20260101	N	\$15.99	Measurement of white blood cell function	Chemotaxis assay, specify method
2026	86156		20260101	N	\$8.07	Measurement of cold agglutinin (protein) to screen for infection or disease	Cold agglutinin; screen
2026	86157		20260101	N	\$8.06	Measurement of cold agglutinin (protein) to detect infection or disease	Cold agglutinin; titer
2026	86160		20260101	N	\$12.00	Measurement of complement (immune system proteins), antigen,	Complement; antigen, each component

2026	86161		20260101	N	\$12.00	Measurement of complement function (immune system proteins)	Complement; functional activity, each component
2026	86162		20260101	N	\$20.32	Measurement of complement (immune system proteins), total hemolytic	Complement; total hemolytic (ch50)
2026	86171		20260101	N	\$10.01	Measurement of complement fixation tests (immune system proteins)	Complement fixation tests, each antigen
2026	86200		20260101	N	\$12.95	Measurement of antibody for rheumatoid arthritis assessment	Cyclic citrullinated peptide (ccp), antibody
2026	86215		20260101	N	\$13.25	Measurement of DNA antibody	Deoxyribonucle ase, antibody
2026	86225		20260101	N	\$13.74	Measurement of DNA antibody, native or double stranded	Deoxyribonucle ic acid (dna) antibody; native or double stranded
2026	86226		20260101	N	\$12.11	Measurement of DNA antibody, single stranded	Deoxyribonucle ic acid (dna) antibody; single stranded

2026	86231		20260101	N	\$12.09	Detection of endomysial antibody (EMA)	Endomysial antibody (ema), each immunoglobulin (ig) class
2026	86235		20260101	N	\$17.93	Measurement of antibody for assessment of autoimmune disorder, any method	Extractable nuclear antigen, antibody to, any method (eg, nrnp, ss-a, ss-b, sm, rnp, sc170, j01), each antibody
2026	86255		20260101	N	\$12.05	Screening test for antibody to noninfectious agent	Fluorescent noninfectious agent antibody; screen, each antibody
2026	86256		20260101	N	\$12.05	Measurement of antibody to noninfectious agent	Fluorescent noninfectious agent antibody; titer, each antibody
2026	86258		20260101	N	\$12.05	Detection of gliadin (deamidated) (DGP) antibody	Gliadin (deamidated) (dgp) antibody, each immunoglobulin (ig) class
2026	86277		20260101	N	\$15.74	Measurement of growth hormone antibody	Growth hormone, human (hgh), antibody
2026	86280		20260101	N	\$8.19	Measurement of immune system protein	Hemagglutination inhibition test (hai)

2026	86294		20260101	N	\$25.57	Immunologic analysis for detection of tumor antigen, qualitative or	Immunoassay for tumor antigen, qualitative or semiquantitative (eg, bladder tumor antigen)
2026	86294	QW	20260101	N	\$25.57	Immunologic analysis for detection of tumor antigen, qualitative or	Immunoassay for tumor antigen, qualitative or semiquantitative (eg, bladder tumor antigen)
2026	86300		20260101	N	\$20.81	Immunologic analysis for detection of tumor antigen, quantitative; CA 15-3	Immunoassay for tumor antigen, quantitative; ca 15-3 (27.29)
2026	86301		20260101	N	\$20.81	Immunologic analysis for detection of tumor antigen, quantitative; CA 19-9	Immunoassay for tumor antigen, quantitative; ca 19-9
2026	86304		20260101	N	\$20.81	Immunologic analysis for detection of tumor antigen, quantitative; CA 125	Immunoassay for tumor antigen, quantitative; ca 125
2026	86305		20260101	N	\$20.81	Analysis of female reproductive genetic marker	Human epididymis protein 4 (he4)

2026	86308		20260101	N	\$5.18	Screening test for mononucleosis (mono)	Heterophile antibodies; screening
2026	86308	QW	20260101	N	\$5.18	Screening test for mononucleosis (mono)	Heterophile antibodies; screening
2026	86309		20260101	N	\$6.47	Mononucleosis antibody level, titer	Heterophile antibodies; titer
2026	86310		20260101	N	\$7.37	Mononucleosis antibody level, titers after absorption	Heterophile antibodies; titers after absorption with beef cells and guinea pig kidney
2026	86316		20260101	N	\$20.81	Analysis for detection of tumor marker	Immunoassay for tumor antigen, other antigen, quantitative (eg, ca 50, 72-4, 549), each
2026	86317		20260101	N	\$14.99	Detection of infectious agent antibody, quantitative	Immunoassay for infectious agent antibody, quantitative, not otherwise specified

2026	86318		20260101	N	\$18.09	Test for detection of infectious agent antibody, qualitative or semiquantitative	Immunoassay for infectious agent antibody (ies), qualitative or semiquantitative, single-step method (eg, reagent strip);
2026	86318	QW	20260101	N	\$18.09	Test for detection of infectious agent antibody, qualitative or semiquantitative	Immunoassay for infectious agent antibody (ies), qualitative or semiquantitative, single-step method (eg, reagent strip);
2026	86320		20260101	N	\$29.92	Immunologic analysis technique on serum	Immuno-electrophoresis; serum
2026	86325		20260101	N	\$23.13	Immunologic analysis technique on body fluid	Immuno-electrophoresis; other fluids (eg, urine, cerebrospinal fluid) with concentration

2026	86328		20260101	N	\$45.28	Test for detection of severe acute respiratory syndrome coronavirus 2	Immunoassay for infectious agent antibody (ies), qualitative or semiquantitative, single-step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])
2026	86328	QW	20260101	N	\$45.28	Test for detection of severe acute respiratory syndrome coronavirus 2	Immunoassay for infectious agent antibody (ies), qualitative or semiquantitative, single-step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])

2026	86329		20260101	N	\$14.05	Immunologic analysis technique, unspecified	Immunodiffusion; not elsewhere specified
2026	86331		20260101	N	\$11.98	Immunologic analysis for detection of antigen or antibody	Immunodiffusion; gel diffusion, qualitative (ouchterlony), each antigen or antibody
2026	86332		20260101	N	\$24.37	Immune complex measurement	Immune complex assay
2026	86334		20260101	N	\$22.34	Immunologic analysis technique on serum (immunofixation)	Immunofixation electrophoresis; serum
2026	86335		20260101	N	\$29.35	Immunologic analysis technique on body fluid, other fluids with concentration	Immunofixation electrophoresis; other fluids with concentration (eg, urine, csf)
2026	86336		20260101	N	\$15.59	Inhibin A (reproductive organ hormone) measurement	Inhibin a
2026	86337		20260101	N	\$21.41	Insulin antibody measurement	Insulin antibodies

2026	86340		20260101	N	\$15.08	Intrinsic factor (stomach protein) antibody measurement	Intrinsic factor antibodies
2026	86341		20260101	N	\$23.57	Islet cell (pancreas) antibody measurement	Islet cell antibody
2026	86343		20260101	N	\$12.46	White blood cell histamine (immune system chemical) release test	Leukocyte histamine release test (Ihr)
2026	86344		20260101	N	\$10.39	White blood cell function measurement	Leukocyte phagocytosis
2026	86352		20260101	N	\$135.86	Analysis of cell function and analysis for genetic marker	Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, atp)
2026	86353		20260101	N	\$49.03	White blood cell function measurement, mitogen or antigen induced blastogenesis	Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis

2026	86355		20260101	N	\$37.73	Total cell count for B cells (white blood cells)	B cells, total count
2026	86356		20260101	N	\$26.78	White blood cell antigen measurement	Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen
2026	86357		20260101	N	\$37.73	Total cell count for natural killer cells (white blood cell)	Natural killer (nk) cells, total count
2026	86359		20260101	N	\$37.73	T cells count, total	T cells; total count
2026	86360		20260101	N	\$46.98	T cell count and ratio, including ratio	T cells; absolute cd4 and cd8 count, including ratio
2026	86361		20260101	N	\$26.78	T cell count and ratio	T cells; absolute cd4 count
2026	86362		20260101	N	\$12.05	Cell-based immunofluorescence (CBA) detection of myelin oligodendrocyte	Myelin oligodendrocyte glycoprotein (mog-igg1) antibody; cell-based immunofluorescence assay (cba), each

2026	86363		20260101	N	\$37.73	Flow cytometry detection of myelin oligodendrocyte glycoprotein (MOG-IgG1)	Myelin oligodendrocyte glycoprotein (mog-igg1) antibody; flow cytometry (ie, fluorescence-activated cell sorting [facs]), each
2026	86364		20260101	N	\$11.53	Measurement of tissue transglutaminase	Tissue transglutaminase, each immunoglobulin (ig) class
2026	86366		20260101	N	\$18.40	Test for muscle-specific kinase antibody	Muscle-specific kinase (musk) antibody
2026	86367		20260101	N	\$77.78	Stem cells count, total	Stem cells (ie, cd34), total count
2026	86376		20260101	N	\$14.55	Microsomal antibodies (autoantibody) measurement	Microsomal antibodies (eg, thyroid or liver-kidney), each
2026	86381		20260101	N	\$25.45	Measurement of mitochondrial antibody	Mitochondrial antibody (eg, m2), each
2026	86382		20260101	N	\$16.91	Viral neutralization test to detect viral antibody level	Neutralization test, viral

2026	86384		20260101	N	\$13.61	Nitroblue tetrazolium dye test to measure white blood cell function	Nitroblue tetrazolium dye test (ntd)
2026	86386		20260101	N	\$21.78	Protein test for diagnosis and monitoring of bladder cancer	Nuclear matrix protein 22 (nmp22), qualitative
2026	86386	QW	20260101	N	\$21.78	Protein test for diagnosis and monitoring of bladder cancer	Nuclear matrix protein 22 (nmp22), qualitative
2026	86403		20260101	N	\$11.54	Screening test for presence of antibody	Particle agglutination; screen, each antibody
2026	86406		20260101	N	\$10.64	Antibody level measurement	Particle agglutination; titer, each antibody
2026	86408		20260101	N	\$42.13	Screening test for detection of severe acute respiratory syndrome coronavirus 2	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]); screen

2026	86409		20260101	N	\$79.61	Measurement of neutralizing antibody to severe acute respiratory syndrome	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]); titer
2026	86413		20260101	N	\$51.43	Quantitative measurement of severe acute respiratory syndrome coronavirus 2	Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) antibody, quantitative
2026	86430		20260101	N	\$6.14	Rheumatoid factor analysis	Rheumatoid factor; qualitative
2026	86431		20260101	N	\$5.67	Rheumatoid factor level	Rheumatoid factor; quantitative
2026	86480		20260101	N	\$61.98	Tuberculosis test, gamma interferon	Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon

2026	86481		20260101	N	\$100.00	Tuberculosis test, enumeration of T-cells	Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing t-cells in cell suspension
2026	86581		20260101	N	\$92.03	Test for streptococcus pneumonia antibody	Streptococcus pneumoniae antibody (igg), serotypes, multiplex immunoassay, quantitative
2026	86590		20260101	N	\$12.66	Measurement of antibody to streptokinase (enzyme)	Streptokinase, antibody
2026	86592		20260101	N	\$4.27	Syphilis detection test	Syphilis test, non-treponemal antibody; qualitative (eg, vdrl, rpr, art)
2026	86593		20260101	N	\$4.40	Syphilis test	Syphilis test, non-treponemal antibody; quantitative

2026	86596		20260101	N	\$12.05	Measurement of voltage-gated calcium channel antibody	Voltage-gated calcium channel antibody, each
2026	86602		20260101	N	\$10.18	Analysis for antibody to actinomyces (bacteria)	Antibody; actinomyces
2026	86603		20260101	N	\$12.87	Analysis for antibody to adenovirus (respiratory virus)	Antibody; adenovirus
2026	86606		20260101	N	\$15.05	Analysis for antibody to aspergillus (fungus)	Antibody; aspergillus
2026	86609		20260101	N	\$12.88	Analysis for antibody bacteria	Antibody; bacterium, not elsewhere specified
2026	86611		20260101	N	\$10.18	Analysis for antibody to Bartonella (bacteria)	Antibody; bartonella
2026	86612		20260101	N	\$12.90	Analysis for antibody to blastomyces (fungus)	Antibody; blastomyces
2026	86615		20260101	N	\$13.19	Analysis for antibody bordetella (respiratory bacteria)	Antibody; bordetella

2026	86617		20260101	N	\$15.49	Confirmation test for antibody to Borrelia burgdorferi (Lyme disease bacteria)	Antibody; borrelia burgdorferi (lyme disease) confirmatory test (eg, western blot or immunoblot)
2026	86618		20260101	N	\$17.03	Analysis for antibody Borrelia burgdorferi (Lyme disease bacteria)	Antibody; borrelia burgdorferi (lyme disease)
2026	86618	QW	20260101	N	\$17.03	Analysis for antibody Borrelia burgdorferi (Lyme disease bacteria)	Antibody; borrelia burgdorferi (lyme disease)
2026	86619		20260101	N	\$13.38	Analysis for antibody to Borrelia (relapsing fever bacteria)	Antibody; borrelia (relapsing fever)
2026	86622		20260101	N	\$8.93	Analysis for antibody to Brucella (bacteria)	Antibody; brucella
2026	86625		20260101	N	\$13.12	Analysis for antibody to Campylobacter (intestinal bacteria)	Antibody; campylobacter

2026	86628		20260101	N	\$12.01	Analysis for antibody to Candida (yeast)	Antibody; candida
2026	86631		20260101	N	\$11.82	Analysis for antibody to Chlamydia (bacteria)	Antibody; chlamydia
2026	86632		20260101	N	\$12.68	Analysis for antibody (Igm) to Chlamydia (bacteria)	Antibody; chlamydia, igm
2026	86635		20260101	N	\$11.47	Analysis for antibody to Coccidioides (bacteria)	Antibody; coccidioides
2026	86638		20260101	N	\$12.12	Analysis for antibody to Coxiella burnetii (Q fever bacteria)	Antibody; coxiella burnetii (q fever)
2026	86641		20260101	N	\$14.41	Analysis for antibody to Cryptococcus (yeast)	Antibody; cryptococcus
2026	86644		20260101	N	\$14.39	Analysis for antibody to Cytomegalovirus (CMV)	Antibody; cytomegalovirus (cmv)
2026	86645		20260101	N	\$16.85	Analysis for antibody (IgM) to Cytomegalovirus (CMV)	Antibody; cytomegalovirus (cmv), igm

2026	86648		20260101	N	\$15.21	Analysis for antibody to Diphtheria (bacteria)	Antibody; diphtheria
2026	86651		20260101	N	\$13.19	Analysis for antibody to La crosse (California) virus (encephalitis causing)	Antibody; encephalitis, california (la crosse)
2026	86652		20260101	N	\$13.19	Analysis for antibody to Eastern equine virus (viral encephalitis)	Antibody; encephalitis, eastern equine
2026	86653		20260101	N	\$13.19	Analysis for antibody to St. Louis virus (viral encephalitis)	Antibody; encephalitis, st. louis
2026	86654		20260101	N	\$13.19	Analysis for antibody to Western equine virus (viral encephalitis)	Antibody; encephalitis, western equine
2026	86658		20260101	N	\$13.03	Analysis for antibody to Enterovirus (gastrointestinal virus)	Antibody; enterovirus (eg, coxsackie, echo, polio)

2026	86663		20260101	N	\$13.12	Analysis for antibody to Epstein-Barr virus (mononucleosis virus), early antigen	Antibody; epstein-barr (eb) virus, early antigen (ea)
2026	86664		20260101	N	\$15.29	Analysis for antibody to Epstein-Barr virus (mononucleosis virus), nuclear	Antibody; epstein-barr (eb) virus, nuclear antigen (ebna)
2026	86665		20260101	N	\$18.14	Analysis for antibody to Epstein-Barr virus (mononucleosis virus), viral capsid	Antibody; epstein-barr (eb) virus, viral capsid (vca)
2026	86666		20260101	N	\$10.18	Analysis for antibody to Ehrlichia (bacteria transmitted by ticks)	Antibody; ehrlichia
2026	86668		20260101	N	\$14.16	Analysis for antibody to Francisella tularensis (bacteria transmitted by	Antibody; francisella tularensis
2026	86671		20260101	N	\$12.25	Analysis for antibody to fungus	Antibody; fungus, not elsewhere specified

2026	86674		20260101	N	\$14.72	Analysis for antibody to Giardia lamblia (intestinal parasite)	Antibody; giardia lamblia
2026	86677		20260101	N	\$16.85	Analysis for antibody to Helicobacter pylori (gastrointestinal bacteria)	Antibody; helicobacter pylori
2026	86682		20260101	N	\$13.01	Analysis for antibody to helminth (intestinal worm)	Antibody; helminth, not elsewhere specified
2026	86684		20260101	N	\$15.84	Analysis for antibody to Haemophilus influenza (respiratory bacteria)	Antibody; haemophilus influenza
2026	86687		20260101	N	\$9.09	Analysis for antibody to Human T-cell lymphotropic virus, type 1 (HTLV-1)	Antibody; htlv-i
2026	86688		20260101	N	\$14.00	Analysis for antibody to Human T-cell lymphotropic virus, type 2 (HTLV-2)	Antibody; htlv-ii

2026	86689		20260101	N	\$19.35	Confirmation test for antibody to Human T-cell lymphotropic virus (HTLV) or HIV	Antibody; htlv or hiv antibody, confirmatory test (eg, western blot)
2026	86692		20260101	N	\$17.16	Analysis for antibody to Hepatitis D virus	Antibody; hepatitis, delta agent
2026	86694		20260101	N	\$14.39	Analysis for antibody to Herpes simplex virus	Antibody; herpes simplex, non-specific type test
2026	86695		20260101	N	\$13.19	Analysis for antibody to Herpes simplex virus, type 1	Antibody; herpes simplex, type 1
2026	86696		20260101	N	\$19.35	Analysis for antibody to Herpes simplex virus, type 2	Antibody; herpes simplex, type 2
2026	86698		20260101	N	\$13.79	Analysis for antibody to histoplasma (fungus)	Antibody; histoplasma
2026	86701		20260101	N	\$8.89	Analysis for antibody to HIV -1 virus	Antibody; hiv-1
2026	86701	QW	20260101	N	\$8.89	Analysis for antibody to HIV -1 virus	Antibody; hiv-1

2026	86702		20260101	N	\$13.52	Analysis for antibody to HIV-2 virus	Antibody; hiv-2
2026	86703		20260101	N	\$13.71	Analysis for antibody to HIV-1 and HIV-2 virus	Antibody; hiv-1 and hiv-2, single result
2026	86704		20260101	N	\$12.05	Hepatitis B core antibody measurement	Hepatitis b core antibody (hbcab); total
2026	86705		20260101	N	\$11.77	Hepatitis B core antibody (IgM) measurement	Hepatitis b core antibody (hbcab); igm antibody
2026	86706		20260101	N	\$10.74	Hepatitis B surface antibody measurement	Hepatitis b surface antibody (hbsab)
2026	86707		20260101	N	\$11.57	Hepatitis Be antibody measurement	Hepatitis be antibody (hbeab)
2026	86708		20260101	N	\$12.39	Measurement of Hepatitis A antibody	Hepatitis a antibody (haab)
2026	86709		20260101	N	\$11.26	Measurement of Hepatitis A antibody (IgM)	Hepatitis a antibody (haab), igm antibody
2026	86710		20260101	N	\$13.55	Analysis for antibody to Influenza virus	Antibody; influenza virus

2026	86711		20260101	N	\$16.89	Analysis for antibody to john cunningham virus	Antibody; jc (john cunningham) virus
2026	86713		20260101	N	\$15.30	Analysis for antibody to Legionella (waterborne bacteria)	Antibody; legionella
2026	86717		20260101	N	\$12.25	Analysis for antibody to Leishmania (parasite)	Antibody; leishmania
2026	86720		20260101	N	\$16.20	Analysis for antibody to Leptospira	Antibody; leptospira
2026	86723		20260101	N	\$13.19	Analysis for antibody to Listeria monocytogenes (bacteria)	Antibody; listeria monocytogenes
2026	86727		20260101	N	\$12.87	Analysis for antibody to lymphocytic choriomeningitis virus (viral meningitis)	Antibody; lymphocytic choriomeningitis
2026	86732		20260101	N	\$15.00	Analysis for antibody to mucormycosis (fungus)	Antibody; mucormycosis
2026	86735		20260101	N	\$13.05	Analysis for antibody to mumps virus	Antibody; mumps

2026	86738		20260101	N	\$13.24	Analysis for antibody to Mycoplasma (bacteria)	Antibody; mycoplasma
2026	86741		20260101	N	\$13.19	Analysis for antibody to Neisseria meningitidis (bacterial meningitis)	Antibody; neisseria meningitidis
2026	86744		20260101	N	\$15.99	Analysis for antibody to Nocardia (bacteria)	Antibody; nocardia
2026	86747		20260101	N	\$15.03	Analysis for antibody to parvovirus	Antibody; parvovirus
2026	86750		20260101	N	\$13.19	Analysis for antibody to Plasmodium (malaria parasite)	Antibody; plasmodium (malaria)
2026	86753		20260101	N	\$12.39	Analysis for antibody to protozoa (parasite)	Antibody; protozoa, not elsewhere specified
2026	86756		20260101	N	\$15.89	Analysis for antibody to respiratory syncytial virus (RSV)	Antibody; respiratory syncytial virus
2026	86757		20260101	N	\$19.35	Analysis for antibody to Rickettsia (bacteria)	Antibody; rickettsia

2026	86759		20260101	N	\$18.23	Analysis for antibody to Rotavirus (intestinal virus)	Antibody; rotavirus
2026	86762		20260101	N	\$14.39	Analysis for antibody to Rubella (German measles virus)	Antibody; rubella
2026	86765		20260101	N	\$12.88	Analysis for antibody to Rubeola (measles virus)	Antibody; rubeola
2026	86768		20260101	N	\$13.19	Analysis for antibody to Salmonella (intestinal bacteria)	Antibody; salmonella
2026	86769		20260101	N	\$42.13	Measure of severe acute respiratory syndrome coronavirus 2 (Covid-19) antibody	Antibody; severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])
2026	86769	QW	20260101	N	\$42.13	Measure of severe acute respiratory syndrome coronavirus 2 (Covid-19) antibody	Antibody; severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])

2026	86771		20260101	N	\$24.48	Analysis for antibody to Shigella (intestinal bacteria)	Antibody; shigella
2026	86774		20260101	N	\$14.80	Analysis for antibody to tetanus bacteria (Clostridium tetanus)	Antibody; tetanus
2026	86777		20260101	N	\$14.39	Analysis for antibody to Toxoplasma (parasite)	Antibody; toxoplasma
2026	86778		20260101	N	\$14.41	Analysis for antibody (IgM) to Toxoplasma (parasite)	Antibody; toxoplasma, igm
2026	86780		20260101	N	\$13.24	Analysis for antibody, Treponema pallidum	Antibody; treponema pallidum
2026	86780	QW	20260101	N	\$13.24	Analysis for antibody, Treponema pallidum	Antibody; treponema pallidum
2026	86784		20260101	N	\$12.56	Analysis for antibody to Trichinella (worm parasite)	Antibody; trichinella
2026	86787		20260101	N	\$12.88	Analysis for antibody to varicella-zoster virus (chicken pox)	Antibody; varicella-zoster

2026	86788		20260101	N	\$16.85	Analysis for antibody (IgM) to West Nile virus	Antibody; west nile virus, igm
2026	86789		20260101	N	\$14.39	Analysis for antibody to West Nile virus	Antibody; west nile virus
2026	86790		20260101	N	\$12.88	Analysis for antibody to virus	Antibody; virus, not elsewhere specified
2026	86793		20260101	N	\$13.19	Analysis for antibody to Yersinia (bacteria)	Antibody; yersinia
2026	86794		20260101	N	\$16.85	Analysis for antibody to Zika virus	Antibody; zika virus, igm
2026	86800		20260101	N	\$15.91	Thyroglobulin (thyroid protein) antibody measurement	Thyroglobulin antibody
2026	86803		20260101	N	\$14.27	Hepatitis C antibody measurement	Hepatitis c antibody;
2026	86803	QW	20260101	N	\$14.27	Hepatitis C antibody measurement	Hepatitis c antibody;
2026	86804		20260101	N	\$15.49	Confirmation test for Hepatitis C antibody	Hepatitis c antibody; confirmatory test (eg, immunoblot)

2026	86805		20260101	N	\$189.51	Immunologic analysis for autoimmune disease, with titration	Lymphocytotoxicity assay, visual crossmatch; with titration
2026	86806		20260101	N	\$47.59	Immunologic analysis for autoimmune disease, without titration	Lymphocytotoxicity assay, visual crossmatch; without titration
2026	86807		20260101	N	\$78.65	Transplant antibody measurement, standard method	Serum screening for cytotoxic percent reactive antibody (pra); standard method
2026	86808		20260101	N	\$29.68	Transplant antibody measurement, quick method	Serum screening for cytotoxic percent reactive antibody (pra); quick method
2026	86812		20260101	N	\$25.81	Immunologic analysis for autoimmune disease, A, B, or C, single antigen	Hla typing; a, b, or c (eg, a10, b7, b27), single antigen

2026	86813		20260101	N	\$58.00	Immunologic analysis for autoimmune disease, A, B, or C, multiple antigens	Hla typing; a, b, or c, multiple antigens
2026	86816		20260101	N	\$30.17	Immunologic analysis for autoimmune disease, DR/DQ, single antigen	Hla typing; dr/dq, single antigen
2026	86817		20260101	N	\$106.14	Immunologic analysis for autoimmune disease, DR/DQ, multiple antigens	Hla typing; dr/dq, multiple antigens
2026	86821		20260101	N	\$36.56	Immunologic analysis for autoimmune disease, lymphocyte culture, mixed	Hla typing; lymphocyte culture, mixed (mlc)
2026	86825		20260101	N	\$109.49	Immunologic analysis for organ transplant, first serum sample or dilution	Human leukocyte antigen (hla) crossmatch, non-cytotoxic (eg, using flow cytometry); first serum sample or dilution

2026	86826		20260101	N	\$36.53	Immunologic analysis for organ transplant, each additional serum sample or	Human leukocyte antigen (hla) crossmatch, non-cytotoxic (eg, using flow cytometry); each additional serum sample or sample dilution (list separately in addition to primary procedure)
2026	86828		20260101	N	\$64.19	Assessment of antibodies to Class I and Class II human leukocyte antigens (HLA)	Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to hla class i and class ii hla antigens

2026	86829		20260101	N	\$64.19	Assessment of antibodies to Class I or Class II human leukocyte antigens (HLA)	Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to hla class i or class ii hla antigens
2026	86830		20260101	N	\$95.52	Assessment of antibody to human leukocyte antigens (HLA) with antibody	Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); antibody identification by qualitative panel using complete hla phenotypes, hla class i

2026	86831		20260101	N	\$81.88	Assessment of antibody to human leukocyte antigens (HLA) with antibody	Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); antibody identification by qualitative panel using complete hla phenotypes, hla class ii
------	-------	--	----------	---	---------	--	---

2026	86832		20260101	N	\$323.75	Assessment of antibody to human leukocyte antigens (HLA) with high definition	Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); high definition qualitative panel for identification of antibody specificities (eg, individual antigen per bead methodology), hla class i
------	-------	--	----------	---	----------	---	--

2026	86833		20260101	N	\$325.80	Assessment of antibody to human leukocyte antigens (HLA) with high definition	Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); high definition qualitative panel for identification of antibody specificities (eg, individual antigen per bead methodology), hla class ii
2026	86834		20260101	N	\$357.56	Assessment of antibody to human leukocyte antigens (HLA), HLA class I	Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); semi-quantitative panel (eg, titer), hla class i

2026	86835		20260101	N	\$322.96	Assessment of antibody to human leukocyte antigens (HLA) with solid phase	Antibody to human leukocyte antigens (hla), solid phase assays (eg, microspheres or beads, elisa, flow cytometry); semi-quantitative panel (eg, titer), hla class ii
2026	86850		20260101	N	\$9.77	Screening test for red blood cell antibodies	Antibody screen, rbc, each serum technique
2026	86880		20260101	N	\$5.39	Red blood cell antibody detection test, direct	Antihuman globulin test (coombs test); direct, each antiserum
2026	86885		20260101	N	\$5.72	Red blood cell antibody detection test, indirect	Antihuman globulin test (coombs test); indirect, qualitative, each reagent red cell
2026	86886		20260101	N	\$5.18	Red blood cell antibody level	Antihuman globulin test (coombs test); indirect, each antibody titer

2026	86900		20260101	N	\$2.99	Blood group typing (ABO)	Blood typing, serologic; abo
2026	86901		20260101	N	\$2.99	Blood typing for Rh (D) antigen	Blood typing, serologic; rh (d)
2026	86902		20260101	N	\$6.35	Screening test for compatible blood unit, using reagent serum	Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test
2026	86904		20260101	N	\$16.34	Screening test for compatible blood unit, using patient serum	Blood typing, serologic; antigen screening for compatible unit using patient serum, per unit screened
2026	86905		20260101	N	\$3.83	Blood typing for red blood cell antigens	Blood typing, serologic; rbc antigens, other than abo or rh (d), each
2026	86906		20260101	N	\$7.75	Blood typing Rh phenotyping	Blood typing, serologic; rh phenotyping, complete
2026	86940		20260101	N	\$8.77	Red blood cell antibody screening test	Hemolysins and agglutinins; auto, screen, each
2026	86941		20260101	N	\$12.11	Red blood cell antibody measurement	Hemolysins and agglutinins; incubated

2026	87003		20260101	N	\$16.84	Animal inoculation, small animal with observation and dissection	Animal inoculation, small animal, with observation and dissection
2026	87015		20260101	N	\$6.68	Concentration of specimen for infectious agents	Concentration (any type), for infectious agents
2026	87040		20260101	N	\$10.32	Bacterial blood culture	Culture, bacterial; blood, aerobic, with isolation and presumptive identification of isolates (includes anaerobic culture, if appropriate)
2026	87045		20260101	N	\$9.44	Stool culture	Culture, bacterial; stool, aerobic, with isolation and preliminary examination (eg, kia, lia), salmonella and shigella species

2026	87046		20260101	N	\$9.44	Stool culture, additional pathogens	Culture, bacterial; stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate
2026	87070		20260101	N	\$8.62	Bacterial culture, any other source except urine, blood or stool, aerobic	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates
2026	87071		20260101	N	\$9.89	Bacterial culture and colony count	Culture, bacterial; quantitative, aerobic with isolation and presumptive identification of isolates, any source except urine, blood or stool

2026	87073		20260101	N	\$9.66	Bacterial culture and colony count for anaerobic bacteria	Culture, bacterial; quantitative, anaerobic with isolation and presumptive identification of isolates, any source except urine, blood or stool
2026	87075		20260101	N	\$9.47	Bacterial culture, any source, except blood, anaerobic	Culture, bacterial; any source, except blood, anaerobic with isolation and presumptive identification of isolates
2026	87076		20260101	N	\$8.08	Bacterial culture for anaerobic isolates	Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate

2026	87077		20260101	N	\$8.08	Bacterial culture for aerobic isolates	Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate
2026	87077	QW	20260101	N	\$8.08	Bacterial culture for aerobic isolates	Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate
2026	87081		20260101	N	\$6.63	Screening test for pathogenic organisms	Culture, presumptive, pathogenic organisms, screening only;
2026	87084		20260101	N	\$27.07	Screening test for pathogenic organisms with colony count	Culture, presumptive, pathogenic organisms, screening only; with colony estimation from density chart
2026	87086		20260101	N	\$8.07	Bacterial colony count, urine	Culture, bacterial; quantitative colony count, urine

2026	87088		20260101	N	\$8.09	Bacterial urine culture	Culture, bacterial; with isolation and presumptive identification of each isolate, urine
2026	87101		20260101	N	\$7.71	Fungal culture (mold or yeast) of skin, hair, or nail	Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; skin, hair, or nail
2026	87102		20260101	N	\$8.41	Fungal culture (mold or yeast)	Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; other source (except blood)
2026	87103		20260101	N	\$20.46	Fungal blood culture (mold or yeast)	Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; blood
2026	87106		20260101	N	\$10.32	Fungal culture, yeast	Culture, fungi, definitive identification, each organism; yeast

2026	87107		20260101	N	\$10.32	Culture for identification of yeast	Culture, fungi, definitive identification, each organism; mold
2026	87109		20260101	N	\$15.39	Mycoplasma culture	Culture, mycoplasma, any source
2026	87110		20260101	N	\$19.60	Culture for chlamydia	Culture, chlamydia, any source
2026	87116		20260101	N	\$10.80	Culture for acid-fast bacilli	Culture, tubercle or other acid-fast bacilli (eg, tb, afb, mycobacteria) any source, with isolation and presumptive identification of isolates
2026	87118		20260101	N	\$14.61	Identification of mycobacteria (TB or TB like organism)	Culture, mycobacterial, definitive identification, each isolate
2026	87140		20260101	N	\$5.57	Identification of organisms by immunologic analysis, immunofluorescent method	Culture, typing; immunofluorescent method, each antiserum

2026	87143		20260101	N	\$12.52	Identification of organism using chromatography	Culture, typing; gas liquid chromatography (glc) or high pressure liquid chromatography (hplc) method
2026	87147		20260101	N	\$5.18	Identification of organisms by immunologic analysis, other than	Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum
2026	87149		20260101	N	\$20.05	Identification of organisms by genetic analysis, direct probe technique	Culture, typing; identification by nucleic acid (dna or rna) probe, direct probe technique, per culture or isolate, each organism probed

2026	87150		20260101	N	\$35.09	Identification of organisms by genetic analysis, amplified probe technique	Culture, typing; identification by nucleic acid (dna or rna) probe, amplified probe technique, per culture or isolate, each organism probed
2026	87152		20260101	N	\$7.74	Identification of organism by pulse field gel typing	Culture, typing; identification by pulse field gel typing
2026	87153		20260101	N	\$115.36	Identification of organisms by nucleic acid sequencing method	Culture, typing; identification by nucleic acid sequencing method, each isolate (eg, sequencing of the 16s rrna gene)

2026	87154		20260101	N	\$218.06	Amplified nucleic acid probe typing of disease agent in blood culture specimen	Culture, typing; identification of blood pathogen and resistance typing, when performed, by nucleic acid (dna or rna) probe, multiplexed amplified probe technique including multiplex reverse transcription, when performed, per culture or isolate, 6 or more targets
2026	87158		20260101	N	\$7.74	Microbial identification	Culture, typing; other methods
2026	87164		20260101	N	\$10.74	Dark field microscopic examination for organism, includes specimen collection	Dark field examination, any source (eg, penile, vaginal, oral, skin); includes specimen collection

2026	87166		20260101	N	\$11.30	Dark field microscopic examination for organism, without collection	Dark field examination, any source (eg, penile, vaginal, oral, skin); without collection
2026	87168		20260101	N	\$4.27	Macroscopic examination (visual inspection) of insect	Macroscopic examination; arthropod
2026	87169		20260101	N	\$4.31	Macroscopic examination (visual inspection) of parasite	Macroscopic examination; parasite
2026	87172		20260101	N	\$4.27	Pinworm test	Pinworm exam (eg, cellophane tape prep)
2026	87176		20260101	N	\$5.88	Tissue preparation for culture	Homogenization, tissue, for culture
2026	87177		20260101	N	\$8.90	Smear for parasites	Ova and parasites, direct smears, concentration and identification

2026	87181		20260101	N	\$4.75	Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), agar	Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)
2026	87182		20260101	L	\$ -	Susceptibility studies by multiplex immunoassay to detect antibiotic enzyme	Susceptibility studies, antimicrobial agent; carbapenemase enzyme detection (eg, klebsiella pneumoniae carbapenemase [kpc], new delhi metallo-beta-lactamase [ndm], verona integron-encoded metallo-beta-lactamase [vim]), multiplex immunoassay, qualitative, per isolate

2026	87183		20260101	N	\$35.09	Susceptibility studies by amplified probe technique to detect antibiotic	Susceptibility studies, antimicrobial agent; carbapenem resistance genes (eg, bla _{kpc} , bla _{ndm} , bla _{vim} , bla _{oxa-48} , bla _{imp}), amplified probe technique, per isolate
2026	87184		20260101	N	\$7.48	Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral)	Susceptibility studies, antimicrobial agent; disk method, per plate (12 or fewer agents)
2026	87185		20260101	N	\$4.75	Detection of antimicrobial drug (antibiotic, antifungal, antiviral)	Susceptibility studies, antimicrobial agent; enzyme detection (eg, beta lactamase), per enzyme

2026	87186		20260101	N	\$8.65	Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral),	Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [mic] or breakpoint), each multi-antimicrobial, per plate
2026	87187		20260101	N	\$40.17	Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral),	Susceptibility studies, antimicrobial agent; microdilution or agar dilution, minimum lethal concentration (mlc), each plate (list separately in addition to code for primary procedure)
2026	87188		20260101	N	\$6.64	Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral),	Susceptibility studies, antimicrobial agent; macrobroth dilution method, each agent

2026	87190		20260101	N	\$7.31	Antimicrobial study, mycobacteria (TB organism family)	Susceptibility studies, antimicrobial agent; mycobacteria, proportion method, each agent
2026	87197		20260101	N	\$15.02	Evaluation of antibiotic therapy	Serum bactericidal titer (schlichter test)
2026	87205		20260101	N	\$4.27	Special Gram or Giemsa stain for microorganism	Smear, primary source with interpretation; gram or giemsa stain for bacteria, fungi, or cell types
2026	87206		20260101	N	\$5.39	Special fluorescent and/or acid fast stain for microorganism	Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types

2026	87207		20260101	N	\$5.99	Special stain for inclusion bodies or parasites	Smear, primary source with interpretation; special stain for inclusion bodies or parasites (eg, malaria, coccidia, microsporidia, trypanosomes, herpes viruses)
2026	87209		20260101	N	\$17.98	Special stain for parasites	Smear, primary source with interpretation; complex special stain (eg, trichrome, iron hemotoxylin) for ova and parasites
2026	87210		20260101	N	\$5.82	Smear for infectious agents	Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, india ink, koh preps)
2026	87210	QW	20260101	N	\$5.82	Smear for infectious agents	Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, india ink, koh preps)

2026	87220		20260101	N	\$4.27	Tissue fungi or parasites	Tissue examination by koh slide of samples from skin, hair, or nails for fungi or ectoparasite ova or mites (eg, scabies)
2026	87230		20260101	N	\$19.74	Microbial toxin or antitoxin assay	Toxin or antitoxin assay, tissue culture (eg, clostridium difficile toxin)
2026	87250		20260101	N	\$19.56	Inoculation of embryonated eggs, or small animal for virus isolation	Virus isolation; inoculation of embryonated eggs, or small animal, includes observation and dissection
2026	87252		20260101	N	\$26.07	Tissue culture inoculation for virus isolation	Virus isolation; tissue culture inoculation, observation, and presumptive identification by cytopathic effect

2026	87253		20260101	N	\$20.20	Tissue culture for virus isolation	Virus isolation; tissue culture, additional studies or definitive identification (eg, hemabsorption, neutralization, immunofluorescence stain), each isolate
2026	87254		20260101	N	\$19.56	Virus isolation, centrifuge enhanced	Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus
2026	87255		20260101	N	\$33.86	Virus isolation	Virus isolation; including identification by non-immunologic method, other than by cytopathic effect (eg, virus specific enzymatic activity)

2026	87260		20260101	N	\$14.43	Detection test for adenovirus (virus)	Infectious agent antigen detection by immunofluorescent technique; adenovirus
2026	87265		20260101	N	\$11.98	Detection test for bordetella pertussis or parapertussis (respiratory bacteria)	Infectious agent antigen detection by immunofluorescent technique; bordetella pertussis/parapertussis
2026	87267		20260101	N	\$13.42	Detection test for enterovirus (intestinal virus), direct fluorescent antibody	Infectious agent antigen detection by immunofluorescent technique; enterovirus, direct fluorescent antibody (dfa)
2026	87269		20260101	N	\$13.61	Detection test by immunofluorescent technique for giardia (intestinal parasite)	Infectious agent antigen detection by immunofluorescent technique; giardia
2026	87270		20260101	N	\$11.98	Detection test by immunofluorescent technique for chlamydia	Infectious agent antigen detection by immunofluorescent technique; chlamydia trachomatis

2026	87271		20260101	N	\$13.42	Detection test by immunofluorescent technique for cytomegalovirus (CMV)	Infectious agent antigen detection by immunofluorescent technique; cytomegalovirus, direct fluorescent antibody (dfa)
2026	87272		20260101	N	\$11.98	Detection test by immunofluorescent technique for cryptosporidium (parasite)	Infectious agent antigen detection by immunofluorescent technique; cryptosporidium
2026	87273		20260101	N	\$11.98	Detection test by immunofluorescent technique for herpes simplex virus type 2	Infectious agent antigen detection by immunofluorescent technique; herpes simplex virus type 2
2026	87274		20260101	N	\$11.98	Detection test by immunofluorescent technique for herpes simplex virus type 1	Infectious agent antigen detection by immunofluorescent technique; herpes simplex virus type 1
2026	87275		20260101	N	\$12.25	Detection test by immunofluorescent technique for influenza B virus	Infectious agent antigen detection by immunofluorescent technique; influenza b virus

2026	87276		20260101	N	\$16.07	Detection test by immunofluorescent technique for influenza A virus	Infectious agent antigen detection by immunofluorescent technique; influenza a virus
2026	87278		20260101	N	\$15.60	Detection test by immunofluorescent technique for legionella pneumophila (water	Infectious agent antigen detection by immunofluorescent technique; legionella pneumophila
2026	87279		20260101	N	\$16.43	Detection test by immunofluorescent technique for parainfluenza virus	Infectious agent antigen detection by immunofluorescent technique; parainfluenza virus, each type
2026	87280		20260101	N	\$13.42	Detection test by immunofluorescent technique for respiratory syncytial virus	Infectious agent antigen detection by immunofluorescent technique; respiratory syncytial virus
2026	87281		20260101	N	\$11.98	Detection test by immunofluorescent technique for pneumocystis carinii	Infectious agent antigen detection by immunofluorescent technique; pneumocystis carinii

2026	87283		20260101	N	\$60.80	Detection test by immunofluorescent technique for rubeola (measles virus)	Infectious agent antigen detection by immunofluorescent technique; rubeola
2026	87285		20260101	N	\$12.18	Detection test by immunofluorescent technique for treponema pallidum (syphilis)	Infectious agent antigen detection by immunofluorescent technique; treponema pallidum
2026	87290		20260101	N	\$13.42	Detection test by immunofluorescent technique for varicella (chicken pox)	Infectious agent antigen detection by immunofluorescent technique; varicella zoster virus
2026	87299		20260101	N	\$16.10	Detection test by immunofluorescent technique for organism	Infectious agent antigen detection by immunofluorescent technique; not otherwise specified, each organism

2026	87300		20260101	N	\$11.98	Detection test by immunofluorescent technique for multiple organisms	Infectious agent antigen detection by immunofluorescent technique, polyvalent for multiple organisms, each polyvalent antiserum
2026	87301		20260101	N	\$11.98	Detection test by immunoassay technique for adenovirus enteric types 40/41	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; adenovirus enteric types 40/41

2026	87305		20260101	N	\$11.98	Detection test by immunoassay technique for aspergillus (fungus)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; aspergillus
------	-------	--	----------	---	---------	--	---

2026	87320		20260101	N	\$15.00	Detection test by immunoassay technique for Chlamydia trachomatis	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; chlamydia trachomatis
------	-------	--	----------	---	---------	---	---

2026	87324		20260101	N	\$11.98	Detection test by immunoassay technique for clostridium difficile toxins (stool	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; clostridium difficile toxin(s)
------	-------	--	----------	---	---------	---	--

2026	87327		20260101	N	\$13.42	Detection test by immunoassay technique, multistep method, for Cryptococcus	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; cryptococcus neoformans
------	-------	--	----------	---	---------	---	---

2026	87328		20260101	N	\$13.82	Detection test by immunoassay technique for cryptosporidium (parasite)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; cryptosporidium
------	-------	--	----------	---	---------	--	---

2026	87329		20260101	N	\$11.98	Detection test by immunoassay technique for giardia (intestinal parasite)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; giardia
------	-------	--	----------	---	---------	---	---

2026	87332		20260101	N	\$11.98	Detection test by immunoassay technique for cytomegalovirus	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; cytomegalovirus
------	-------	--	----------	---	---------	---	---

2026	87335		20260101	N	\$12.66	Detection test by immunoassay technique for Escherichia coli 0157 (E. coli)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; escherichia coli 0157
------	-------	--	----------	---	---------	---	---

2026	87336		20260101	N	\$16.00	Detection test by immunoassay technique for entamoeba histolytica dispar group	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; entamoeba histolytica dispar group
------	-------	--	----------	---	---------	--	--

2026	87337		20260101	N	\$11.98	Detection test by immunoassay technique for entamoeba histolytica group	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; entamoeba histolytica group
------	-------	--	----------	---	---------	---	---

2026	87338		20260101	N	\$14.38	Detection test by immunoassay technique for Helicobacter pylori (GI tract	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; helicobacter pylori, stool
------	-------	--	----------	---	---------	---	--

2026	87338	QW	20260101	N	\$14.38	Detection test by immunoassay technique for Helicobacter pylori (GI tract	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; helicobacter pylori, stool
------	-------	----	----------	---	---------	---	--

2026	87339		20260101	N	\$16.00	Detection test by immunoassay technique for helicobacter pylori (GI tract	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; helicobacter pylori
------	-------	--	----------	---	---------	---	---

2026	87340		20260101	N	\$10.33	Detection test by immunoassay technique for Hepatitis B surface antigen	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hepatitis b surface antigen (hbsag)
------	-------	--	----------	---	---------	---	---

2026	87341		20260101	N	\$10.33	Detection test by immunoassay technique for Hepatitis B surface antigen	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hepatitis b surface antigen (hbsag) neutralization
------	-------	--	----------	---	---------	---	--

2026	87350		20260101	N	\$11.53	Detection test by immunoassay technique for Hepatitis Be surface antigen	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hepatitis be antigen (hbeag)
------	-------	--	----------	---	---------	--	--

2026	87380		20260101	N	\$18.36	Detection test by immunoassay technique for Hepatitis D	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hepatitis, delta agent
------	-------	--	----------	---	---------	---	--

2026	87385		20260101	N	\$13.25	Detection test by immunoassay technique for histoplasma capsulatum (parasite)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; histoplasma capsulatum
------	-------	--	----------	---	---------	---	--

2026	87389		20260101	N	\$24.08	Detection test by immunoassay technique for HIV-1 antigen and HIV-1 and HIV-2	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hiv-1 antigen(s), with hiv-1 and hiv-2 antibodies, single result
------	-------	--	----------	---	---------	---	--

2026	87389	QW	20260101	N	\$24.08	Detection test by immunoassay technique for HIV-1 antigen and HIV-1 and HIV-2	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hiv-1 antigen (s), with hiv-1 and hiv-2 antibodies, single result
------	-------	----	----------	---	---------	---	---

2026	87390		20260101	N	\$24.06	Detection test by immunoassay technique for HIV-1 antigen	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hiv-1
------	-------	--	----------	---	---------	---	---

2026	87391		20260101	N	\$21.90	Detection test by immunoassay technique for HIV-2 antigen	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hiv-2
------	-------	--	----------	---	---------	---	---

2026	87400		20260101	N	\$14.13	Detection test by immunoassay technique for influenza virus	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; influenza, a or b, each
------	-------	--	----------	---	---------	---	---

2026	87400	QW	20260101	N	\$14.13	Detection test by immunoassay technique for influenza virus	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; influenza, a or b, each
------	-------	----	----------	---	---------	---	---

2026	87420		20260101	N	\$13.91	Detection test by immunoassay technique for respiratory syncytial virus (RSV)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; respiratory syncytial virus
------	-------	--	----------	---	---------	---	---

2026	87420	QW	20260101	N	\$13.91	Detection test by immunoassay technique for respiratory syncytial virus (RSV)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; respiratory syncytial virus
------	-------	----	----------	---	---------	---	---

2026	87425		20260101	N	\$11.98	Detection test by immunoassay technique for Rotavirus	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; rotavirus
------	-------	--	----------	---	---------	---	---

2026	87426		20260101	N	\$35.33	Detection test by immunoassay technique for severe acute respiratory syndrome	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, sars-cov, sars-cov-2 [covid-19])
------	-------	--	----------	---	---------	---	---

2026	87426	QW	20260101	N	\$35.33	Detection test by immunoassay technique for severe acute respiratory syndrome	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, sars-cov, sars-cov-2 [covid-19])
------	-------	----	----------	---	---------	---	---

2026	87427		20260101	N	\$11.98	Detection test by immunoassay technique for Shiga-like toxin (bacterial toxin)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; shiga-like toxin
------	-------	--	----------	---	---------	--	--

2026	87428		20260101	N	\$70.29	Detection test by immunoassay technique for severe acute respiratory syndrome	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, sars-cov, sars-cov-2 [covid-19]) and influenza virus types a and b
------	-------	--	----------	---	---------	---	---

2026	87428	QW	20260101	N	\$70.29	Detection test by immunoassay technique for severe acute respiratory syndrome	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, sars-cov, sars-cov-2 [covid-19]) and influenza virus types a and b
------	-------	----	----------	---	---------	---	---

2026	87430		20260101	N	\$16.81	Detection test by immunoassay technique for Streptococcus, group A (strep)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; streptococcus, group a
------	-------	--	----------	---	---------	--	--

2026	87430	QW	20260101	N	\$16.81	Detection test by immunoassay technique for Streptococcus, group A (strep)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; streptococcus, group a
------	-------	----	----------	---	---------	--	--

2026	87449		20260101	N	\$11.98	Detection test by immunoassay technique for other organism	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; not otherwise specified, each organism
------	-------	--	----------	---	---------	--	--

2026	87449	QW	20260101	N	\$11.98	Detection test by immunoassay technique for other organism	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; not otherwise specified, each organism
------	-------	----	----------	---	---------	--	--

2026	87451		20260101	N	\$10.51	Detection test by immunoassay technique for multiple organisms, each polyvalent	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; polyvalent for multiple organisms, each polyvalent antiserum
------	-------	--	----------	---	---------	---	--

2026	87467		20260101	N	\$25.32	Detection of Hepatitis B surface antigen (HBsAg)	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]), qualitative or semiquantitative; hepatitis b surface antigen (hbsag), quantitative
2026	87468		20260101	N	\$35.09	Detection of Anaplasma phagocytophilum by amplified nucleic acid probe technique	Infectious agent detection by nucleic acid (dna or rna); anaplasma phagocytophilum, amplified probe technique

2026	87469		20260101	N	\$35.09	Detection of Babesia microtim by amplified nucleic acid probe technique	Infectious agent detection by nucleic acid (dna or rna); babesia microti, amplified probe technique
2026	87471		20260101	N	\$35.09	Detection by nucleic acid Bartonella henselae and Bartonella quintana	Infectious agent detection by nucleic acid (dna or rna); bartonella henselae and bartonella quintana, amplified probe technique
2026	87472		20260101	N	\$42.84	Detection by nucleic acid Bartonella henselae and Bartonella quintana	Infectious agent detection by nucleic acid (dna or rna); bartonella henselae and bartonella quintana, quantification
2026	87475		20260101	N	\$20.05	Detection by nucleic acid for borrelia burgdorferi (bacteria), direct probe	Infectious agent detection by nucleic acid (dna or rna); borrelia burgdorferi, direct probe technique

2026	87476		20260101	N	\$35.09	Detection by nucleic acid for borrelia burgdorferi (bacteria), amplified probe	Infectious agent detection by nucleic acid (dna or rna); borrelia burgdorferi, amplified probe technique
2026	87478		20260101	N	\$35.09	Detection of Babesia Borrelia miyamotoi by amplified nucleic acid probe	Infectious agent detection by nucleic acid (dna or rna); borrelia miyamotoi, amplified probe technique
2026	87480		20260101	N	\$20.05	Detection test for candida species (yeast), direct probe technique	Infectious agent detection by nucleic acid (dna or rna); candida species, direct probe technique
2026	87481		20260101	N	\$35.09	Detection test for candida species (yeast), amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); candida species, amplified probe technique

2026	87482		20260101	N	\$55.74	Detection test for candida species (yeast), quantification	Infectious agent detection by nucleic acid (dna or rna); candida species, quantification
------	-------	--	----------	---	---------	--	--

2026	87483		20260101	N	\$416.78	Test for detecting nucleic acid of organism causing infection of central	Infectious agent detection by nucleic acid (dna or rna); central nervous system pathogen (eg, neisseria meningitidis, streptococcus pneumoniae, listeria, haemophilus influenzae, e. coli, streptococcus agalactiae, enterovirus, human parechovirus, herpes simplex virus type 1 and 2, human herpesvirus 6, cytomegalovirus, varicella zoster virus, cryptococcus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
------	-------	--	----------	---	----------	--	--

2026	87484		20260101	N	\$35.09	Detection of Ehrlichia chaffeensis by amplified nucleic acid probe technique	Infectious agent detection by nucleic acid (dna or rna); ehrlichia chaffeensis, amplified probe technique
2026	87485		20260101	N	\$20.05	Detection test by nucleic acid for chlamydia pneumoniae, direct probe technique	Infectious agent detection by nucleic acid (dna or rna); chlamydia pneumoniae, direct probe technique
2026	87486		20260101	N	\$35.09	Detection test by nucleic acid for Chlamydia pneumoniae, amplified probe	Infectious agent detection by nucleic acid (dna or rna); chlamydia pneumoniae, amplified probe technique
2026	87487		20260101	N	\$42.84	Detection test by nucleic acid for chlamydia pneumoniae, quantification	Infectious agent detection by nucleic acid (dna or rna); chlamydia pneumoniae, quantification

2026	87490		20260101	N	\$22.75	Detection test by nucleic acid for chlamydia, direct probe technique	Infectious agent detection by nucleic acid (dna or rna); chlamydia trachomatis, direct probe technique
2026	87491		20260101	N	\$35.09	Detection test by nucleic acid for chlamydia trachomatis, amplified probe	Infectious agent detection by nucleic acid (dna or rna); chlamydia trachomatis, amplified probe technique
2026	87491	QW	20260101	N	\$35.09	Detection test by nucleic acid for chlamydia trachomatis, amplified probe	Infectious agent detection by nucleic acid (dna or rna); chlamydia trachomatis, amplified probe technique
2026	87492		20260101	N	\$53.47	Detection test by nucleic acid for chlamydia trachomatis, quantification	Infectious agent detection by nucleic acid (dna or rna); chlamydia trachomatis, quantification

2026	87493		20260101	N	\$37.27	Detection test by nucleic acid for clostridium difficile, amplified probe	Infectious agent detection by nucleic acid (dna or rna); clostridium difficile, toxin gene(s), amplified probe technique
2026	87494		20260101	N	\$70.18	Detection test by nucleic acid (DNA or RNA) multiplex amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); chlamydia trachomatis and neisseria gonorrhoeae, multiplex amplified probe technique
2026	87494	QW	20260101	N	\$70.18	Detection test by nucleic acid (DNA or RNA) multiplex amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); chlamydia trachomatis and neisseria gonorrhoeae, multiplex amplified probe technique

2026	87495		20260101	N	\$30.03	Detection test by nucleic acid for cytomegalovirus (CMV), direct probe technique	Infectious agent detection by nucleic acid (dna or rna); cytomegalovirus, direct probe technique
2026	87496		20260101	N	\$35.09	Detection test by nucleic acid for Cytomegalovirus (CMV), amplified probe	Infectious agent detection by nucleic acid (dna or rna); cytomegalovirus, amplified probe technique
2026	87497		20260101	N	\$42.84	Detection test by nucleic acid for cytomegalovirus, quantification	Infectious agent detection by nucleic acid (dna or rna); cytomegalovirus, quantification
2026	87498		20260101	N	\$35.09	Detection test by nucleic acid for enterovirus (intestinal virus), amplified	Infectious agent detection by nucleic acid (dna or rna); enterovirus, amplified probe technique, includes reverse transcription when performed

2026	87500		20260101	N	\$35.09	Detection test by nucleic acid for Vancomycin resistance strep (VRE), amplified	Infectious agent detection by nucleic acid (dna or rna); vancomycin resistance (eg, enterococcus species van a, van b), amplified probe technique
2026	87501		20260101	N	\$51.31	Detection test by nucleic acid for influenza virus, each type or subtype	Infectious agent detection by nucleic acid (dna or rna); influenza virus, includes reverse transcription, when performed, and amplified probe technique, each type or subtype

2026	87502		20260101	N	\$95.80	Detection test by nucleic acid for multiple types influenza virus	Infectious agent detection by nucleic acid (dna or rna); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types
2026	87502	QW	20260101	N	\$95.80	Detection test by nucleic acid for multiple types influenza virus	Infectious agent detection by nucleic acid (dna or rna); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types

2026	87503		20260101	N	\$29.22	Detection test by nucleic acid for multiple types influenza virus, each	Infectious agent detection by nucleic acid (dna or rna); influenza virus, for multiple types or subtypes, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, each additional influenza virus type or subtype beyond 2 (list separately in addition to code for primary procedure)
------	-------	--	----------	---	---------	---	---

2026	87505		20260101	N	\$128.29	Detection test by nucleic acid for digestive tract pathogen, multiple types or	Infectious agent detection by nucleic acid (dna or rna); gastrointestinal pathogen (eg, clostridium difficile, e. coli, salmonella, shigella, norovirus, giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets
------	-------	--	----------	---	----------	--	---

2026	87506		20260101	N	\$262.99	Detection test by nucleic acid for digestive tract pathogen, multiple types or	Infectious agent detection by nucleic acid (dna or rna); gastrointestinal pathogen (eg, clostridium difficile, e. coli, salmonella, shigella, norovirus, giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets
------	-------	--	----------	---	----------	--	--

2026	87507		20260101	N	\$416.78	Detection test by nucleic acid for digestive tract pathogen, multiple types or	Infectious agent detection by nucleic acid (dna or rna); gastrointestinal pathogen (eg, clostridium difficile, e. coli, salmonella, shigella, norovirus, giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
2026	87510		20260101	N	\$20.05	Detection test for gardnerella vaginalis (bacteria), direct probe technique	Infectious agent detection by nucleic acid (dna or rna); gardnerella vaginalis, direct probe technique

2026	87511		20260101	N	\$35.09	Detection test for gardnerella vaginalis (bacteria), amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); gardnerella vaginalis, amplified probe technique
2026	87512		20260101	N	\$41.76	Detection test for gardnerella vaginalis (bacteria), quantification	Infectious agent detection by nucleic acid (dna or rna); gardnerella vaginalis, quantification
2026	87513		20260101	N	\$35.09	Detection test by nucleic acid for helicobacter pylori clarithromycin	Infectious agent detection by nucleic acid (dna or rna); helicobacter pylori (h. pylori), clarithromycin resistance, amplified probe technique
2026	87516		20260101	N	\$35.09	Detection test by nucleic acid for Hepatitis B virus, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); hepatitis b virus, amplified probe technique

2026	87517		20260101	N	\$42.84	Detection test by nucleic acid for Hepatitis B virus, quantification	Infectious agent detection by nucleic acid (dna or rna); hepatitis b virus, quantification
2026	87520		20260101	N	\$31.22	Detection test by nucleic acid for Hepatitis C virus, direct probe technique	Infectious agent detection by nucleic acid (dna or rna); hepatitis c, direct probe technique
2026	87521		20260101	N	\$35.09	Detection test by nucleic acid for Hepatitis C virus, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); hepatitis c, amplified probe technique, includes reverse transcription when performed

2026	87521	QW	20260101	N	\$35.09	Detection test by nucleic acid for Hepatitis C virus, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); hepatitis c, amplified probe technique, includes reverse transcription when performed
2026	87522		20260101	N	\$42.84	Detection test by nucleic acid for Hepatitis C virus, quantification	Infectious agent detection by nucleic acid (dna or rna); hepatitis c, quantification, includes reverse transcription when performed
2026	87523		20260101	N	\$42.84	Detection of Hepatitis D (delta)	Infectious agent detection by nucleic acid (dna or rna); hepatitis d (delta), quantification, including reverse transcription, when performed

2026	87525		20260101	N	\$29.80	Detection test by nucleic acid for Hepatitis G virus, direct probe technique	Infectious agent detection by nucleic acid (dna or rna); hepatitis g, direct probe technique
2026	87526		20260101	N	\$39.26	Detection test by nucleic acid for Hepatitis G virus, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); hepatitis g, amplified probe technique
2026	87527		20260101	N	\$41.76	Detection test by nucleic acid for Hepatitis G virus, quantification	Infectious agent detection by nucleic acid (dna or rna); hepatitis g, quantification
2026	87528		20260101	N	\$20.05	Detection test by nucleic acid for herpes simplex virus, direct probe technique	Infectious agent detection by nucleic acid (dna or rna); herpes simplex virus, direct probe technique
2026	87529		20260101	N	\$35.09	Detection test by nucleic acid for herpes simplex virus, amplified probe	Infectious agent detection by nucleic acid (dna or rna); herpes simplex virus, amplified probe technique

2026	87530		20260101	N	\$42.84	Detection test by nucleic acid for herpes simplex virus, quantification	Infectious agent detection by nucleic acid (dna or rna); herpes simplex virus, quantification
2026	87531		20260101	N	\$58.00	Detection test by nucleic acid for herpes virus-6, direct probe technique	Infectious agent detection by nucleic acid (dna or rna); herpes virus-6, direct probe technique
2026	87532		20260101	N	\$35.09	Detection test by nucleic acid for herpes virus-6, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); herpes virus-6, amplified probe technique
2026	87533		20260101	N	\$41.76	Detection test by nucleic acid for herpes virus-6, quantification	Infectious agent detection by nucleic acid (dna or rna); herpes virus-6, quantification
2026	87534		20260101	N	\$21.92	Detection test by nucleic acid for HIV-1 virus, direct probe technique	Infectious agent detection by nucleic acid (dna or rna); hiv-1, direct probe technique

2026	87535		20260101	N	\$35.09	Detection test by nucleic acid for HIV-1 virus, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); hiv-1, amplified probe technique, includes reverse transcription when performed
2026	87536		20260101	N	\$85.10	Detection test by nucleic acid for HIV-1 virus, quantification	Infectious agent detection by nucleic acid (dna or rna); hiv-1, quantification, includes reverse transcription when performed
2026	87537		20260101	N	\$21.92	Detection test by nucleic acid for HIV-2 virus, direct probe technique	Infectious agent detection by nucleic acid (dna or rna); hiv-2, direct probe technique

2026	87538		20260101	N	\$35.09	Detection test by nucleic acid for HIV-2 virus, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); hiv-2, amplified probe technique, includes reverse transcription when performed
2026	87539		20260101	N	\$58.62	Detection test by nucleic acid for HIV-2 virus, quantification	Infectious agent detection by nucleic acid (dna or rna); hiv-2, quantification, includes reverse transcription when performed
2026	87540		20260101	N	\$20.05	Detection test by nucleic acid for legionella pneumophila (water borne	Infectious agent detection by nucleic acid (dna or rna); legionella pneumophila, direct probe technique

2026	87541		20260101	N	\$35.09	Detection test by nucleic acid for legionella pneumophila (water borne	Infectious agent detection by nucleic acid (dna or rna); legionella pneumophila, amplified probe technique
2026	87542		20260101	N	\$41.76	Detection test by nucleic acid for legionella pneumophila (water borne	Infectious agent detection by nucleic acid (dna or rna); legionella pneumophila, quantification
2026	87550		20260101	N	\$20.05	Detection test by nucleic acid for Mycobacteria species (bacteria), direct	Infectious agent detection by nucleic acid (dna or rna); mycobacteria species, direct probe technique
2026	87551		20260101	N	\$48.24	Detection test by nucleic acid for Mycobacteria species (bacteria), amplified	Infectious agent detection by nucleic acid (dna or rna); mycobacteria species, amplified probe technique

2026	87552		20260101	N	\$42.84	Detection test by nucleic acid for Mycobacteria species (bacteria),	Infectious agent detection by nucleic acid (dna or rna); mycobacteria species, quantification
2026	87555		20260101	N	\$26.88	Detection test by nucleic acid for Mycobacteria tuberculosis (TB bacteria),	Infectious agent detection by nucleic acid (dna or rna); mycobacteria tuberculosis, direct probe technique
2026	87556		20260101	N	\$41.68	Detection test by nucleic acid for Mycobacteria tuberculosis (TB bacteria),	Infectious agent detection by nucleic acid (dna or rna); mycobacteria tuberculosis, amplified probe technique
2026	87557		20260101	N	\$42.84	Detection test by nucleic acid for Mycobacteria tuberculosis (TB bacteria),	Infectious agent detection by nucleic acid (dna or rna); mycobacteria tuberculosis, quantification

2026	87560		20260101	N	\$27.29	Detection test by nucleic acid for Mycobacteria avium-intracellulare	Infectious agent detection by nucleic acid (dna or rna); mycobacteria avium-intracellulare, direct probe technique
2026	87561		20260101	N	\$35.09	Detection test by nucleic acid for Mycobacteria avium-intracellulare	Infectious agent detection by nucleic acid (dna or rna); mycobacteria avium-intracellulare, amplified probe technique
2026	87562		20260101	N	\$42.84	Detection test by nucleic acid for Mycobacteria avium-intracellulare	Infectious agent detection by nucleic acid (dna or rna); mycobacteria avium-intracellulare, quantification
2026	87563		20260101	N	\$35.09	Detection of Mycoplasma genitalium by DNA or RNA probe	Infectious agent detection by nucleic acid (dna or rna); mycoplasma genitalium, amplified probe technique

2026	87563	QW	20260101	N	\$35.09	Detection of Mycoplasma genitalium by DNA or RNA probe	Infectious agent detection by nucleic acid (dna or rna); mycoplasma genitalium, amplified probe technique
2026	87564		20260101	N	\$76.77	Detection test by nucleic acid for mycobacterium tuberculosis rifampin	Infectious agent detection by nucleic acid (dna or rna); mycobacterium tuberculosis, rifampin resistance, amplified probe technique
2026	87580		20260101	N	\$20.05	Detection test by nucleic acid for Mycoplasma pneumoniae (bacteria), direct	Infectious agent detection by nucleic acid (dna or rna); mycoplasma pneumoniae, direct probe technique
2026	87581		20260101	N	\$35.09	Detection test by nucleic acid for Mycoplasma pneumoniae (bacteria), amplified	Infectious agent detection by nucleic acid (dna or rna); mycoplasma pneumoniae, amplified probe technique

2026	87582		20260101	N	\$302.62	Detection test by nucleic acid for Mycoplasma pneumoniae (bacteria),	Infectious agent detection by nucleic acid (dna or rna); mycoplasma pneumoniae, quantification
2026	87590		20260101	N	\$26.88	Detection test by nucleic acid for Neisseria gonorrhoeae (gonorrhoeae	Infectious agent detection by nucleic acid (dna or rna); neisseria gonorrhoeae, direct probe technique
2026	87591		20260101	N	\$35.09	Detection test by nucleic acid for Neisseria gonorrhoeae (gonorrhoeae	Infectious agent detection by nucleic acid (dna or rna); neisseria gonorrhoeae, amplified probe technique
2026	87591	QW	20260101	N	\$35.09	Detection test by nucleic acid for Neisseria gonorrhoeae (gonorrhoeae	Infectious agent detection by nucleic acid (dna or rna); neisseria gonorrhoeae, amplified probe technique

2026	87592		20260101	N	\$42.84	Detection test by nucleic acid for Neisseria gonorrhoeae (gonorrhoeae)	Infectious agent detection by nucleic acid (dna or rna); neisseria gonorrhoeae, quantification
2026	87593		20260101	N	\$51.31	Detection of orthopoxvirus	Infectious agent detection by nucleic acid (dna or rna); orthopoxvirus (eg, monkeypox virus, cowpox virus, vaccinia virus), amplified probe technique, each
2026	87594		20260101	N	\$35.09	Detection test by nucleic acid for pneumocystis jirovecii	Infectious agent detection by nucleic acid (dna or rna); pneumocystis jirovecii, amplified probe technique
2026	87623		20260101	N	\$35.09	Detection test by nucleic acid for human papillomavirus (hpv), low-risk types	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), low-risk types (eg, 6, 11, 42, 43, 44)

2026	87624		20260101	N	\$35.09	Detection test by nucleic acid for human papillomavirus (hpv), high-risk types	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result
2026	87625		20260101	N	\$40.55	Detection test by nucleic acid for human papillomavirus (hpv), types 16 and 18	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), types 16 and 18 only, includes type 45, if performed
2026	87626		20260101	N	\$70.20	Detection test by nucleic acid for Human Papillomavirus (HPV), separately	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), separately reported high-risk types (eg, 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)

2026	87627		20260101	N	\$679.77	Detection test for joint space pathogens and drug resistance genes	Infectious agent detection by nucleic acid (dna or rna); joint space pathogens and drug resistance genes, multiplex amplified probe technique, 26 or more targets
------	-------	--	----------	---	----------	--	---

2026	87631		20260101	N	\$142.63	Detection test by nucleic acid for multiple types of respiratory virus,	Infectious agent detection by nucleic acid (dna or rna); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets
------	-------	--	----------	---	----------	---	--

2026	87631	QW	20260101	N	\$142.63	Detection test by nucleic acid for multiple types of respiratory virus,	Infectious agent detection by nucleic acid (dna or rna); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets
------	-------	----	----------	---	----------	---	--

2026	87632		20260101	N	\$218.06	Detection test by nucleic acid for multiple types of respiratory virus,	Infectious agent detection by nucleic acid (dna or rna); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets
------	-------	--	----------	---	----------	---	---

2026	87633		20260101	N	\$416.78	Detection test by nucleic acid for multiple types of respiratory virus,	Infectious agent detection by nucleic acid (dna or rna); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
------	-------	--	----------	---	----------	---	--

2026	87633	QW	20260101	N	\$416.78	Detection test by nucleic acid for multiple types of respiratory virus,	Infectious agent detection by nucleic acid (dna or rna); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
2026	87634		20260101	N	\$70.20	Detection test by nucleic acid for respiratory syncytial virus, amplified probe	Infectious agent detection by nucleic acid (dna or rna); respiratory syncytial virus, amplified probe technique

2026	87634	QW	20260101	N	\$70.20	Detection test by nucleic acid for respiratory syncytial virus, amplified probe	Infectious agent detection by nucleic acid (dna or rna); respiratory syncytial virus, amplified probe technique
2026	87635		20260101	N	\$51.31	Amplified DNA or RNA probe detection of severe acute respiratory syndrome	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique
2026	87635	QW	20260101	N	\$51.31	Amplified DNA or RNA probe detection of severe acute respiratory syndrome	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique

2026	87636		20260101	N	\$142.63	Detection test by multiplex amplified probe technique for severe acute	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) and influenza virus types a and b, multiplex amplified probe technique
2026	87636	QW	20260101	N	\$142.63	Detection test by multiplex amplified probe technique for severe acute	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) and influenza virus types a and b, multiplex amplified probe technique

2026	87637		20260101	N	\$142.63	Detection test by multiplex amplified probe technique for severe acute	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), influenza virus types a and b, and respiratory syncytial virus, multiplex amplified probe technique
------	-------	--	----------	---	----------	--	---

2026	87637	QW	20260101	N	\$142.63	Detection test by multiplex amplified probe technique for severe acute	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), influenza virus types a and b, and respiratory syncytial virus, multiplex amplified probe technique
2026	87640		20260101	N	\$35.09	Detection test by nucleic acid for Staphylococcus aureus (bacteria), amplified	Infectious agent detection by nucleic acid (dna or rna); staphylococcus aureus, amplified probe technique
2026	87641		20260101	N	\$35.09	Detection test by nucleic acid for Staphylococcus aureus, methicillin resistant	Infectious agent detection by nucleic acid (dna or rna); staphylococcus aureus, methicillin resistant, amplified probe technique

2026	87650		20260101	N	\$20.05	Detection test by nucleic acid for Strep (Streptococcus, group A), direct probe	Infectious agent detection by nucleic acid (dna or rna); streptococcus, group a, direct probe technique
2026	87650	QW	20260101	N	\$20.05	Detection test by nucleic acid for Strep (Streptococcus, group A), direct probe	Infectious agent detection by nucleic acid (dna or rna); streptococcus, group a, direct probe technique
2026	87651		20260101	N	\$35.09	Detection test by nucleic acid for Strep (Streptococcus, group A), amplified	Infectious agent detection by nucleic acid (dna or rna); streptococcus, group a, amplified probe technique
2026	87651	QW	20260101	N	\$35.09	Detection test by nucleic acid for Strep (Streptococcus, group A), amplified	Infectious agent detection by nucleic acid (dna or rna); streptococcus, group a, amplified probe technique

2026	87652		20260101	N	\$41.76	Detection test by nucleic acid for Strep (Streptococcus, group A),	Infectious agent detection by nucleic acid (dna or rna); streptococcus, group a, quantification
2026	87653		20260101	N	\$35.09	Detection test by nucleic acid for Strep (Streptococcus, group B), amplified	Infectious agent detection by nucleic acid (dna or rna); streptococcus, group b, amplified probe technique
2026	87660		20260101	N	\$20.05	Detection test by nucleic acid for Trichomonas vaginalis (genital parasite),	Infectious agent detection by nucleic acid (dna or rna); trichomonas vaginalis, direct probe technique
2026	87661		20260101	N	\$35.09	Infectious agent detection by nucleic acid (dna or rna); trichomonas vaginalis,	Infectious agent detection by nucleic acid (dna or rna); trichomonas vaginalis, amplified probe technique

2026	87662		20260101	N	\$51.31	Detection test by nucleic acid for Zika virus, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna); zika virus, amplified probe technique
2026	87797		20260101	N	\$30.03	Detection test by nucleic acid for organism, direct probe technique	Infectious agent detection by nucleic acid (dna or rna), not otherwise specified; direct probe technique, each organism
2026	87798		20260101	N	\$35.09	Detection test by nucleic acid for organism, amplified probe technique	Infectious agent detection by nucleic acid (dna or rna), not otherwise specified; amplified probe technique, each organism
2026	87799		20260101	N	\$42.84	Detection test by nucleic acid for organism, quantification	Infectious agent detection by nucleic acid (dna or rna), not otherwise specified; quantification, each organism

2026	87800		20260101	N	\$43.67	Detection test by nucleic acid for multiple organisms, direct probe(s) technique	Infectious agent detection by nucleic acid (dna or rna), multiple organisms; direct probe(s) technique
2026	87801		20260101	N	\$70.20	Detection test by nucleic acid for multiple organisms, amplified probe (s)	Infectious agent detection by nucleic acid (dna or rna), multiple organisms; amplified probe (s) technique
2026	87801	QW	20260101	N	\$70.20	Detection test by nucleic acid for multiple organisms, amplified probe (s)	Infectious agent detection by nucleic acid (dna or rna), multiple organisms; amplified probe (s) technique
2026	87802		20260101	N	\$12.73	Detection test by immunoassay with direct visual observation for Streptococcus,	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; streptococcus, group b

2026	87803		20260101	N	\$16.00	Detection test by immunoassay with direct visual observation for Clostridium	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; clostridium difficile toxin a
2026	87804		20260101	N	\$16.55	Detection test by immunoassay with direct visual observation for influenza virus	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; influenza
2026	87804	QW	20260101	N	\$16.55	Detection test by immunoassay with direct visual observation for influenza virus	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; influenza

2026	87806		20260101	N	\$32.77	Detection test by immunoassay with direct visual observation for HIV-1 antigen,	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; hiv-1 antigen(s), with hiv-1 and hiv-2 antibodies
2026	87806	QW	20260101	N	\$32.77	Detection test by immunoassay with direct visual observation for HIV-1 antigen,	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; hiv-1 antigen(s), with hiv-1 and hiv-2 antibodies
2026	87807		20260101	N	\$13.10	Detection test by immunoassay with direct visual observation for respiratory	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; respiratory syncytial virus

2026	87807	QW	20260101	N	\$13.10	Detection test by immunoassay with direct visual observation for respiratory	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; respiratory syncytial virus
2026	87808		20260101	N	\$15.29	Detection test by immunoassay with direct visual observation for Trichomonas	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; trichomonas vaginalis
2026	87808	QW	20260101	N	\$15.29	Detection test by immunoassay with direct visual observation for Trichomonas	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; trichomonas vaginalis

2026	87809		20260101	N	\$21.76	Detection test by immunoassay with direct visual observation for adenovirus	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; adenovirus
2026	87809	QW	20260101	N	\$21.76	Detection test by immunoassay with direct visual observation for adenovirus	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; adenovirus
2026	87810		20260101	N	\$35.29	Detection test by immunoassay with direct visual observation for Chlamydia	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; chlamydia trachomatis

2026	87811		20260101	N	\$41.38	Detection test by immunoassay with direct visual observation for severe acute	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])
2026	87811	QW	20260101	N	\$41.38	Detection test by immunoassay with direct visual observation for severe acute	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])

2026	87812		20260101	N	\$74.48	Detection test for severe acute respiratory syndrome coronavirus 2 and	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) and influenza virus types a and b
2026	87812	QW	20260101	N	\$74.48	Detection test for severe acute respiratory syndrome coronavirus 2 and	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) and influenza virus types a and b

2026	87850		20260101	N	\$24.56	Detection test by immunoassay with direct visual observation for Neisseria	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; neisseria gonorrhoeae
2026	87880		20260101	N	\$16.53	Detection test by immunoassay with direct visual observation for Streptococcus,	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; streptococcus, group a
2026	87880	QW	20260101	N	\$16.53	Detection test by immunoassay with direct visual observation for Streptococcus,	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; streptococcus, group a

2026	87899		20260101	N	\$16.07	Detection test by immunoassay with direct visual observation for other organism	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; not otherwise specified
2026	87899	QW	20260101	N	\$16.07	Detection test by immunoassay with direct visual observation for other organism	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; not otherwise specified
2026	87900		20260101	N	\$130.35	Infectious agent drug susceptibility analysis	Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics

2026	87901		20260101	N	\$257.45	Analysis test by nucleic acid for HIV-1 virus	Infectious agent genotype analysis by nucleic acid (dna or rna); hiv-1, reverse transcriptase and protease regions
2026	87902		20260101	N	\$257.45	Analysis test by nucleic acid for Hepatitis C virus	Infectious agent genotype analysis by nucleic acid (dna or rna); hepatitis c virus
2026	87903		20260101	N	\$488.66	Analysis test by nucleic acid for HIV-1 virus, first through 10 drugs tested	Infectious agent phenotype analysis by nucleic acid (dna or rna) with drug resistance tissue culture analysis, hiv 1; first through 10 drugs tested

2026	87904		20260101	N	\$26.07	Analysis test by nucleic acid for HIV-1 virus, each additional drug tested	Infectious agent phenotype analysis by nucleic acid (dna or rna) with drug resistance tissue culture analysis, hiv 1; each additional drug tested (list separately in addition to code for primary procedure)
2026	87905		20260101	N	\$12.22	Infectious agent enzymatic activity to detect organism	Infectious agent enzymatic activity other than virus (eg, sialidase activity in vaginal fluid)
2026	87905	QW	20260101	N	\$12.22	Infectious agent enzymatic activity to detect organism	Infectious agent enzymatic activity other than virus (eg, sialidase activity in vaginal fluid)

2026	87906		20260101	N	\$128.73	Analysis test by nucleic acid for HIV-1 virus, other region	Infectious agent genotype analysis by nucleic acid (dna or rna); hiv-1, other region (eg, integrase, fusion)
2026	87910		20260101	N	\$257.45	Analysis test by nucleic acid for cytomegalovirus, cytomegalovirus	Infectious agent genotype analysis by nucleic acid (dna or rna); cytomegalovirus
2026	87912		20260101	N	\$257.45	Analysis test by nucleic acid for hepatitis b virus	Infectious agent genotype analysis by nucleic acid (dna or rna); hepatitis b virus

2026	87913		20260101	N	\$257.45	Genotype analysis of severe acute respiratory syndrome coronavirus 2 (COVID-19)	Infectious agent genotype analysis by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), mutation identification in targeted region (s)
2026	88130		20260101	N	\$17.98	Sex identification, Barr bodies	Sex chromatin identification; barr bodies
2026	88140		20260101	N	\$7.99	Sex identification, peripheral blood smear	Sex chromatin identification; peripheral blood smear, polymorphonuclear drumsticks

2026	88142		20260101	N	\$20.26	Pap test, manual screening	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision
2026	88143		20260101	N	\$23.04	Pap test, manual screening and rescreening	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision

2026	88147		20260101	N	\$50.56	Pap test (Pap smear), automated system	Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision
2026	88148		20260101	N	\$18.54	Pap test (Pap smear), automated system with manual rescreening	Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision
2026	88150		20260101	N	\$18.54	Pap test, slides, manual screening	Cytopathology, slides, cervical or vaginal; manual screening under physician supervision
2026	88152		20260101	N	\$27.64	Pap test, slides, automated system with computer-assisted rescreening	Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision

2026	88153		20260101	N	\$24.03	Pap test, slides, manual screening and rescreening	Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision
2026	88155		20260101	N	\$14.65	Pap test, slides, definitive hormonal evaluation	Cytopathology, slides, cervical or vaginal, definitive hormonal evaluation (eg, maturation index, karyopyknotic index, estrogenic index) (list separately in addition to code[s] for other technical and interpretation services)
2026	88164		20260101	N	\$18.54	Pap test, slides, manual screening (the Bethesda System)	Cytopathology, slides, cervical or vaginal (the Bethesda system); manual screening under physician supervision

2026	88165		20260101	N	\$42.22	Pap test, slides, manual screening and rescreening (the Bethesda System)	Cytopathology, slides, cervical or vaginal (the Bethesda system); with manual screening and rescreening under physician supervision
2026	88166		20260101	N	\$18.54	Pap test, slides, manual screening and computer-assisted rescreening (the	Cytopathology, slides, cervical or vaginal (the Bethesda system); with manual screening and computer-assisted rescreening under physician supervision
2026	88167		20260101	N	\$18.54	Pap test, slides, manual screening and computer-assisted rescreening using cell	Cytopathology, slides, cervical or vaginal (the Bethesda system); with manual screening and computer-assisted rescreening using cell selection and review under physician supervision

2026	88174		20260101	N	\$25.37	Pap test, automated thin layer preparation; automated system	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision
2026	88175		20260101	N	\$26.61	Pap test, automated thin layer preparation; automated system and manual	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision

2026	88230		20260101	N	\$116.49	Tissue culture to identify white blood cell disorders	Tissue culture for non-neoplastic disorders; lymphocyte
2026	88233		20260101	N	\$140.73	Tissue culture to identify skin disorders	Tissue culture for non-neoplastic disorders; skin or other solid tissue biopsy
2026	88235		20260101	N	\$150.30	Tissue culture for disorders of amniotic fluid or placenta cells	Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells
2026	88237		20260101	N	\$143.75	Tissue culture for tumor disorders of bone marrow and blood cells	Tissue culture for neoplastic disorders; bone marrow, blood cells
2026	88239		20260101	N	\$147.52	Tissue culture for tumor disorders	Tissue culture for neoplastic disorders; solid tumor
2026	88240		20260101	N	\$13.07	Cryopreservation, freezing and storage of cells	Cryopreservation, freezing and storage of cells, each cell line
2026	88241		20260101	N	\$12.09	Thawing and expansion of frozen cells	Thawing and expansion of frozen cells, each aliquot

2026	88245		20260101	N	\$173.17	Chromosome analysis for genetic defects, baseline Sister Chromatid Exchange	Chromosome analysis for breakage syndromes; baseline sister chromatid exchange (sce), 20-25 cells
2026	88248		20260101	N	\$173.17	Chromosome analysis for genetic defects, baseline breakage, score 50-100 cells,	Chromosome analysis for breakage syndromes; baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes (eg, for ataxia telangiectasia, fanconi anemia, fragile x)
2026	88249		20260101	N	\$173.17	Chromosome analysis for genetic defects, score 100 cells, clastogen stress	Chromosome analysis for breakage syndromes; score 100 cells, clastogen stress (eg, diepoxybutane, mitomycin c, ionizing radiation, uv radiation)

2026	88261		20260101	N	\$264.34	Chromosome analysis for genetic defects, count 5 cells	Chromosome analysis; count 5 cells, 1 karyotype, with banding
2026	88262		20260101	N	\$125.49	Chromosome analysis for genetic defects, count 15-20 cells	Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding
2026	88263		20260101	N	\$150.29	Chromosome analysis for genetic defects, count 45 cells for mosaicism	Chromosome analysis; count 45 cells for mosaicism, 2 karyotypes, with banding
2026	88264		20260101	N	\$144.61	Chromosome analysis for genetic defects, analyze 20-25 cells	Chromosome analysis; analyze 20-25 cells
2026	88267		20260101	N	\$188.57	Chromosome analysis of amniotic fluid or placenta for genetic defects	Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells, 1 karyotype, with banding

2026	88269		20260101	N	\$173.66	Chromosome analysis of amniotic fluid for genetic defects	Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding
2026	88271		20260101	N	\$21.42	DNA testing for genetic defects	Molecular cytogenetics; dna probe, each (eg, fish)
2026	88272		20260101	N	\$40.70	Chromosome analysis for genetic defects, analyze 3-5 cells	Molecular cytogenetics; chromosomal in situ hybridization, analyze 3-5 cells (eg, for derivatives and markers)
2026	88273		20260101	N	\$34.81	Chromosome analysis for genetic defects, analyze 10-30 cells	Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)
2026	88274		20260101	N	\$42.38	Chromosome analysis for genetic defects, analyze 25-99 cells	Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells

2026	88275		20260101	N	\$51.19	Chromosome analysis for genetic defects, analyze 100-300 cells	Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells
2026	88280		20260101	N	\$33.47	Chromosome analysis for genetic defects, additional karyotypes, each study	Chromosome analysis; additional karyotypes, each study
2026	88283		20260101	N	\$68.60	Chromosome analysis for genetic defects, additional specialized banding	Chromosome analysis; additional specialized banding technique (eg, nor, c-banding)
2026	88285		20260101	N	\$26.91	Chromosome analysis for genetic defects, additional cells counted, each study	Chromosome analysis; additional cells counted, each study
2026	88289		20260101	N	\$34.43	Chromosome analysis for genetic defects, additional high resolution study	Chromosome analysis; additional high resolution study

2026	88371		20260101	N	\$22.23	Protein analysis of tissue with interpretation and report	Protein analysis of tissue by western blot, with interpretation and report;
2026	88372		20260101	N	\$26.22	Protein analysis of tissue by western blot, with interpretation and report	Protein analysis of tissue by western blot, with interpretation and report; immunological probe for band identification, each
2026	88720		20260101	N	\$5.02	Measurement of bilirubin	Bilirubin, total, transcutaneous
2026	88738		20260101	N	\$5.02	Hemoglobin measurement	Hemoglobin (hgb), quantitative, transcutaneous
2026	88740		20260101	N	\$9.37	Hemoglobin measurement, per day	Hemoglobin, quantitative, transcutaneous, per day; carboxyhemoglobin
2026	88741		20260101	N	\$9.37	Hemoglobin measurement, per day, methemoglobin	Hemoglobin, quantitative, transcutaneous, per day; methemoglobin

2026	89050		20260101	N	\$4.72	Body fluid cell count	Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid), except blood;
2026	89051		20260101	N	\$5.60	Body fluid cell count with cell identification	Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid), except blood; with differential count
2026	89055		20260101	N	\$4.27	White blood cell measure, stool specimen	Leukocyte assessment, fecal, qualitative or semiquantitative
2026	89060		20260101	N	\$7.33	Crystal identification from tissue or body fluid	Crystal identification by light microscopy with or without polarizing lens analysis, tissue or any body fluid (except urine)
2026	89125		20260101	N	\$5.88	Fat stain of stool, urine, or respiratory secretions	Fat stain, feces, urine, or respiratory secretions

2026	89160		20260101	N	\$4.85	Examination of stool for meat fibers	Meat fibers, feces
2026	89190		20260101	N	\$5.79	Nasal smear for eosinophils (allergy related white blood cells)	Nasal smear for eosinophils
2026	89300		20260101	N	\$9.84	Semen analysis presence and/or motility of sperm	Semen analysis; presence and/or motility of sperm including huhner test (post coital)
2026	89300	QW	20260101	N	\$9.84	Semen analysis presence and/or motility of sperm	Semen analysis; presence and/or motility of sperm including huhner test (post coital)
2026	89310		20260101	N	\$8.61	Semen analysis motility and count	Semen analysis; motility and count (not including huhner test)
2026	89320		20260101	N	\$12.31	Semen evaluation volume, sperm count, motility and analysis	Semen analysis; volume, count, motility, and differential

2026	89321		20260101	N	\$12.05	Semen analysis for sperm presence	Semen analysis; sperm presence and motility of sperm, if performed
2026	89321	QW	20260101	N	\$12.05	Semen analysis for sperm presence	Semen analysis; sperm presence and motility of sperm, if performed
2026	89322		20260101	N	\$15.50	Semen evaluation, volume, sperm count, motility, and analysis	Semen analysis; volume, count, motility, and differential using strict morphologic criteria (eg, kruger)
2026	89325		20260101	N	\$10.67	Sperm antibody measurement	Sperm antibodies
2026	89329		20260101	N	\$19.59	Sperm evaluation, hamster penetration test	Sperm evaluation; hamster penetration test
2026	89330		20260101	N	\$10.38	Sperm evaluation, cervical mucus penetration test	Sperm evaluation; cervical mucus penetration test, with or without spinnbarkeit test

2026	89331		20260101	N	\$19.59	Sperm evaluation, for reverse ejaculation, urine specimen	Sperm evaluation, for retrograde ejaculation, urine (sperm concentration, motility, and morphology, as indicated)
2026	G0027		20260101	N	\$6.50	Semen analysis; presence and/or motility of sperm excluding hühner	Semen analysis; presence and/or motility of sperm excluding hühner
2026	G0103		20260101	N	\$19.31	Prostate cancer screening; prostate specific antigen test (psa)	Prostate cancer screening; prostate specific antigen test (psa)
2026	G0123		20260101	N	\$20.26	Screening cytopathology, cervical or vaginal (any reporting system), collected	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision

2026	G0143		20260101	N	\$27.05	Screening cytopathology, cervical or vaginal (any reporting system), collected	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision
2026	G0144		20260101	N	\$43.97	Screening cytopathology, cervical or vaginal (any reporting system), collected	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision

2026	G0145		20260101	N	\$26.49	Screening cytopathology, cervical or vaginal (any reporting system), collected	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision
2026	G0147		20260101	N	\$18.54	Screening cytopathology smears, cervical or vaginal, performed by automated	Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision
2026	G0148		20260101	N	\$31.94	Screening cytopathology smears, cervical or vaginal, performed by automated	Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening

2026	G0306		20260101	N	\$7.77	Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and	Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count
2026	G0307		20260101	N	\$6.47	Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count)	Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count)
2026	G0327		20260101	L	\$ -	Colorectal cancer screening; blood-based biomarker	Colorectal cancer screening; blood-based biomarker
2026	G0328		20260101	N	\$18.05	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous
2026	G0328	QW	20260101	N	\$18.05	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous

2026	G0432		20260101	N	\$19.57	Infectious agent antibody detection by enzyme immunoassay (eia) technique,	Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening
2026	G0433		20260101	N	\$18.29	Infectious agent antibody detection by enzyme-linked immunosorbent assay	Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening
2026	G0433	QW	20260101	N	\$18.29	Infectious agent antibody detection by enzyme-linked immunosorbent assay	Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening
2026	G0435		20260101	N	\$11.98	Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2,	Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening

2026	G0471		20260101	N	\$11.34	Collection of venous blood by venipuncture or urine sample by catheterization	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)
2026	G0472		20260101	N	\$46.35	Hepatitis c antibody screening, for individual at high risk and other covered	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)
2026	G0472	QW	20260101	N	\$46.35	Hepatitis c antibody screening, for individual at high risk and other covered	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)
2026	G0475		20260101	N	\$24.08	Hiv antigen/antibody, combination assay, screening	Hiv antigen/antibody, combination assay, screening

2026	G0475	QW	20260101	N	\$24.08	Hiv antigen/antibody, combination assay, screening	Hiv antigen/antibody, combination assay, screening
2026	G0476		20260101	N	\$35.09	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test

2026	G0480		20260101	N	\$114.43	Drug test(s), definitive, utilizing (1) drug identification methods able to	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal
------	-------	--	----------	---	----------	---	---

2026	G0481		20260101	N	\$156.59	Drug test(s), definitive, utilizing (1) drug identification methods able to	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal
------	-------	--	----------	---	----------	---	---

2026	G0482		20260101	N	\$198.74	Drug test(s), definitive, utilizing (1) drug identification methods able to	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal
------	-------	--	----------	---	----------	---	---

2026	G0483		20260101	N	\$246.92	Drug test(s), definitive, utilizing (1) drug identification methods able to	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal
------	-------	--	----------	---	----------	---	---

2026	G0499		20260101	N	\$28.27	Hepatitis b screening in non-pregnant, high risk individual includes hepatitis	Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result
2026	G0567		20260101	N	\$35.09	Infectious agent detection by nucleic acid (dna or rna); hepatitis c,	Infectious agent detection by nucleic acid (dna or rna); hepatitis c, screening, amplified probe technique

2026	G0567	QW	20260101	N	\$35.09	Infectious agent detection by nucleic acid (dna or rna); hepatitis c,	Infectious agent detection by nucleic acid (dna or rna); hepatitis c, screening, amplified probe technique
------	-------	----	----------	---	---------	---	--

2026	G0659		20260101	N	\$62.14	Drug test(s), definitive, utilizing drug identification methods able to	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase) , performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized
------	-------	--	----------	---	---------	---	--

2026	G9143		20260101	N	\$120.72	Warfarin responsiveness testing by genetic technique using any method, any	Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)
2026	P2028		20260101	N	\$4.95	Cephalin flocculation, blood	Cephalin flocculation, blood
2026	P2029		20260101	N	\$4.95	Congo red, blood	Congo red, blood
2026	P2031		20260101	N	\$4.95	Hair analysis (excluding arsenic)	Hair analysis (excluding arsenic)
2026	P2033		20260101	N	\$4.95	Thymol turbidity, blood	Thymol turbidity, blood
2026	P2038		20260101	N	\$4.95	Mucoprotein, blood (seromuroid) (medical necessity procedure)	Mucoprotein, blood (seromuroid) (medical necessity procedure)
2026	P3000		20260101	N	\$18.54	Screening papanicolaou smear, cervical or vaginal, up to three smears, by	Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision

2026	P9612		20260101	N	\$9.34	Catheterization for collection of specimen, single patient, all places of	Catheterization for collection of specimen, single patient, all places of service
2026	P9615		20260101	N	\$9.34	Catheterization for collection of specimen(s) (multiple patients)	Catheterization for collection of specimen(s) (multiple patients)
2026	Q0111		20260101	N	\$18.54	Wet mounts, including preparations of vaginal, cervical or skin specimens	Wet mounts, including preparations of vaginal, cervical or skin specimens
2026	Q0112		20260101	N	\$5.83	All potassium hydroxide (koh) preparations	All potassium hydroxide (koh) preparations
2026	Q0113		20260101	N	\$4.27	Pinworm examinations	Pinworm examinations
2026	Q0114		20260101	N	\$9.74	Fern test	Fern test
2026	Q0115		20260101	N	\$25.00	Post-coital direct, qualitative examinations of vaginal or cervical mucous	Post-coital direct, qualitative examinations of vaginal or cervical mucous
2026	U0001		20260101	N	\$35.92	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel

2026	U0002		20260101	N	\$51.31	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc
2026	U0002	QW	20260101	N	\$51.31	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc